Other Sites:
Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About: RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE
RJR: Recommended Bibliography 17 Nov 2026 at 01:51 Created:
Macular Degeneration
Wikipedia: Macular Degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Macular degeneration typically occurs in older people, and is caused by damage to the macula of the retina. No cure or treatment restores the vision already lost. Age-related macular degeneration is a main cause of central blindness among the working-aged population worldwide. As of 2022, it affects more than 200 million people globally with the prevalence expected to increase to 300 million people by 2040 as the proportion of elderly persons in the population increases. It is more common in those of European or North American ancestry, and is about equally common in males and females. In 2013, it was the fourth most common cause of blindness, after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group] About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.
Created with PubMed® Query: "macular degeneration"[TIAB] NOT pmcbook NOT ispreviousversion
Citations The Papers (from PubMed®)
RevDate: 2026-11-16
CmpDate: 2026-11-16
PROGRESSION OF CHORIOCAPILLARIS FLOW DEFICIT IN EYES WITH DRUSENOID PIGMENT EPITHELIAL DETACHMENT.
Retina (Philadelphia, Pa.), 46(12):2223-2231.
PURPOSE: The aim of this study was to quantitatively evaluate choriocapillaris flow deficits (CCFDs) in eyes with drusenoid pigment epithelial detachment (PED) and examine their associations with disease progression and visual outcomes.
METHODS: This retrospective longitudinal cohort study included 42 eyes with drusenoid PED. Choriocapillaris flow deficit percentage (CCFD%) was quantified using compensation-corrected optical coherence tomography angiography imaging with standardized thresholding algorithms. Longitudinal changes in CCFD%, risk factors of geographic atrophy (GA) progression, and predictors of final best-corrected visual acuity were analyzed.
RESULTS: Mean baseline CCFD% was 36.26 ± 5.06%, with gradual worsening over 4 years to 38.47 ± 5.34% (0.60 ± 2.06%/year, P = 0.012). Eyes progressing to GA demonstrated significantly higher baseline CCFD% than stable eyes (37.94 ± 2.31% vs. 35.12 ± 6.07%, P < 0.001). During follow-up, 17 eyes (40.5%) developed GA, 23 (54.8%) remained stable, and 2 (4.8%) progressed to neovascular age-related macular degeneration. Multivariate Cox regression identified baseline CCFD (hazard ratio: 1.804; P = 0.006) and annual CCFD change rate (hazard ratio: 2.262; P = 0.024) as independent risk factors of GA progression. Multiple linear regression demonstrated that baseline CCFD and CCFD change rate independently predicted final best-corrected visual acuity (adjusted R 2 = 0.961, P < 0.001).
CONCLUSION: Both baseline CCFD and progressive CCFD deterioration serve as independent predictors of anatomical and functional outcomes in drusenoid PED, emphasizing the pathophysiologic role of choroidal hemodynamic dysfunction in age-related macular degeneration progression.
Additional Links: PMID-42560399
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42560399,
year = {2026},
author = {Kim, M and Park, YH},
title = {PROGRESSION OF CHORIOCAPILLARIS FLOW DEFICIT IN EYES WITH DRUSENOID PIGMENT EPITHELIAL DETACHMENT.},
journal = {Retina (Philadelphia, Pa.)},
volume = {46},
number = {12},
pages = {2223-2231},
doi = {10.1097/IAE.0000000000004955},
pmid = {42560399},
issn = {1539-2864},
support = {RS-2022-KH125938(HI22C0733)//Ministry of Health & Welfare/ ; RS-2023-00253065//Korean government (MSIT)/ ; },
mesh = {Humans ; Retrospective Studies ; Disease Progression ; *Choroid/blood supply ; Tomography, Optical Coherence/methods ; *Retinal Detachment/physiopathology/diagnosis ; Fluorescein Angiography/methods ; *Visual Acuity ; Female ; *Retinal Drusen/physiopathology/diagnosis ; Male ; Aged ; *Retinal Pigment Epithelium/pathology ; *Regional Blood Flow/physiology ; Fundus Oculi ; Follow-Up Studies ; Capillaries/physiopathology ; Aged, 80 and over ; Middle Aged ; },
abstract = {PURPOSE: The aim of this study was to quantitatively evaluate choriocapillaris flow deficits (CCFDs) in eyes with drusenoid pigment epithelial detachment (PED) and examine their associations with disease progression and visual outcomes.
METHODS: This retrospective longitudinal cohort study included 42 eyes with drusenoid PED. Choriocapillaris flow deficit percentage (CCFD%) was quantified using compensation-corrected optical coherence tomography angiography imaging with standardized thresholding algorithms. Longitudinal changes in CCFD%, risk factors of geographic atrophy (GA) progression, and predictors of final best-corrected visual acuity were analyzed.
RESULTS: Mean baseline CCFD% was 36.26 ± 5.06%, with gradual worsening over 4 years to 38.47 ± 5.34% (0.60 ± 2.06%/year, P = 0.012). Eyes progressing to GA demonstrated significantly higher baseline CCFD% than stable eyes (37.94 ± 2.31% vs. 35.12 ± 6.07%, P < 0.001). During follow-up, 17 eyes (40.5%) developed GA, 23 (54.8%) remained stable, and 2 (4.8%) progressed to neovascular age-related macular degeneration. Multivariate Cox regression identified baseline CCFD (hazard ratio: 1.804; P = 0.006) and annual CCFD change rate (hazard ratio: 2.262; P = 0.024) as independent risk factors of GA progression. Multiple linear regression demonstrated that baseline CCFD and CCFD change rate independently predicted final best-corrected visual acuity (adjusted R 2 = 0.961, P < 0.001).
CONCLUSION: Both baseline CCFD and progressive CCFD deterioration serve as independent predictors of anatomical and functional outcomes in drusenoid PED, emphasizing the pathophysiologic role of choroidal hemodynamic dysfunction in age-related macular degeneration progression.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Retrospective Studies
Disease Progression
*Choroid/blood supply
Tomography, Optical Coherence/methods
*Retinal Detachment/physiopathology/diagnosis
Fluorescein Angiography/methods
*Visual Acuity
Female
*Retinal Drusen/physiopathology/diagnosis
Male
Aged
*Retinal Pigment Epithelium/pathology
*Regional Blood Flow/physiology
Fundus Oculi
Follow-Up Studies
Capillaries/physiopathology
Aged, 80 and over
Middle Aged
RevDate: 2026-11-13
Bioactive hydroxyethyl starch-curcumin nanoparticles for sustained intravitreal delivery of rapamycin in dry age-related macular degeneration.
Colloids and surfaces. B, Biointerfaces, 270:116327 pii:S0927-7765(26)00915-X [Epub ahead of print].
Effective treatment of dry age-related macular degeneration (AMD) remains challenging because sustained intraocular delivery of therapeutic agents and simultaneous modulation of multiple pathological processes are difficult to achieve. Herein, rapamycin (RAP) -loaded hydroxyethyl starch (HES)-curcumin (CUR) nanoparticles (RHC NPs) were developed as a bioactive polymeric nanomedicine, in which HES-CUR functioned not only as the carrier but also as a therapeutic polymer with intrinsic antioxidant activity. The optimized RHC NPs exhibited a uniform nanoscale size, excellent lyophilization-redispersion capability, good colloidal stability under physiological ionic conditions, and sustained RAP release. In vitro studies demonstrated excellent cytocompatibility, efficient cellular uptake, and effective intracellular ROS scavenging, indicating that the biological activity of conjugated CUR was preserved after nanoparticle formation. In a NaIO3-induced dry AMD rat model, intravitreal administration of RHC NPs significantly preserved retinal morphology and retinal thickness, resulting in superior therapeutic efficacy compared with free drugs or HC NPs, while showing excellent in vivo biosafety. Collectively, this study demonstrates that integrating sustained RAP delivery with a therapeutic polymer capable of providing complementary antioxidant protection represents an effective strategy for dry AMD treatment and offers a promising platform for the intravitreal delivery of poorly water-soluble therapeutics.
Additional Links: PMID-43025267
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43025267,
year = {2026},
author = {Xue, Y and Qin, M and Zhang, R and Zou, M and Wang, W and Huang, D and Zhang, X and Chen, X and Weng, Z and Rao, H},
title = {Bioactive hydroxyethyl starch-curcumin nanoparticles for sustained intravitreal delivery of rapamycin in dry age-related macular degeneration.},
journal = {Colloids and surfaces. B, Biointerfaces},
volume = {270},
number = {},
pages = {116327},
doi = {10.1016/j.colsurfb.2026.116327},
pmid = {43025267},
issn = {1873-4367},
abstract = {Effective treatment of dry age-related macular degeneration (AMD) remains challenging because sustained intraocular delivery of therapeutic agents and simultaneous modulation of multiple pathological processes are difficult to achieve. Herein, rapamycin (RAP) -loaded hydroxyethyl starch (HES)-curcumin (CUR) nanoparticles (RHC NPs) were developed as a bioactive polymeric nanomedicine, in which HES-CUR functioned not only as the carrier but also as a therapeutic polymer with intrinsic antioxidant activity. The optimized RHC NPs exhibited a uniform nanoscale size, excellent lyophilization-redispersion capability, good colloidal stability under physiological ionic conditions, and sustained RAP release. In vitro studies demonstrated excellent cytocompatibility, efficient cellular uptake, and effective intracellular ROS scavenging, indicating that the biological activity of conjugated CUR was preserved after nanoparticle formation. In a NaIO3-induced dry AMD rat model, intravitreal administration of RHC NPs significantly preserved retinal morphology and retinal thickness, resulting in superior therapeutic efficacy compared with free drugs or HC NPs, while showing excellent in vivo biosafety. Collectively, this study demonstrates that integrating sustained RAP delivery with a therapeutic polymer capable of providing complementary antioxidant protection represents an effective strategy for dry AMD treatment and offers a promising platform for the intravitreal delivery of poorly water-soluble therapeutics.},
}
RevDate: 2026-11-14
CmpDate: 2026-11-14
Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study.
International journal of molecular sciences, 27(21):.
Exudative age-related macular degeneration (AMD) is driven by choroidal angiogenesis, and the response to anti-vascular endothelial growth factor (anti-VEGF) therapy varies between patients. In this pilot study, we investigated whether the pretreatment nasopharyngeal microbiota differs between patients with exudative AMD and controls and whether it is associated with treatment response. Nasopharyngeal swabs were analysed by 16S rRNA gene (V3-V4) amplicon sequencing; after removal of host-derived, chloroplast and contaminant sequences and rarefaction, 55 samples (25 patients and 30 controls) were retained. Treatment response was assessed six months after starting therapy. Community composition was compared using permutational multivariate analysis of variance (PERMANOVA) adjusted for age, sex and statin use. Alpha and beta diversity did not differ between patients and controls (Shannon index, p = 0.892; PERMANOVA, p = 0.067). Pretreatment community composition differed between 19 responders and five non-responders (Bray-Curtis R[2] = 0.057, p = 0.015; weighted UniFrac R[2] = 0.143, p = 0.006), and non-responders had lower diversity (observed ASVs, p = 0.004). Non-responders had a higher relative abundance of Corynebacterium (median 71% vs. 19%; p = 0.009), which did not remain significant after correction for all genera tested. Pretreatment nasopharyngeal microbiota composition was associated with the response to anti-VEGF therapy but not with AMD status. These preliminary findings require confirmation in larger, independent cohorts.
Additional Links: PMID-43027921
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43027921,
year = {2026},
author = {Cebatoriene, D and Bruzaite, A and Vilkeviciute-Petraite, A and Zaliuniene, D and Lukosevicius, R and Skieceviciene, J and Kupcinskas, J and Liutkeviciene, R},
title = {Nasopharyngeal Microbial Signatures Associated with Anti-VEGF Therapeutic Outcomes in Exudative Age-Related Macular Degeneration: A Pilot Study.},
journal = {International journal of molecular sciences},
volume = {27},
number = {21},
pages = {},
pmid = {43027921},
issn = {1422-0067},
support = {S-MIP-23-96//Research Council of Lithuania/ ; },
mesh = {Humans ; Pilot Projects ; *Vascular Endothelial Growth Factor A/antagonists & inhibitors ; *Microbiota ; *Macular Degeneration/drug therapy/microbiology ; *Nasopharynx/microbiology ; Female ; Male ; Aged ; RNA, Ribosomal, 16S/genetics ; Aged, 80 and over ; Treatment Outcome ; *Angiogenesis Inhibitors/therapeutic use ; },
abstract = {Exudative age-related macular degeneration (AMD) is driven by choroidal angiogenesis, and the response to anti-vascular endothelial growth factor (anti-VEGF) therapy varies between patients. In this pilot study, we investigated whether the pretreatment nasopharyngeal microbiota differs between patients with exudative AMD and controls and whether it is associated with treatment response. Nasopharyngeal swabs were analysed by 16S rRNA gene (V3-V4) amplicon sequencing; after removal of host-derived, chloroplast and contaminant sequences and rarefaction, 55 samples (25 patients and 30 controls) were retained. Treatment response was assessed six months after starting therapy. Community composition was compared using permutational multivariate analysis of variance (PERMANOVA) adjusted for age, sex and statin use. Alpha and beta diversity did not differ between patients and controls (Shannon index, p = 0.892; PERMANOVA, p = 0.067). Pretreatment community composition differed between 19 responders and five non-responders (Bray-Curtis R[2] = 0.057, p = 0.015; weighted UniFrac R[2] = 0.143, p = 0.006), and non-responders had lower diversity (observed ASVs, p = 0.004). Non-responders had a higher relative abundance of Corynebacterium (median 71% vs. 19%; p = 0.009), which did not remain significant after correction for all genera tested. Pretreatment nasopharyngeal microbiota composition was associated with the response to anti-VEGF therapy but not with AMD status. These preliminary findings require confirmation in larger, independent cohorts.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Pilot Projects
*Vascular Endothelial Growth Factor A/antagonists & inhibitors
*Microbiota
*Macular Degeneration/drug therapy/microbiology
*Nasopharynx/microbiology
Female
Male
Aged
RNA, Ribosomal, 16S/genetics
Aged, 80 and over
Treatment Outcome
*Angiogenesis Inhibitors/therapeutic use
RevDate: 2026-11-15
CmpDate: 2026-11-14
Deep Learning-Based Automated Detection, Segmentation, and Quantification of Retinal Fluid on Optical Coherence Tomography: A Validation Study.
Diagnostics (Basel, Switzerland), 16(21):.
Objectives: To validate a deep learning-based algorithm for automated detection, segmentation, and quantitative assessment of retinal fluid on optical coherence tomography (OCT) across multiple retinal diseases. Methods: In this retrospective validation study, spectral-domain OCT volume scans from eyes with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular telangiectasia type 2 (MacTel) were analyzed. Automated segmentation was performed using the fluid analyzer on Skopix by NetraMind Innovations, a deep learning-based framework trained to identify intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and subretinal hyperreflective material (SHRM). Automated segmentations were reviewed and manually corrected by two masked experienced retina graders, with discrepancies adjudicated by a senior retina specialist. Scan-level detection performance was evaluated using accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the receiver operating characteristic curve (AUC), and Gwet's first-order agreement coefficient (AC1). Spatial segmentation agreement across all B-scans was assessed using the Dice coefficient. Quantitative agreement between automated and manually corrected fluid volumes was evaluated using correlation and Bland-Altman analyses. Inter-grader reliability was assessed using the intraclass correlation coefficient (ICC). Results: A total of 98 OCT volumes comprising 31 nAMD, 25 DME, and 42 MacTel eyes were included. In nAMD, IRF detection demonstrated a sensitivity of 81.8%, specificity of 83.0%, and AUC of 0.876, while SRF demonstrated a sensitivity of 81.4%, specificity of 96.7%, and AUC of 0.901. In DME, sensitivity, specificity, and AUC were 99.6%, 97.3%, and 0.989 for IRF and 98.4%, 96.4%, and 0.978 for SRF, respectively. In MacTel, IRF demonstrated a sensitivity of 87.3%, specificity of 95.1%, and AUC of 0.927, while SRF demonstrated a sensitivity of 86.8%, specificity of 98.4%, and AUC of 0.929. Segmentation agreement between automated and manually corrected annotations was high across disease groups, with Dice coefficients of 0.829 and 0.922 for IRF and SRF in nAMD, 0.858 and 0.941 in DME, and 0.908 and 0.97 in MacTel, respectively. Automated fluid volumes demonstrated strong correlations with manually corrected measurements, with minimal systematic bias on Bland-Altman analysis. Conclusions: The automated segmentation algorithm demonstrated strong validation performance for the detection and quantitative assessment of retinal fluid across nAMD, DME, and MacTel. High segmentation agreement, particularly for IRF and SRF, and strong volumetric agreement with expert-corrected measurements support the potential use of automated OCT fluid quantification in clinical practice and research.
Additional Links: PMID-43028370
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028370,
year = {2026},
author = {Hasan, N and Gadari, A and Vupparaboina, SC and Lall, SR and Emfietzoglou, M and Flores-Pena, D and Gregori, G and Vichare, AA and Doshi, U and Sadeghi, E and Sahoo, NK and Gagliardi, OM and Bollepalli, SC and Vupparaboina, KK and Chhablani, J},
title = {Deep Learning-Based Automated Detection, Segmentation, and Quantification of Retinal Fluid on Optical Coherence Tomography: A Validation Study.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {21},
pages = {},
pmid = {43028370},
issn = {2075-4418},
support = {P30 EY008098/EY/NEI NIH HHS/United States ; },
abstract = {Objectives: To validate a deep learning-based algorithm for automated detection, segmentation, and quantitative assessment of retinal fluid on optical coherence tomography (OCT) across multiple retinal diseases. Methods: In this retrospective validation study, spectral-domain OCT volume scans from eyes with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular telangiectasia type 2 (MacTel) were analyzed. Automated segmentation was performed using the fluid analyzer on Skopix by NetraMind Innovations, a deep learning-based framework trained to identify intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and subretinal hyperreflective material (SHRM). Automated segmentations were reviewed and manually corrected by two masked experienced retina graders, with discrepancies adjudicated by a senior retina specialist. Scan-level detection performance was evaluated using accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the receiver operating characteristic curve (AUC), and Gwet's first-order agreement coefficient (AC1). Spatial segmentation agreement across all B-scans was assessed using the Dice coefficient. Quantitative agreement between automated and manually corrected fluid volumes was evaluated using correlation and Bland-Altman analyses. Inter-grader reliability was assessed using the intraclass correlation coefficient (ICC). Results: A total of 98 OCT volumes comprising 31 nAMD, 25 DME, and 42 MacTel eyes were included. In nAMD, IRF detection demonstrated a sensitivity of 81.8%, specificity of 83.0%, and AUC of 0.876, while SRF demonstrated a sensitivity of 81.4%, specificity of 96.7%, and AUC of 0.901. In DME, sensitivity, specificity, and AUC were 99.6%, 97.3%, and 0.989 for IRF and 98.4%, 96.4%, and 0.978 for SRF, respectively. In MacTel, IRF demonstrated a sensitivity of 87.3%, specificity of 95.1%, and AUC of 0.927, while SRF demonstrated a sensitivity of 86.8%, specificity of 98.4%, and AUC of 0.929. Segmentation agreement between automated and manually corrected annotations was high across disease groups, with Dice coefficients of 0.829 and 0.922 for IRF and SRF in nAMD, 0.858 and 0.941 in DME, and 0.908 and 0.97 in MacTel, respectively. Automated fluid volumes demonstrated strong correlations with manually corrected measurements, with minimal systematic bias on Bland-Altman analysis. Conclusions: The automated segmentation algorithm demonstrated strong validation performance for the detection and quantitative assessment of retinal fluid across nAMD, DME, and MacTel. High segmentation agreement, particularly for IRF and SRF, and strong volumetric agreement with expert-corrected measurements support the potential use of automated OCT fluid quantification in clinical practice and research.},
}
RevDate: 2026-11-14
CmpDate: 2026-11-14
A Review of Machine Learning Approaches to Eye Disease Detection: Current Trends, Challenges and Future Directions.
Diagnostics (Basel, Switzerland), 16(21):.
Background/Objectives: Vision impairment and blindness remain a major global health challenge, with glaucoma, diabetic retinopathy, age-related macular degeneration, cataract, corneal disease, and retinopathy of prematurity representing important causes of preventable or treatable vision loss when detected early. This clinical need has accelerated research on machine learning approaches for automatic detection of eye diseases, grading, and segmentation. However, existing reviews often focus on a single disease or method. They also give limited attention to their suitability and applicability for reliable clinical deployments. This review synthesizes traditional machine learning, deep learning, vision transformers, ensemble and hybrid models, segmentation methods, and explainable AI approaches for eye disease detection. It further examines task formulation, dataset characteristics, evaluation practices, and deployment constraints, with emphasis on clinical readiness rather than benchmark performance alone. Methods: A structured narrative review was conducted using recently published articles from reputable databases and repositories, including IEEE Xplore, PubMed/MEDLINE, ScienceDirect, Scopus and arXiv. The review critically analyzes the progression from traditional machine learning to advanced models, including deep learning, vision transformers, ensemble models and explainable artificial intelligence. Studies were critically analyzed according to task formulations, dataset characteristics, segmentation approaches, evaluation metrics, explainability, and deployment constraints. Results: The synthesis shows that class imbalance, limited demographic and geographic diversity in available datasets, weak external validation, and scarce prospective evidence continue to separate benchmark performance from clinical readiness. Explainability is also often evaluated through visual plausibility rather than validated faithfulness. Currently, data-driven diabetic retinopathy screening is closest to clinical readiness, particularly for distinguishing referable from non-referable cases, whereas multi-label detection, rare disease detection, and cross-device deployment remain at the research stage. Conclusions: Progress towards clinical adoption requires stronger alignment between experimental evaluation and real-world deployment. This includes external validation and the development of equitable, interpretable, and resource-aware systems.
Additional Links: PMID-43028416
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43028416,
year = {2026},
author = {Oladele, MO and Alimi, OA and Olugbara, OO},
title = {A Review of Machine Learning Approaches to Eye Disease Detection: Current Trends, Challenges and Future Directions.},
journal = {Diagnostics (Basel, Switzerland)},
volume = {16},
number = {21},
pages = {},
pmid = {43028416},
issn = {2075-4418},
abstract = {Background/Objectives: Vision impairment and blindness remain a major global health challenge, with glaucoma, diabetic retinopathy, age-related macular degeneration, cataract, corneal disease, and retinopathy of prematurity representing important causes of preventable or treatable vision loss when detected early. This clinical need has accelerated research on machine learning approaches for automatic detection of eye diseases, grading, and segmentation. However, existing reviews often focus on a single disease or method. They also give limited attention to their suitability and applicability for reliable clinical deployments. This review synthesizes traditional machine learning, deep learning, vision transformers, ensemble and hybrid models, segmentation methods, and explainable AI approaches for eye disease detection. It further examines task formulation, dataset characteristics, evaluation practices, and deployment constraints, with emphasis on clinical readiness rather than benchmark performance alone. Methods: A structured narrative review was conducted using recently published articles from reputable databases and repositories, including IEEE Xplore, PubMed/MEDLINE, ScienceDirect, Scopus and arXiv. The review critically analyzes the progression from traditional machine learning to advanced models, including deep learning, vision transformers, ensemble models and explainable artificial intelligence. Studies were critically analyzed according to task formulations, dataset characteristics, segmentation approaches, evaluation metrics, explainability, and deployment constraints. Results: The synthesis shows that class imbalance, limited demographic and geographic diversity in available datasets, weak external validation, and scarce prospective evidence continue to separate benchmark performance from clinical readiness. Explainability is also often evaluated through visual plausibility rather than validated faithfulness. Currently, data-driven diabetic retinopathy screening is closest to clinical readiness, particularly for distinguishing referable from non-referable cases, whereas multi-label detection, rare disease detection, and cross-device deployment remain at the research stage. Conclusions: Progress towards clinical adoption requires stronger alignment between experimental evaluation and real-world deployment. This includes external validation and the development of equitable, interpretable, and resource-aware systems.},
}
RevDate: 2026-11-12
Visual Outcomes of Autologous RPE-Based Transplantation for Massive Submacular Hemorrhage in Neovascular AMD and PCV: A Systematic Review and Meta-Analysis.
Ophthalmology and therapy [Epub ahead of print].
INTRODUCTION: Massive submacular hemorrhage (SMH) secondary to age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) has a poor visual prognosis, and the role of autologous retinal pigment epithelium (RPE)-based transplantation remains uncertain. To synthesize visual, anatomical, and safety outcomes after autologous RPE monolayer or RPE complex transplantation for AMD/PCV-related massive SMH, with BCVA at 12 ± 6 months as the primary continuous outcome.
METHODS: The protocol was registered in PROSPERO (CRD420251164359). We searched seven English- and Chinese-language databases from inception through June 1, 2026. The primary outcome was within-eye BCVA change, defined as postoperative minus preoperative logMAR; negative values indicated improvement. For each eye, the primary analysis used the measurement closest to 12 months within an inclusive 6-18-month window. Continuous outcomes were synthesized using random-effects models fitted by restricted maximum likelihood, and single-arm binary outcomes using logistic-normal generalized linear mixed models. Certainty was assessed using GRADE.
RESULTS: Thirteen studies involving 140 eyes were included. Eight cohorts comprising 54 eyes contributed to the primary 12 ± 6-month analysis. The pooled mean BCVA change was - 0.276 logMAR (95% CI, - 0.534 to - 0.019; P = 0.0355; I[2] = 63.2%), with a 95% prediction interval of - 0.894 to 0.341 logMAR. The 12 ± 3-month analysis and the joint exclusion of Karasu et al. 2019, MacLaren et al. 2007, and the Chen et al. 2022 RPE-monolayer cohort were compatible with no mean change. All-available best and last available BCVA analyses remained favorable but showed substantial heterogeneity. Graft perfusion was confirmed in 96.7% of eyes (95% CI, 74.4-99.7%); 34.6% achieved BCVA better than 20/200, and 2.9% achieved 20/40 or better. Retinal detachment occurred in 16.5%, postoperative subretinal hemorrhage in 18.2%, epiretinal membrane in 16.7%, postoperative neovascularization in 11.8%, and reoperation in 28.2%. Certainty was very low. The fixed-effect sensitivity analysis of the same primary dataset yielded a pooled mean change of - 0.254 logMAR (95% CI, - 0.403 to - 0.105; P = 0.0008), supporting the direction of the random-effects estimate but with a narrower confidence interval.
CONCLUSIONS: Autologous RPE-based transplantation may offer salvage value for highly selected eyes with AMD/PCV-related SMH. However, the primary prediction interval crossed no mean change, sensitivity results depended on follow-up definition and cohort inclusion, and complications were frequent. Heterogeneous, non-randomized evidence of very low certainty cannot establish comparative effectiveness.
PROSPERO: CRD420251164359.
Additional Links: PMID-43018913
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43018913,
year = {2026},
author = {Gong, L and Io, II and Chen, H},
title = {Visual Outcomes of Autologous RPE-Based Transplantation for Massive Submacular Hemorrhage in Neovascular AMD and PCV: A Systematic Review and Meta-Analysis.},
journal = {Ophthalmology and therapy},
volume = {},
number = {},
pages = {},
pmid = {43018913},
issn = {2193-8245},
abstract = {INTRODUCTION: Massive submacular hemorrhage (SMH) secondary to age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) has a poor visual prognosis, and the role of autologous retinal pigment epithelium (RPE)-based transplantation remains uncertain. To synthesize visual, anatomical, and safety outcomes after autologous RPE monolayer or RPE complex transplantation for AMD/PCV-related massive SMH, with BCVA at 12 ± 6 months as the primary continuous outcome.
METHODS: The protocol was registered in PROSPERO (CRD420251164359). We searched seven English- and Chinese-language databases from inception through June 1, 2026. The primary outcome was within-eye BCVA change, defined as postoperative minus preoperative logMAR; negative values indicated improvement. For each eye, the primary analysis used the measurement closest to 12 months within an inclusive 6-18-month window. Continuous outcomes were synthesized using random-effects models fitted by restricted maximum likelihood, and single-arm binary outcomes using logistic-normal generalized linear mixed models. Certainty was assessed using GRADE.
RESULTS: Thirteen studies involving 140 eyes were included. Eight cohorts comprising 54 eyes contributed to the primary 12 ± 6-month analysis. The pooled mean BCVA change was - 0.276 logMAR (95% CI, - 0.534 to - 0.019; P = 0.0355; I[2] = 63.2%), with a 95% prediction interval of - 0.894 to 0.341 logMAR. The 12 ± 3-month analysis and the joint exclusion of Karasu et al. 2019, MacLaren et al. 2007, and the Chen et al. 2022 RPE-monolayer cohort were compatible with no mean change. All-available best and last available BCVA analyses remained favorable but showed substantial heterogeneity. Graft perfusion was confirmed in 96.7% of eyes (95% CI, 74.4-99.7%); 34.6% achieved BCVA better than 20/200, and 2.9% achieved 20/40 or better. Retinal detachment occurred in 16.5%, postoperative subretinal hemorrhage in 18.2%, epiretinal membrane in 16.7%, postoperative neovascularization in 11.8%, and reoperation in 28.2%. Certainty was very low. The fixed-effect sensitivity analysis of the same primary dataset yielded a pooled mean change of - 0.254 logMAR (95% CI, - 0.403 to - 0.105; P = 0.0008), supporting the direction of the random-effects estimate but with a narrower confidence interval.
CONCLUSIONS: Autologous RPE-based transplantation may offer salvage value for highly selected eyes with AMD/PCV-related SMH. However, the primary prediction interval crossed no mean change, sensitivity results depended on follow-up definition and cohort inclusion, and complications were frequent. Heterogeneous, non-randomized evidence of very low certainty cannot establish comparative effectiveness.
PROSPERO: CRD420251164359.},
}
RevDate: 2026-11-13
Beyond the Black Patch: A Composable, Gaze-Contingent Framework for Simulating Central Vision Loss in XR.
IEEE transactions on visualization and computer graphics, PP: [Epub ahead of print].
Central vision loss (CVL) from macular diseases such as age-related macular degeneration and Stargardt disease is commonly simulated in extended reality (XR) using a single mechanism, typically a dark patch or blur overlay. Yet clinical reports suggest that people with CVL reject this depiction and instead report a broad range of perceptual effects, including spatial distortion, perceptual invisibility, dynamic noise, dimming, filling-in, and temporal disturbances. We present XR-VIEU (e $\underline{X}$ tended $\underline{R}$eality for $\underline{V}$isual $\underline{I}$mpairment $\underline{E}$xploration & $\underline{U}$nderstanding), a modular, real-time, gaze-contingent framework for simulating CVL in XR through seven clinically grounded, independent, composable shader modules implemented in Unity HDRP, with formal mathematical specifications and over 120 configurable parameters per eye. To probe whether our simulation can capture lived CVL experiences, we conducted a profile reconstruction design study with two individuals with late-stage Stargardt disease. Despite sharing the same diagnosis, the two participants required significantly different module configurations: one profile was dominated by content displacement and dimming, while the other relied primarily on dense fractal noise. These cases provide initial evidence that modular, composable simulation is needed to represent the heterogeneity of CVL experience. The full seven-module pipeline adds only 0.20 ms of rendering overhead (2.9%) while maintaining approximately 90 Hz on the Varjo XR-4 at native resolution. XR-VIEU provides a foundation for more faithful and personalized CVL simulation in research, clinical education, and accessibility-oriented design.
Additional Links: PMID-43019259
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43019259,
year = {2026},
author = {Ghasemi, P and Primo, SA and Seepersad, CC and Moghaddam, M},
title = {Beyond the Black Patch: A Composable, Gaze-Contingent Framework for Simulating Central Vision Loss in XR.},
journal = {IEEE transactions on visualization and computer graphics},
volume = {PP},
number = {},
pages = {},
doi = {10.1109/TVCG.2026.3747406},
pmid = {43019259},
issn = {1941-0506},
abstract = {Central vision loss (CVL) from macular diseases such as age-related macular degeneration and Stargardt disease is commonly simulated in extended reality (XR) using a single mechanism, typically a dark patch or blur overlay. Yet clinical reports suggest that people with CVL reject this depiction and instead report a broad range of perceptual effects, including spatial distortion, perceptual invisibility, dynamic noise, dimming, filling-in, and temporal disturbances. We present XR-VIEU (e $\underline{X}$
tended $\underline{R}$
eality for $\underline{V}$
isual $\underline{I}$
mpairment $\underline{E}$
xploration & $\underline{U}$
nderstanding), a modular, real-time, gaze-contingent framework for simulating CVL in XR through seven clinically grounded, independent, composable shader modules implemented in Unity HDRP, with formal mathematical specifications and over 120 configurable parameters per eye. To probe whether our simulation can capture lived CVL experiences, we conducted a profile reconstruction design study with two individuals with late-stage Stargardt disease. Despite sharing the same diagnosis, the two participants required significantly different module configurations: one profile was dominated by content displacement and dimming, while the other relied primarily on dense fractal noise. These cases provide initial evidence that modular, composable simulation is needed to represent the heterogeneity of CVL experience. The full seven-module pipeline adds only 0.20 ms of rendering overhead (2.9%) while maintaining approximately 90 Hz on the Varjo XR-4 at native resolution. XR-VIEU provides a foundation for more faithful and personalized CVL simulation in research, clinical education, and accessibility-oriented design.},
}
RevDate: 2026-11-12
Is pachychoroid geographic atrophy an underestimated diagnosis? A retrospective optical coherence tomography analysis.
Journal francais d'ophtalmologie, 49(10):105023 pii:S0181-5512(26)00249-4 [Epub ahead of print].
PURPOSE: This study aims to evaluate potentially underestimated pachychoroid geographic atrophy (PGA) cases and their clinical characteristics among conventional geographic atrophy (CGA) patients previously diagnosed with non-neovascular age-related macular degeneration (AMD).
METHODS: Patients with non-neovascular AMD were retrospectively included. Optical coherence tomography (OCT) images served as the primary diagnostic modality. Central subfoveal choroidal thickness (CSCT), pachyvessel diameters, and areas of GA were measured on OCT slices. Pachychoroid was defined based on major and minor auxiliary criteria. CSCT>250μm was accepted as the main criterion. The presence of at least two auxiliary criteria along with the main criterion confirmed the diagnosis of pachychoroid.
RESULTS: A total of 229 non-neovascular AMD patients with geographic atrophy were included; 183 were assigned to the CGA group and 46 to the PGA group. The mean age was 77.7±9.1 years, and the PGA group was significantly younger (78.5±9.0 vs. 74.3±8.9 years; P=0.005). CSCT was significantly thinner in the CGA group (148.8±53.5 vs. 287.3±42.9; P<0.001). Pachyvessel presence in the subfoveal area was significantly higher in the PGA group [22.4% vs. 65.2%; P<0.001]. Absence of drusen was also higher in the PGA group [16.4% vs. 32.6%; P=0.013]. The PGA group showed significantly slower GA progression (P=0.012).
CONCLUSION: Recognizing PGA is essential for a more accurate clinical classification and for better understanding the prognostic differences within the geographic atrophy spectrum.
Additional Links: PMID-43019707
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43019707,
year = {2026},
author = {Kutlutürk Karagöz, I and Arici, M and Koser, E and Altas, O and Ariman, S and Artunay, HO},
title = {Is pachychoroid geographic atrophy an underestimated diagnosis? A retrospective optical coherence tomography analysis.},
journal = {Journal francais d'ophtalmologie},
volume = {49},
number = {10},
pages = {105023},
doi = {10.1016/j.jfo.2026.105023},
pmid = {43019707},
issn = {1773-0597},
abstract = {PURPOSE: This study aims to evaluate potentially underestimated pachychoroid geographic atrophy (PGA) cases and their clinical characteristics among conventional geographic atrophy (CGA) patients previously diagnosed with non-neovascular age-related macular degeneration (AMD).
METHODS: Patients with non-neovascular AMD were retrospectively included. Optical coherence tomography (OCT) images served as the primary diagnostic modality. Central subfoveal choroidal thickness (CSCT), pachyvessel diameters, and areas of GA were measured on OCT slices. Pachychoroid was defined based on major and minor auxiliary criteria. CSCT>250μm was accepted as the main criterion. The presence of at least two auxiliary criteria along with the main criterion confirmed the diagnosis of pachychoroid.
RESULTS: A total of 229 non-neovascular AMD patients with geographic atrophy were included; 183 were assigned to the CGA group and 46 to the PGA group. The mean age was 77.7±9.1 years, and the PGA group was significantly younger (78.5±9.0 vs. 74.3±8.9 years; P=0.005). CSCT was significantly thinner in the CGA group (148.8±53.5 vs. 287.3±42.9; P<0.001). Pachyvessel presence in the subfoveal area was significantly higher in the PGA group [22.4% vs. 65.2%; P<0.001]. Absence of drusen was also higher in the PGA group [16.4% vs. 32.6%; P=0.013]. The PGA group showed significantly slower GA progression (P=0.012).
CONCLUSION: Recognizing PGA is essential for a more accurate clinical classification and for better understanding the prognostic differences within the geographic atrophy spectrum.},
}
RevDate: 2026-11-12
Dopaminergic Modulation and L-DOPA in Retinal Disease: A Scoping Review of Mechanistic, Preclinical, and Clinical Evidence.
Progress in retinal and eye research pii:S1350-9462(26)00109-6 [Epub ahead of print].
Additional Links: PMID-43020318
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43020318,
year = {2026},
author = {Anwar, M and Mulchandani, S and Lengyel, I and Kozak, I and McKay, BS and Lee, H and Peto, T and Curran, K},
title = {Dopaminergic Modulation and L-DOPA in Retinal Disease: A Scoping Review of Mechanistic, Preclinical, and Clinical Evidence.},
journal = {Progress in retinal and eye research},
volume = {},
number = {},
pages = {101543},
doi = {10.1016/j.preteyeres.2026.101543},
pmid = {43020318},
issn = {1873-1635},
}
RevDate: 2026-11-13
Engineered compact TnpB epigenetic editors prevent choroidal neovascularization via Vegfa repression.
Protein & cell pii:9040956 [Epub ahead of print].
Epigenetic editing enables programmable and heritable gene regulation without altering DNA sequence, yet existing platforms remain constrained by large size, cumbersome target design, and limited applicability. Here we engineered catalytically inactive ISDge10 and ISAam1 TnpB systems and developed highly compact RNA-guided epigenetic editors compatible with single adeno-associated virus (AAV) delivery for either transcriptional activation or repression. Activators based on these TnpBs (Dge10on and Aam1on) efficiently activated diverse endogenous genes in vitro, and AAV9-delivered Aam1on achieved robust pancreatic and duodenal homeobox 1 (Pdx1) activation in vivo. For gene repression, by screening 248 human Krüppel-associated box (KRAB) domains with verified effector activity, we identified the most potent effector domain for each TnpB system, resulting in the optimization of Dge10off and Aam1off. These epigenetic editors mediated durable transcriptional repression across multiple loci in diverse cell types. In a mouse model, single-AAV delivery of these editors efficiently suppressed vascular endothelial growth factor A (Vegfa) expression with no detectable activation of DNA damage response markers (γH2AX and p53), resulting in marked reductions in choroidal neovascularization area. Our study expands the epigenetic editing toolbox and provides a potentially safe and durable single-administration therapeutic strategy for wet age-related macular degeneration (wAMD).
Additional Links: PMID-43021643
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43021643,
year = {2026},
author = {Tian, X and Sun, J and Huo, Y and Ge, C and Liu, W and Li, K and Sun, W and Xiang, G and Tao, Y and Wang, H},
title = {Engineered compact TnpB epigenetic editors prevent choroidal neovascularization via Vegfa repression.},
journal = {Protein & cell},
volume = {},
number = {},
pages = {},
doi = {10.1093/procel/pwag077},
pmid = {43021643},
issn = {1674-8018},
abstract = {Epigenetic editing enables programmable and heritable gene regulation without altering DNA sequence, yet existing platforms remain constrained by large size, cumbersome target design, and limited applicability. Here we engineered catalytically inactive ISDge10 and ISAam1 TnpB systems and developed highly compact RNA-guided epigenetic editors compatible with single adeno-associated virus (AAV) delivery for either transcriptional activation or repression. Activators based on these TnpBs (Dge10on and Aam1on) efficiently activated diverse endogenous genes in vitro, and AAV9-delivered Aam1on achieved robust pancreatic and duodenal homeobox 1 (Pdx1) activation in vivo. For gene repression, by screening 248 human Krüppel-associated box (KRAB) domains with verified effector activity, we identified the most potent effector domain for each TnpB system, resulting in the optimization of Dge10off and Aam1off. These epigenetic editors mediated durable transcriptional repression across multiple loci in diverse cell types. In a mouse model, single-AAV delivery of these editors efficiently suppressed vascular endothelial growth factor A (Vegfa) expression with no detectable activation of DNA damage response markers (γH2AX and p53), resulting in marked reductions in choroidal neovascularization area. Our study expands the epigenetic editing toolbox and provides a potentially safe and durable single-administration therapeutic strategy for wet age-related macular degeneration (wAMD).},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Progression to Advanced Age-Related Macular Degeneration in Drusen-Driven and Pachychoroid-Driven Disease: The Korean Age-Related Maculopathy Study.
Ophthalmology science, 6(12):101430.
PURPOSE: To estimate the 5-year progression to advanced age-related macular degeneration (AMD), exudative AMD, or any geographic atrophy (GA), and to identify phenotype-specific risk factors in 2 preadvanced macular phenotypes: drusen-driven nonadvanced AMD and pachychoroid-driven disease.
DESIGN: Nationwide, multicenter, prospective cohort study with 5-year annual follow-up.
PARTICIPANTS: A total of 868 Korean participants with preadvanced macular disease at risk of advanced AMD in the Korean Age-Related Maculopathy Study: 551 with drusen-driven nonadvanced AMD (Arm 1) and 317 with pachychoroid-driven disease (Arm 2); 335 (196 Arm 1, 139 Arm 2) completed the 5-year follow-up.
METHODS: Phenotypes were classified by multimodal imaging, and incident exudative AMD and GA were adjudicated by retinal specialists. Two prespecified analyses were performed: a complete-case analysis of the 5-year incidence and risk factors using logistic generalized estimating equations (Analysis 1) and a full-cohort time-to-event analysis using inverse-probability-of-censoring-weighted Cox models with a competing-risk extension (Analysis 2).
MAIN OUTCOME MEASURES: Five-year incidence of, and risk factors for, exudative AMD and any GA.
RESULTS: In the complete-case cohort (Analysis 1), the 5-year incidence in Arm 1 was 20.4% (95% confidence interval [CI], 14.8-26.0) for exudative AMD and 12.2% (7.6-16.9) for GA, versus 5.0% (1.4-8.7) and 2.2% (0.5-6.2) in Arm 2. In Arm 1, large soft drusen (odds ratio [OR], 5.12; 95% CI, 1.85-14.19) and reticular pseudodrusen (RPD) (OR, 2.21; 95% CI, 1.02-4.81) were independently associated with exudative AMD and RPD (OR, 10.21; 95% CI, 3.02-34.49) with GA; large soft drusen and RPD acted additively on exudative conversion, whereas GA was driven by RPD. The full-cohort time-to-event analysis (Analysis 2) gave consistent estimates, additionally quantified a strong calcified drusen-GA association (hazard ratio [HR], 7.67; 95% CI, 2.93-20.07), and showed a lower hazard of both outcomes in Arm 2 (exudative AMD HR, 0.47; 95% CI, 0.22-1.00; GA HR, 0.13; 95% CI, 0.03-0.48). In Arm 2, pachydrusen was not associated with progression, whereas exudative conversion was confined to eyes with both pigmentary abnormality and the double-layer sign.
CONCLUSIONS: Five-year progression to advanced AMD differs by phenotype, with substantially higher risk in drusen-driven disease. Distinct biomarker profiles support drusen-driven and pachychoroid-driven disease as distinct phenotypic groups, which may inform risk stratification.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Additional Links: PMID-43022085
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022085,
year = {2026},
author = {Hwang, S and Kang, SW and Kim, SJ and Park, KH and Oh, J and Jo, YJ and Byeon, SH and Kim, JH and Son, KY and Choi, J and Sagong, M and Kim, K and Yu, SY and Duck-Jin Hwang, D and Park, YH and Lee, H and Choi, EJ and Lee, J and , },
title = {Progression to Advanced Age-Related Macular Degeneration in Drusen-Driven and Pachychoroid-Driven Disease: The Korean Age-Related Maculopathy Study.},
journal = {Ophthalmology science},
volume = {6},
number = {12},
pages = {101430},
pmid = {43022085},
issn = {2666-9145},
abstract = {PURPOSE: To estimate the 5-year progression to advanced age-related macular degeneration (AMD), exudative AMD, or any geographic atrophy (GA), and to identify phenotype-specific risk factors in 2 preadvanced macular phenotypes: drusen-driven nonadvanced AMD and pachychoroid-driven disease.
DESIGN: Nationwide, multicenter, prospective cohort study with 5-year annual follow-up.
PARTICIPANTS: A total of 868 Korean participants with preadvanced macular disease at risk of advanced AMD in the Korean Age-Related Maculopathy Study: 551 with drusen-driven nonadvanced AMD (Arm 1) and 317 with pachychoroid-driven disease (Arm 2); 335 (196 Arm 1, 139 Arm 2) completed the 5-year follow-up.
METHODS: Phenotypes were classified by multimodal imaging, and incident exudative AMD and GA were adjudicated by retinal specialists. Two prespecified analyses were performed: a complete-case analysis of the 5-year incidence and risk factors using logistic generalized estimating equations (Analysis 1) and a full-cohort time-to-event analysis using inverse-probability-of-censoring-weighted Cox models with a competing-risk extension (Analysis 2).
MAIN OUTCOME MEASURES: Five-year incidence of, and risk factors for, exudative AMD and any GA.
RESULTS: In the complete-case cohort (Analysis 1), the 5-year incidence in Arm 1 was 20.4% (95% confidence interval [CI], 14.8-26.0) for exudative AMD and 12.2% (7.6-16.9) for GA, versus 5.0% (1.4-8.7) and 2.2% (0.5-6.2) in Arm 2. In Arm 1, large soft drusen (odds ratio [OR], 5.12; 95% CI, 1.85-14.19) and reticular pseudodrusen (RPD) (OR, 2.21; 95% CI, 1.02-4.81) were independently associated with exudative AMD and RPD (OR, 10.21; 95% CI, 3.02-34.49) with GA; large soft drusen and RPD acted additively on exudative conversion, whereas GA was driven by RPD. The full-cohort time-to-event analysis (Analysis 2) gave consistent estimates, additionally quantified a strong calcified drusen-GA association (hazard ratio [HR], 7.67; 95% CI, 2.93-20.07), and showed a lower hazard of both outcomes in Arm 2 (exudative AMD HR, 0.47; 95% CI, 0.22-1.00; GA HR, 0.13; 95% CI, 0.03-0.48). In Arm 2, pachydrusen was not associated with progression, whereas exudative conversion was confined to eyes with both pigmentary abnormality and the double-layer sign.
CONCLUSIONS: Five-year progression to advanced AMD differs by phenotype, with substantially higher risk in drusen-driven disease. Distinct biomarker profiles support drusen-driven and pachychoroid-driven disease as distinct phenotypic groups, which may inform risk stratification.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
From homeostasis to neurodegeneration: Müller glia in retinal disease.
Frontiers in cell and developmental biology, 14:1980008.
Müller glia are the principal macroglia cells of the retina and are essential for maintaining structural, metabolic, synaptic, and vascular homeostasis. They regulate neurotransmitter recycling, ion and water balance, antioxidant defense, and neurovascular coupling, positioning them as central coordinators of retinal function in health and disease. In response to injury or stress, Müller glia transition from homeostatic support to reactive states that may initially preserve tissue integrity but, when sustained, contribute to chronic neuroinflammation, barrier dysfunction, and neuronal degeneration. In this review, we examine the core physiological functions of Müller glia and highlight emerging evidence that their responses are heterogeneous, reflecting spatial, molecular, and disease-specific differences across retinal layers and pathological contexts. We discuss major drivers of Müller glia activation, including mechanical stress, metabolic and oxidative imbalance, and inflammatory signaling, with emphasis on convergent pathways such as gp130-JAK-STAT3, NFκB, and mechanosensitive calcium signaling. We then consider how disruption of Müller glia homeostatic functions contributes to retinal disease, focusing on glaucoma, diabetic retinopathy, and age-related macular degeneration. Across these disorders, Müller glia emerge not as passive support cells, but as active regulators of neuronal and vascular microenvironments whose state of transition may shape disease progression. Finally, we discuss therapeutic strategies aimed at modulating Müller glia states, including lipid metabolism and signaling, restoration of ion and metabolic homeostasis, gene-based targeting, and regenerative reprogramming, and consider how single-cell, spatial, and multi-omic approaches define distinct layers of Müller glia state. Defining when and how Müller glia shift from adaptive to maladaptive states will be critical for developing therapies that restore retinal homeostasis and limit neurodegeneration.
Additional Links: PMID-43022721
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43022721,
year = {2026},
author = {Kumar, M and Karnam, S and Flanagan, JG and Gronert, K},
title = {From homeostasis to neurodegeneration: Müller glia in retinal disease.},
journal = {Frontiers in cell and developmental biology},
volume = {14},
number = {},
pages = {1980008},
pmid = {43022721},
issn = {2296-634X},
abstract = {Müller glia are the principal macroglia cells of the retina and are essential for maintaining structural, metabolic, synaptic, and vascular homeostasis. They regulate neurotransmitter recycling, ion and water balance, antioxidant defense, and neurovascular coupling, positioning them as central coordinators of retinal function in health and disease. In response to injury or stress, Müller glia transition from homeostatic support to reactive states that may initially preserve tissue integrity but, when sustained, contribute to chronic neuroinflammation, barrier dysfunction, and neuronal degeneration. In this review, we examine the core physiological functions of Müller glia and highlight emerging evidence that their responses are heterogeneous, reflecting spatial, molecular, and disease-specific differences across retinal layers and pathological contexts. We discuss major drivers of Müller glia activation, including mechanical stress, metabolic and oxidative imbalance, and inflammatory signaling, with emphasis on convergent pathways such as gp130-JAK-STAT3, NFκB, and mechanosensitive calcium signaling. We then consider how disruption of Müller glia homeostatic functions contributes to retinal disease, focusing on glaucoma, diabetic retinopathy, and age-related macular degeneration. Across these disorders, Müller glia emerge not as passive support cells, but as active regulators of neuronal and vascular microenvironments whose state of transition may shape disease progression. Finally, we discuss therapeutic strategies aimed at modulating Müller glia states, including lipid metabolism and signaling, restoration of ion and metabolic homeostasis, gene-based targeting, and regenerative reprogramming, and consider how single-cell, spatial, and multi-omic approaches define distinct layers of Müller glia state. Defining when and how Müller glia shift from adaptive to maladaptive states will be critical for developing therapies that restore retinal homeostasis and limit neurodegeneration.},
}
RevDate: 2026-11-13
CmpDate: 2026-11-13
Epivascular glia mimicking drusen in dry age related macular degeneration.
American journal of ophthalmology case reports, 44:102694.
PURPOSE: We describe a case of epivascular glia (EVG) masquerading as dry age-related macular degeneration (AMD).
OBSERVATIONS: A 64-year-old healthy man with 20/20 vision bilaterally was referred for evaluation of macular lesions thought to be drusen due to dry AMD. Fundus autofluorescence (FAF) was unremarkable, indicating preserved retinal pigment epithelium (RPE) and photoreceptor integrity. Spectral-domain optical coherence tomography (SD-OCT) demonstrated a normal ellipsoid zone and intact RPE without evidence of drusen but revealed hyperreflective epivascular material that co-localized with the findings on near infrared reflectance and on clinical examination. En face OCT segmented at the level of the internal limiting membrane showed hyperreflectivity corresponding to the macular lesions on near infrared reflectance and on clinical examination.
CONCLUSIONS AND IMPORTANCE: These lesions are consistent with benign epivascular glia, presumably a Muller cell derived entity, underscoring the value of recognizing this entity and use of multimodal imaging in avoiding misdiagnosis of AMD.
Additional Links: PMID-43023183
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43023183,
year = {2026},
author = {Bagheri, S and Quarta, A and Abbasgholizadeh, R and Forte, P and Feo, A and Sadda, S and Sarraf, D and Ip, M},
title = {Epivascular glia mimicking drusen in dry age related macular degeneration.},
journal = {American journal of ophthalmology case reports},
volume = {44},
number = {},
pages = {102694},
pmid = {43023183},
issn = {2451-9936},
abstract = {PURPOSE: We describe a case of epivascular glia (EVG) masquerading as dry age-related macular degeneration (AMD).
OBSERVATIONS: A 64-year-old healthy man with 20/20 vision bilaterally was referred for evaluation of macular lesions thought to be drusen due to dry AMD. Fundus autofluorescence (FAF) was unremarkable, indicating preserved retinal pigment epithelium (RPE) and photoreceptor integrity. Spectral-domain optical coherence tomography (SD-OCT) demonstrated a normal ellipsoid zone and intact RPE without evidence of drusen but revealed hyperreflective epivascular material that co-localized with the findings on near infrared reflectance and on clinical examination. En face OCT segmented at the level of the internal limiting membrane showed hyperreflectivity corresponding to the macular lesions on near infrared reflectance and on clinical examination.
CONCLUSIONS AND IMPORTANCE: These lesions are consistent with benign epivascular glia, presumably a Muller cell derived entity, underscoring the value of recognizing this entity and use of multimodal imaging in avoiding misdiagnosis of AMD.},
}
RevDate: 2026-11-13
Registry-based definition of neovascular age-related macular degeneration in Denmark: A nationwide multicentre validation study.
Acta ophthalmologica [Epub ahead of print].
PURPOSE: Neovascular age-related macular degeneration (AMD) is a common chronic disease with substantial societal impact. The validity of approaches to identify neovascular AMD in the Danish National Patient Registry (DNPR) remains uncertain. We evaluated the accuracy of different registry-based definitions for identifying patients with neovascular AMD.
METHODS: Patients with and without neovascular AMD were identified through medical record review at hospital-based ophthalmology departments and private practice ophthalmologists across all five Danish regions. Three registry-based definitions were evaluated: Model 1: ICD-10 H353J or H353K; Model 2: H353J or H353K combined with either of the intravitreal procedure codes KCKD05 or KCKD05B; Model 3: H353 or H353J or H353K combined with either of the intravitreal procedure codes KCKD05 or KCKD05B. Sensitivity, specificity, and accuracy were calculated using medical record review as the reference standard. Analyses were performed overall and stratified by hospital-based ophthalmology departments and private practice ophthalmologists.
RESULTS: We included 571 individuals (306 with and 265 without neovascular AMD). All three definitions demonstrated >90% sensitivity, specificity, and accuracy overall. H353 or H353J or H353K combined with an intravitreal procedure code had the highest observed sensitivity and accuracy (sensitivity 98.0%, specificity 98.9%, and accuracy 98.4%). Stratified analyses demonstrated high diagnostic validity in both hospital-based ophthalmology departments and private practice ophthalmology clinics.
CONCLUSION: Registry-based definitions of neovascular AMD in the DNPR demonstrated high diagnostic validity overall and across both hospital-based and private ophthalmology settings. H353 or H353J or H353K combined with an intravitreal procedure code provided the highest sensitivity and accuracy while maintaining high specificity, suggesting that this definition may reduce under-ascertainment of treated neovascular AMD in contemporary Danish registry-based studies.
Additional Links: PMID-43023810
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43023810,
year = {2026},
author = {Schou, MG and Stokholm, L and Andresen, JL and Arnold-Vangsted, A and Datta, N and Hyldgaard, MT and Klefter, ON and Schneider, M and Sørensen, TL and Spangsberg, M and Thinggaard, BS and Vorum, H and Grauslund, J and Subhi, Y},
title = {Registry-based definition of neovascular age-related macular degeneration in Denmark: A nationwide multicentre validation study.},
journal = {Acta ophthalmologica},
volume = {},
number = {},
pages = {},
doi = {10.1111/aos.70273},
pmid = {43023810},
issn = {1755-3768},
support = {00063467//Velux Foundation/ ; },
abstract = {PURPOSE: Neovascular age-related macular degeneration (AMD) is a common chronic disease with substantial societal impact. The validity of approaches to identify neovascular AMD in the Danish National Patient Registry (DNPR) remains uncertain. We evaluated the accuracy of different registry-based definitions for identifying patients with neovascular AMD.
METHODS: Patients with and without neovascular AMD were identified through medical record review at hospital-based ophthalmology departments and private practice ophthalmologists across all five Danish regions. Three registry-based definitions were evaluated: Model 1: ICD-10 H353J or H353K; Model 2: H353J or H353K combined with either of the intravitreal procedure codes KCKD05 or KCKD05B; Model 3: H353 or H353J or H353K combined with either of the intravitreal procedure codes KCKD05 or KCKD05B. Sensitivity, specificity, and accuracy were calculated using medical record review as the reference standard. Analyses were performed overall and stratified by hospital-based ophthalmology departments and private practice ophthalmologists.
RESULTS: We included 571 individuals (306 with and 265 without neovascular AMD). All three definitions demonstrated >90% sensitivity, specificity, and accuracy overall. H353 or H353J or H353K combined with an intravitreal procedure code had the highest observed sensitivity and accuracy (sensitivity 98.0%, specificity 98.9%, and accuracy 98.4%). Stratified analyses demonstrated high diagnostic validity in both hospital-based ophthalmology departments and private practice ophthalmology clinics.
CONCLUSION: Registry-based definitions of neovascular AMD in the DNPR demonstrated high diagnostic validity overall and across both hospital-based and private ophthalmology settings. H353 or H353J or H353K combined with an intravitreal procedure code provided the highest sensitivity and accuracy while maintaining high specificity, suggesting that this definition may reduce under-ascertainment of treated neovascular AMD in contemporary Danish registry-based studies.},
}
RevDate: 2026-11-12
CmpDate: 2026-11-11
Metabolic mediators linking gut microbiota to age-related macular degeneration: A Mendelian randomization study.
Medicine, 105(44):e51352.
The gut microbiota (GM) plays a crucial role in maintaining homeostasis, and emerging evidence suggests its involvement in ocular health through the gut-eye axis. Given that metabolites have been implicated in age-related macular degeneration (AMD) and GM can influence metabolic processes, we hypothesized that GM may contribute to AMD risk via specific metabolic pathways. We utilized summary statistics from large genome-wide association studies in European populations. A two-sample Mendelian randomization analysis was conducted to assess the causal relationships between GM, circulating metabolites, and AMD risk. Additionally, a two-step Mendelian randomization approach was applied to investigate metabolites as potential mediators in the GM-AMD relationship. We identified 22 gut microbial taxa and 59 metabolites significantly associated with AMD risk. Mediation analysis further revealed 21 potential metabolic pathways linking GM to AMD development. These findings suggest that GM may influence AMD pathogenesis by modulating circulating metabolites. The identified metabolites could serve as potential biomarkers for AMD risk stratification, while also offering insights into the underlying biological mechanisms, providing a foundation for future research and therapeutic interventions.
Additional Links: PMID-43012772
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43012772,
year = {2026},
author = {Wang, G and Li, Y and Su, J and Lu, X},
title = {Metabolic mediators linking gut microbiota to age-related macular degeneration: A Mendelian randomization study.},
journal = {Medicine},
volume = {105},
number = {44},
pages = {e51352},
pmid = {43012772},
issn = {1536-5964},
mesh = {*Macular Degeneration/metabolism/genetics/microbiology ; Humans ; Mendelian Randomization Analysis ; *Gastrointestinal Microbiome/genetics/physiology ; Genome-Wide Association Study ; Biomarkers ; Metabolic Networks and Pathways ; Risk Factors ; },
abstract = {The gut microbiota (GM) plays a crucial role in maintaining homeostasis, and emerging evidence suggests its involvement in ocular health through the gut-eye axis. Given that metabolites have been implicated in age-related macular degeneration (AMD) and GM can influence metabolic processes, we hypothesized that GM may contribute to AMD risk via specific metabolic pathways. We utilized summary statistics from large genome-wide association studies in European populations. A two-sample Mendelian randomization analysis was conducted to assess the causal relationships between GM, circulating metabolites, and AMD risk. Additionally, a two-step Mendelian randomization approach was applied to investigate metabolites as potential mediators in the GM-AMD relationship. We identified 22 gut microbial taxa and 59 metabolites significantly associated with AMD risk. Mediation analysis further revealed 21 potential metabolic pathways linking GM to AMD development. These findings suggest that GM may influence AMD pathogenesis by modulating circulating metabolites. The identified metabolites could serve as potential biomarkers for AMD risk stratification, while also offering insights into the underlying biological mechanisms, providing a foundation for future research and therapeutic interventions.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Macular Degeneration/metabolism/genetics/microbiology
Humans
Mendelian Randomization Analysis
*Gastrointestinal Microbiome/genetics/physiology
Genome-Wide Association Study
Biomarkers
Metabolic Networks and Pathways
Risk Factors
RevDate: 2026-11-11
Extrafoveal type 1 macular neovascularisations presenting as pigmentary abnormalities.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Epub ahead of print].
PURPOSE: To describe the clinical and multimodal imaging characteristics of extrafoveal type 1 macular neovascularisations (MNV) presenting as pigmentary abnormalities.
METHODS: This retrospective longitudinal study included 10 eyes from 10 patients (3 females) with asymptomatic type 1 macular neovascularisation located along the temporal vascular arcades. The median age was 75 years (interquartile range, 63-79). All patients underwent best-corrected visual acuity (BCVA) assessment, optical coherence tomography (OCT), OCT angiography (OCTA), and short-wavelength fundus autofluorescence (SW-AF). Fluorescein angiography (FA) and indocyanine green angiography (ICGA) were performed in selected cases.
RESULTS: On OCT, all lesions corresponded to flat irregular pigment epithelium detachments (FIPEDs); eight were non-exudative, while two showed minimal subretinal fluid. Dilated choroidal vessels beneath the MNV were observed in seven of ten eyes. OCTA identified neovascular networks in all cases. Over a median follow-up of 33 months (range, 6-114), all patients remained asymptomatic, with no development of new intraretinal or subretinal fluid, despite the absence of intravitreal treatment.
CONCLUSION: Extrafoveal pigmentary abnormalities may harbour asymptomatic MNV in eyes with pachychoroid features, with or without coexisting signs of age-related macular degeneration. OCTA is essential for identification of these lesions, which followed an asymptomatic, low-exudative course over the follow-up.
Additional Links: PMID-43013074
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43013074,
year = {2026},
author = {Antropoli, A and Deiro, AP and Bianco, L and Del Fabbro, S and Arrigo, A and Ricciotti, G and Loperfido, F and Bandello, F and Cicinelli, MV and Coppola, M and Parodi, MB},
title = {Extrafoveal type 1 macular neovascularisations presenting as pigmentary abnormalities.},
journal = {Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie},
volume = {},
number = {},
pages = {},
pmid = {43013074},
issn = {1435-702X},
abstract = {PURPOSE: To describe the clinical and multimodal imaging characteristics of extrafoveal type 1 macular neovascularisations (MNV) presenting as pigmentary abnormalities.
METHODS: This retrospective longitudinal study included 10 eyes from 10 patients (3 females) with asymptomatic type 1 macular neovascularisation located along the temporal vascular arcades. The median age was 75 years (interquartile range, 63-79). All patients underwent best-corrected visual acuity (BCVA) assessment, optical coherence tomography (OCT), OCT angiography (OCTA), and short-wavelength fundus autofluorescence (SW-AF). Fluorescein angiography (FA) and indocyanine green angiography (ICGA) were performed in selected cases.
RESULTS: On OCT, all lesions corresponded to flat irregular pigment epithelium detachments (FIPEDs); eight were non-exudative, while two showed minimal subretinal fluid. Dilated choroidal vessels beneath the MNV were observed in seven of ten eyes. OCTA identified neovascular networks in all cases. Over a median follow-up of 33 months (range, 6-114), all patients remained asymptomatic, with no development of new intraretinal or subretinal fluid, despite the absence of intravitreal treatment.
CONCLUSION: Extrafoveal pigmentary abnormalities may harbour asymptomatic MNV in eyes with pachychoroid features, with or without coexisting signs of age-related macular degeneration. OCTA is essential for identification of these lesions, which followed an asymptomatic, low-exudative course over the follow-up.},
}
RevDate: 2026-11-12
Enhancing Foundation Models for AMD Detection with Controllable OCT-B Synthetic Image Generation.
IEEE journal of biomedical and health informatics, PP: [Epub ahead of print].
Age-Related Macular Degeneration (AMD) is a primary cause of central blindness worldwide, affecting over 200 million people, a figure expected to reach 300 million by 2040. The main tool for managing AMD is the Optical Coherence Tomography (OCT-B) scan. Automating analysis of these scans with FMs is promising, but performance is fundamentally constrained by the scarcity of diverse, well-annotated data. To address this bottleneck, we present a dedicated pipeline for the fine-grained, controllable generation of high-utility OCT-B scans specifically for AMD pathology. Our method employs a dual conditioning strategy, integrating a Stable Diffusion backbone with a ControlNet. This enables precise control by coupling (1) quantitative, biomarker-focused text prompts (Biomarker-to-Prompt Conditioning) with (2) image conditioning of biomarker location (Biomarker-to-Mask Conditioning). We evaluated this framework by measuring its downstream clinical utility and perceptual fidelity. In a challenging, low-data, out-of-distribution (OOD) scenario, augmenting a real dataset with our synthetic images improved the AMD classification F1-score of the RETFound FM by 38.3% (from 0.619 to 0.856).
Additional Links: PMID-43013433
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43013433,
year = {2026},
author = {Castro, B and Mesquita, G and Facoco, I and Rosado, L and Soares, F},
title = {Enhancing Foundation Models for AMD Detection with Controllable OCT-B Synthetic Image Generation.},
journal = {IEEE journal of biomedical and health informatics},
volume = {PP},
number = {},
pages = {},
doi = {10.1109/JBHI.2026.3752249},
pmid = {43013433},
issn = {2168-2208},
abstract = {Age-Related Macular Degeneration (AMD) is a primary cause of central blindness worldwide, affecting over 200 million people, a figure expected to reach 300 million by 2040. The main tool for managing AMD is the Optical Coherence Tomography (OCT-B) scan. Automating analysis of these scans with FMs is promising, but performance is fundamentally constrained by the scarcity of diverse, well-annotated data. To address this bottleneck, we present a dedicated pipeline for the fine-grained, controllable generation of high-utility OCT-B scans specifically for AMD pathology. Our method employs a dual conditioning strategy, integrating a Stable Diffusion backbone with a ControlNet. This enables precise control by coupling (1) quantitative, biomarker-focused text prompts (Biomarker-to-Prompt Conditioning) with (2) image conditioning of biomarker location (Biomarker-to-Mask Conditioning). We evaluated this framework by measuring its downstream clinical utility and perceptual fidelity. In a challenging, low-data, out-of-distribution (OOD) scenario, augmenting a real dataset with our synthetic images improved the AMD classification F1-score of the RETFound FM by 38.3% (from 0.619 to 0.856).},
}
RevDate: 2026-11-12
Keratoconus - Common, yet uncommon.
Acta ophthalmologica [Epub ahead of print].
In this Acta Ophthalmologica Award and Gold Medal Honorary Lecture (the Lundsgaard Gold Medal Honorary Lecture) I will summarize and review the work on the elusive corneal disease keratoconus (KC) I have carried out together with collaborators and research students over more than 30 years. It has been a long journey, from basic biochemical work to clinical studies comparing and evaluating different regimens for corneal crosslinking. KC is a bilateral, albeit usually asymmetric, progressive ectatic corneal disorder, in which the cornea becomes thinner and regionally biomechanically weaker. Due to the intraocular pressure the weakest part of the cornea is extruded, forming a central or paracentral cone, which in turn generates irregular optical aberrations and deterioration of the quality of vision. KC has traditionally been considered a noninflammatory, rather rare corneal degeneration, but over the past decades such a description has become increasingly difficult to defend. KC shares many biochemical features with inflammatory diseases for example in the pattern of cytokine expression and is-at least according to some studies-associated with atopic dermatitis and eye rubbing. Furthermore, with the emerge of modern corneal imaging techniques, an increasing number of KC cases is discovered today, and today's consensus is that KC should be considered as a relatively common eye disease with a prevalence "approaching" 1:300. It typically begins during adolescence or early adulthood and progresses until the age of 30-35. Thus-in contrast to many of the major causes of visual impairment such as cataract, glaucoma and age-related macular degeneration-KC is uncommon, almost unique, in being predominantly a disease of young people. I have spent the past 30 odd years trying to understand this intriguing corneal degeneration and will try to explain why and how in this article.
Additional Links: PMID-43017756
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43017756,
year = {2026},
author = {Behndig, A},
title = {Keratoconus - Common, yet uncommon.},
journal = {Acta ophthalmologica},
volume = {},
number = {},
pages = {},
doi = {10.1111/aos.70269},
pmid = {43017756},
issn = {1755-3768},
support = {//Ögonfonden/ ; //Cronqvists Stiftelse/ ; //Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för Synskadade/ ; //Region Västerbotten/ ; },
abstract = {In this Acta Ophthalmologica Award and Gold Medal Honorary Lecture (the Lundsgaard Gold Medal Honorary Lecture) I will summarize and review the work on the elusive corneal disease keratoconus (KC) I have carried out together with collaborators and research students over more than 30 years. It has been a long journey, from basic biochemical work to clinical studies comparing and evaluating different regimens for corneal crosslinking. KC is a bilateral, albeit usually asymmetric, progressive ectatic corneal disorder, in which the cornea becomes thinner and regionally biomechanically weaker. Due to the intraocular pressure the weakest part of the cornea is extruded, forming a central or paracentral cone, which in turn generates irregular optical aberrations and deterioration of the quality of vision. KC has traditionally been considered a noninflammatory, rather rare corneal degeneration, but over the past decades such a description has become increasingly difficult to defend. KC shares many biochemical features with inflammatory diseases for example in the pattern of cytokine expression and is-at least according to some studies-associated with atopic dermatitis and eye rubbing. Furthermore, with the emerge of modern corneal imaging techniques, an increasing number of KC cases is discovered today, and today's consensus is that KC should be considered as a relatively common eye disease with a prevalence "approaching" 1:300. It typically begins during adolescence or early adulthood and progresses until the age of 30-35. Thus-in contrast to many of the major causes of visual impairment such as cataract, glaucoma and age-related macular degeneration-KC is uncommon, almost unique, in being predominantly a disease of young people. I have spent the past 30 odd years trying to understand this intriguing corneal degeneration and will try to explain why and how in this article.},
}
RevDate: 2026-11-12
A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020-present).
Expert opinion on therapeutic patents [Epub ahead of print].
INTRODUCTION: Anti-VEGF therapy remains central to the management of neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, but treatment burden and limited durability remain major unmet needs. This review examines how recent patenting has shifted from first-generation anti-VEGF binders toward approaches designed to extend intraocular durability and strengthen product differentiation.
AREAS COVERED: This article reviews the patent landscape for antibody-based VEGF inhibition in ophthalmology from 1 January 2020 to 18 September 2026. Patent databases of the World Intellectual Property Organization (WIPO), US Patent and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA) were searched for composition-of-matter, formulation, method-of-treatment, and delivery claims. The review covers bispecific antibodies, antibody-biopolymer conjugates, gene-encoded antibody fragments, and high-concentration ophthalmic formulations, with relevant clinical programs used to provide context.
EXPERT OPINION: Anti-VEGF antibody patenting is now driven mainly by durability rather than by new binding targets alone. Over the next few years, competitive advantage is likely to depend on the successful integration of molecular format, formulation, delivery, and manufacturability into clinically reliable long-acting products.
Additional Links: PMID-43018387
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43018387,
year = {2026},
author = {Panos, GD},
title = {A patent review of anti‑VEGF antibodies for the treatment of ocular diseases (2020-present).},
journal = {Expert opinion on therapeutic patents},
volume = {},
number = {},
pages = {1-18},
doi = {10.1080/13543776.2026.2760557},
pmid = {43018387},
issn = {1744-7674},
abstract = {INTRODUCTION: Anti-VEGF therapy remains central to the management of neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, but treatment burden and limited durability remain major unmet needs. This review examines how recent patenting has shifted from first-generation anti-VEGF binders toward approaches designed to extend intraocular durability and strengthen product differentiation.
AREAS COVERED: This article reviews the patent landscape for antibody-based VEGF inhibition in ophthalmology from 1 January 2020 to 18 September 2026. Patent databases of the World Intellectual Property Organization (WIPO), US Patent and Trademark Office (USPTO), European Patent Office (EPO), Japan Patent Office (JPO), and China National Intellectual Property Administration (CNIPA) were searched for composition-of-matter, formulation, method-of-treatment, and delivery claims. The review covers bispecific antibodies, antibody-biopolymer conjugates, gene-encoded antibody fragments, and high-concentration ophthalmic formulations, with relevant clinical programs used to provide context.
EXPERT OPINION: Anti-VEGF antibody patenting is now driven mainly by durability rather than by new binding targets alone. Over the next few years, competitive advantage is likely to depend on the successful integration of molecular format, formulation, delivery, and manufacturability into clinically reliable long-acting products.},
}
RevDate: 2026-11-12
CmpDate: 2026-11-12
Epigenetic regulation of the complement system in age-related chronic inflammation: mechanisms and therapeutic prospects.
Molecular biology reports, 53(1):.
Aging is accompanied by progressive changes in epigenetic regulation, immune function, and tissue homeostasis, which may contribute to chronic low-grade inflammation and age-related disease. The complement system is an important component of innate immunity and participates in immune surveillance, tissue homeostasis, and inflammatory regulation. Increasing evidence suggests that DNA methylation, histone modifications, and non-coding RNAs can influence the expression of complement components and regulatory proteins, while complement-associated inflammatory signaling may reciprocally affect cellular epigenetic states. In this review, we summarize current evidence linking epigenetic regulation with complement biology during aging and discuss how this relationship varies across tissues and disease contexts. Particular attention is given to the central nervous system, where complement-dependent synaptic remodeling can support physiological circuit refinement but may become excessive or dysregulated under pathological conditions. We further examine the epigenetic-complement relationship in Alzheimer's disease, age-related macular degeneration, and atherosclerosis, and consider age-associated clonal hematopoiesis as a potential modifier of myeloid and inflammatory states. Rather than proposing a uniform linear pathway from epigenetic aging to complement activation and disease, we propose a context-dependent framework in which age-associated epigenetic remodeling may coexist with physiological adaptation or, under specific genetic, metabolic, environmental, cellular, and tissue contexts, contribute to reduced regulatory reserve and persistent complement-associated inflammation. This framework highlights the potential of cell-, tissue-, and disease-stage-specific strategies targeting the epigenetic-complement axis while preserving physiological complement functions.
Additional Links: PMID-43018660
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43018660,
year = {2026},
author = {Wang, Y and Zhao, H and Kong, M and Qin, K and Teng, Y and Zhu, Z and Li, Y and Liu, D and Cui, L and Sun, Y},
title = {Epigenetic regulation of the complement system in age-related chronic inflammation: mechanisms and therapeutic prospects.},
journal = {Molecular biology reports},
volume = {53},
number = {1},
pages = {},
pmid = {43018660},
issn = {1573-4978},
support = {#82371153 and #82571317//the National Natural Science Foundation of China/ ; #ZR2022QH073 and #ZR2025MS1188//the Natural Science Foundation of Shandong Province/ ; #ZR2025LZ044//Natural Science Foundation of Yantai/ ; },
mesh = {Humans ; *Epigenesis, Genetic ; *Inflammation/genetics/immunology ; *Aging/genetics/immunology ; *Complement System Proteins/genetics/metabolism ; Animals ; DNA Methylation/genetics ; Alzheimer Disease/genetics/immunology ; Complement Activation/genetics ; Macular Degeneration/genetics ; Chronic Disease ; },
abstract = {Aging is accompanied by progressive changes in epigenetic regulation, immune function, and tissue homeostasis, which may contribute to chronic low-grade inflammation and age-related disease. The complement system is an important component of innate immunity and participates in immune surveillance, tissue homeostasis, and inflammatory regulation. Increasing evidence suggests that DNA methylation, histone modifications, and non-coding RNAs can influence the expression of complement components and regulatory proteins, while complement-associated inflammatory signaling may reciprocally affect cellular epigenetic states. In this review, we summarize current evidence linking epigenetic regulation with complement biology during aging and discuss how this relationship varies across tissues and disease contexts. Particular attention is given to the central nervous system, where complement-dependent synaptic remodeling can support physiological circuit refinement but may become excessive or dysregulated under pathological conditions. We further examine the epigenetic-complement relationship in Alzheimer's disease, age-related macular degeneration, and atherosclerosis, and consider age-associated clonal hematopoiesis as a potential modifier of myeloid and inflammatory states. Rather than proposing a uniform linear pathway from epigenetic aging to complement activation and disease, we propose a context-dependent framework in which age-associated epigenetic remodeling may coexist with physiological adaptation or, under specific genetic, metabolic, environmental, cellular, and tissue contexts, contribute to reduced regulatory reserve and persistent complement-associated inflammation. This framework highlights the potential of cell-, tissue-, and disease-stage-specific strategies targeting the epigenetic-complement axis while preserving physiological complement functions.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Epigenesis, Genetic
*Inflammation/genetics/immunology
*Aging/genetics/immunology
*Complement System Proteins/genetics/metabolism
Animals
DNA Methylation/genetics
Alzheimer Disease/genetics/immunology
Complement Activation/genetics
Macular Degeneration/genetics
Chronic Disease
RevDate: 2026-11-09
Doyne honeycomb retinal dystrophy with primary angle closure: a case report.
Documenta ophthalmologica. Advances in ophthalmology [Epub ahead of print].
OBJECTIVE: To report a clinical case of Doyne honeycomb retinal dystrophy (DHRD) caused by an EFEMP1 gene mutation complicated by primary angle closure, and to discuss its clinical characteristics, reasons for misdiagnosis, and therapeutic challenges.
METHODS: The clinical data of a 53-year-old male patient were retrospectively analyzed. The patient presented with binocular metamorphopsia and decreased visual acuity persisting for over 9 years. He had been previously misdiagnosed with "macular degeneration" and "macular edema" and received corresponding treatments for a prolonged period. During the current consultation, multimodal fundus imaging (FFA/ICGA/OCT), ultrasound biomicroscopy (UBM), and ophthalmic genetic testing were performed.
RESULTS: Fundus examination and imaging revealed characteristic radial drusen in the posterior pole and nasal to the optic disc, retinal pigment epithelium (RPE) atrophy, and secondary choroidal neovascularization (CNV) in the macular region. Genetic testing identified a heterozygous c.1033C>T (p.Arg345Trp) variant in the EFEMP1 gene, confirming the diagnosis of DHRD. The patient was also diagnosed with primary angle closure due to bilateral angle closure/narrowing and initially underwent bilateral laser peripheral iridotomy (LPI). Subsequently, intravitreal injections of faricimab were administered for the secondary CNV. However, due to the advanced stage of the disease, severe disruption of retinal structures, and fibrosis, no significant improvement was observed in visual acuity or anatomical structure.
CONCLUSION: The clinical manifestations of DHRD significantly overlap with age-related macular degeneration (AMD), leading to a high risk of misdiagnosis. For patients with early onset (< 50 years) and typical drusen nasal to the optic disc, genetic testing is crucial for confirmation. This case presents a rare concurrence of primary angle closure, differing from the previously reported association with open-angle glaucoma, which adds to the therapeutic complexity. Furthermore, the limited response observed in this patient may be attributed to the advanced atrophic and cicatricial macular changes, rather than indicating generalized resistance to anti-VEGF therapy in late-stage DHRD, highlighting the importance of early precise diagnosis and comprehensive management.
Additional Links: PMID-43002290
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43002290,
year = {2026},
author = {Xu, C and Ye, H},
title = {Doyne honeycomb retinal dystrophy with primary angle closure: a case report.},
journal = {Documenta ophthalmologica. Advances in ophthalmology},
volume = {},
number = {},
pages = {},
pmid = {43002290},
issn = {1573-2622},
support = {82474580//National Natural Science Foundation of China/ ; },
abstract = {OBJECTIVE: To report a clinical case of Doyne honeycomb retinal dystrophy (DHRD) caused by an EFEMP1 gene mutation complicated by primary angle closure, and to discuss its clinical characteristics, reasons for misdiagnosis, and therapeutic challenges.
METHODS: The clinical data of a 53-year-old male patient were retrospectively analyzed. The patient presented with binocular metamorphopsia and decreased visual acuity persisting for over 9 years. He had been previously misdiagnosed with "macular degeneration" and "macular edema" and received corresponding treatments for a prolonged period. During the current consultation, multimodal fundus imaging (FFA/ICGA/OCT), ultrasound biomicroscopy (UBM), and ophthalmic genetic testing were performed.
RESULTS: Fundus examination and imaging revealed characteristic radial drusen in the posterior pole and nasal to the optic disc, retinal pigment epithelium (RPE) atrophy, and secondary choroidal neovascularization (CNV) in the macular region. Genetic testing identified a heterozygous c.1033C>T (p.Arg345Trp) variant in the EFEMP1 gene, confirming the diagnosis of DHRD. The patient was also diagnosed with primary angle closure due to bilateral angle closure/narrowing and initially underwent bilateral laser peripheral iridotomy (LPI). Subsequently, intravitreal injections of faricimab were administered for the secondary CNV. However, due to the advanced stage of the disease, severe disruption of retinal structures, and fibrosis, no significant improvement was observed in visual acuity or anatomical structure.
CONCLUSION: The clinical manifestations of DHRD significantly overlap with age-related macular degeneration (AMD), leading to a high risk of misdiagnosis. For patients with early onset (< 50 years) and typical drusen nasal to the optic disc, genetic testing is crucial for confirmation. This case presents a rare concurrence of primary angle closure, differing from the previously reported association with open-angle glaucoma, which adds to the therapeutic complexity. Furthermore, the limited response observed in this patient may be attributed to the advanced atrophic and cicatricial macular changes, rather than indicating generalized resistance to anti-VEGF therapy in late-stage DHRD, highlighting the importance of early precise diagnosis and comprehensive management.},
}
RevDate: 2026-11-12
CmpDate: 2026-11-10
Multiple pit-drilling phacoemulsification for complex hard nucleus cataract in elderly patients: a case report.
BMC ophthalmology, 26(1):.
BACKGROUND: Ultra-elderly patients with small pupils, shallow anterior chambers and gradeⅤbrunescent nuclear cataract represent an extremely high-risk subtype of cataract surgery, with markedly elevated risks of intraoperative complications including corneal endothelial injury, posterior capsule rupture, nucleus descent and Descemet's membrane detachment. Conventional pre-chopping techniques have significant technical limitations in such anatomically constrained and high-risk eyes. This study aims to present the technical details, quantified intraoperative parameters, safety advantages, and three-month standardized follow-up outcomes of modified multiple pit-drilling phacoemulsification in the management of extreme complex grade Ⅴbrunescent nuclear cataract in a 95-year-old diabetic patient.
CASE PRESENTATION: A 95-year-old female patient with a 15-year history of type 2 diabetes mellitus presented with long-standing bilateral progressive visual loss. Preoperative ocular examination revealed multiple compound high-risk factors in the right eye, including gradeⅤ brunescent nuclear cataract, small pupil, shallow anterior chamber, short axial lengths, and reduced corneal endothelial cell density. Modified multiple pit-drilling phacoemulsification, instead of conventional pre-chopping strategy, was performed combined with intraocular lens implantation. Standardized follow-up assessments were conducted at postoperative day 1, 1 month, and 3 months. No severe intraoperative or postoperative complications occurred. The patient showed typical visual changes of ultra-elderly patients with initial visual improvement followed by mild stable decline caused by age-related macular degeneration, rather than surgical trauma.
CONCLUSIONS: Multiple pit-drilling phacoemulsification is safe and effective for ultra-complex gradeⅤbrunescent nuclear cataract in ultra-elderly diabetic patients with small pupils and shallow anterior chambers. Unlike conventional forceful pre-chopping, this technique achieves stepwise intranuclear volume reduction and tension release, maintains continuous anterior chamber stability, minimizes mechanical and thermal endothelial trauma, and reduces the risk of capsular rupture and zonular injury. It provides a reliable and individualized surgical option for extreme high-risk complex cataract surgery and has promising clinical application value.
Additional Links: PMID-43004242
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43004242,
year = {2026},
author = {Zhai, R and Lu, M and Yu, J and Zhao, H and Liu, Y and Ye, Y and Cheng, W and Zhou, L and Chen, K and Ding, D},
title = {Multiple pit-drilling phacoemulsification for complex hard nucleus cataract in elderly patients: a case report.},
journal = {BMC ophthalmology},
volume = {26},
number = {1},
pages = {},
pmid = {43004242},
issn = {1471-2415},
support = {No. 2023A1515140024//the Guangdong Basic and Applied Basic Research Foundation/ ; },
mesh = {Humans ; *Phacoemulsification/methods ; Female ; *Cataract/complications ; Aged, 80 and over ; Visual Acuity ; Lens Implantation, Intraocular ; *Lens Nucleus, Crystalline/surgery/pathology ; },
abstract = {BACKGROUND: Ultra-elderly patients with small pupils, shallow anterior chambers and gradeⅤbrunescent nuclear cataract represent an extremely high-risk subtype of cataract surgery, with markedly elevated risks of intraoperative complications including corneal endothelial injury, posterior capsule rupture, nucleus descent and Descemet's membrane detachment. Conventional pre-chopping techniques have significant technical limitations in such anatomically constrained and high-risk eyes. This study aims to present the technical details, quantified intraoperative parameters, safety advantages, and three-month standardized follow-up outcomes of modified multiple pit-drilling phacoemulsification in the management of extreme complex grade Ⅴbrunescent nuclear cataract in a 95-year-old diabetic patient.
CASE PRESENTATION: A 95-year-old female patient with a 15-year history of type 2 diabetes mellitus presented with long-standing bilateral progressive visual loss. Preoperative ocular examination revealed multiple compound high-risk factors in the right eye, including gradeⅤ brunescent nuclear cataract, small pupil, shallow anterior chamber, short axial lengths, and reduced corneal endothelial cell density. Modified multiple pit-drilling phacoemulsification, instead of conventional pre-chopping strategy, was performed combined with intraocular lens implantation. Standardized follow-up assessments were conducted at postoperative day 1, 1 month, and 3 months. No severe intraoperative or postoperative complications occurred. The patient showed typical visual changes of ultra-elderly patients with initial visual improvement followed by mild stable decline caused by age-related macular degeneration, rather than surgical trauma.
CONCLUSIONS: Multiple pit-drilling phacoemulsification is safe and effective for ultra-complex gradeⅤbrunescent nuclear cataract in ultra-elderly diabetic patients with small pupils and shallow anterior chambers. Unlike conventional forceful pre-chopping, this technique achieves stepwise intranuclear volume reduction and tension release, maintains continuous anterior chamber stability, minimizes mechanical and thermal endothelial trauma, and reduces the risk of capsular rupture and zonular injury. It provides a reliable and individualized surgical option for extreme high-risk complex cataract surgery and has promising clinical application value.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Phacoemulsification/methods
Female
*Cataract/complications
Aged, 80 and over
Visual Acuity
Lens Implantation, Intraocular
*Lens Nucleus, Crystalline/surgery/pathology
RevDate: 2026-11-10
Precursor lesions are associated with distinct growth kinetics after atrophy onset.
American journal of ophthalmology pii:S0002-9394(26)00614-8 [Epub ahead of print].
PURPOSE: To evaluate whether atrophic lesions arising from different retinal precursors show distinct temporal growth kinetics in age-related macular degeneration (AMD).
DESIGN: Retrospective longitudinal cohort study.
PARTICIPANTS: 109 eyes of 88 patients with intermediate AMD (iAMD) developing cRORA.
METHODS: Consecutive eyes with iAMD progressing to complete retinal pigment epithelium and outer retinal atrophy (cRORA) were identified by retrospective back-tracking of serial spectral-domain OCT. Precursors, defined as lesions that progressed to cRORA at the site of onset, were classified as drusenoid, subretinal drusenoid deposit (SDD), or acquired vitelliform lesion (AVL). Atrophy was segmented automatically on en face projections and manually corrected when needed. Temporal kinetics during the first 3 years after cRORA onset were assessed using piecewise linear time with knots at 1 and 2 years, adjusting for atrophic area, eccentricity, and number of foci at onset.
MAIN OUTCOME MEASURES: Rate and temporal kinetics of square-root-transformed total atrophic area growth by precursor.
RESULTS: Of 109 eyes progressing to cRORA, 66 arose from drusenoid, 31 from SDD, and 12 from AVL. After cRORA, the model-estimated growth rate was different according to the precursor lesions, with 0.197 mm/year in the drusenoid group, 0.383 mm/year in the SDD group, and 0.429 mm/year in the AVL group (P<0.001). Both SDD and AVL groups grew faster than the drusenoid group (both P<0.001), whereas SDD and AVL did not differ (P=0.44). Temporal kinetics also differed by precursor lesion (P<0.001). Compared with the drusenoid group, the SDD group did not differ in year 1 (difference, 0.041 mm/year; P=0.43) but grew faster in year 2 (0.306; P<0.001) and year 3 (0.237; P<0.001). AVL group showed faster growth in year 1 (0.396; P<0.001) and year 2 (0.248; P=0.002), but not year 3 (0.060; P=0.57). Differences persisted after adjustment for atrophy characteristics at onset. Parafoveal SDD burden provided no additional information once precursor lesion was accounted for (P=0.12).
CONCLUSION: The study finds distinct temporal trajectories: atrophy arising from drusenoid lesions grows more steadily, whereas from SDD accelerates later, and from AVL grows rapidly early then decelerates. SDD presence elsewhere may be less important than whether the atrophy arose from SDD. The findings may have prognostic implications, representing a stratification variable in clinical trials.
Additional Links: PMID-43009086
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43009086,
year = {2026},
author = {Gagliardi, OM and Doshi, U and Amin, R and Peña, DF and Jiang, J and Gregori, G and Sahoo, NK and Hasan, N and Iannetta, D and Chhablani, J},
title = {Precursor lesions are associated with distinct growth kinetics after atrophy onset.},
journal = {American journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.ajo.2026.11.006},
pmid = {43009086},
issn = {1879-1891},
abstract = {PURPOSE: To evaluate whether atrophic lesions arising from different retinal precursors show distinct temporal growth kinetics in age-related macular degeneration (AMD).
DESIGN: Retrospective longitudinal cohort study.
PARTICIPANTS: 109 eyes of 88 patients with intermediate AMD (iAMD) developing cRORA.
METHODS: Consecutive eyes with iAMD progressing to complete retinal pigment epithelium and outer retinal atrophy (cRORA) were identified by retrospective back-tracking of serial spectral-domain OCT. Precursors, defined as lesions that progressed to cRORA at the site of onset, were classified as drusenoid, subretinal drusenoid deposit (SDD), or acquired vitelliform lesion (AVL). Atrophy was segmented automatically on en face projections and manually corrected when needed. Temporal kinetics during the first 3 years after cRORA onset were assessed using piecewise linear time with knots at 1 and 2 years, adjusting for atrophic area, eccentricity, and number of foci at onset.
MAIN OUTCOME MEASURES: Rate and temporal kinetics of square-root-transformed total atrophic area growth by precursor.
RESULTS: Of 109 eyes progressing to cRORA, 66 arose from drusenoid, 31 from SDD, and 12 from AVL. After cRORA, the model-estimated growth rate was different according to the precursor lesions, with 0.197 mm/year in the drusenoid group, 0.383 mm/year in the SDD group, and 0.429 mm/year in the AVL group (P<0.001). Both SDD and AVL groups grew faster than the drusenoid group (both P<0.001), whereas SDD and AVL did not differ (P=0.44). Temporal kinetics also differed by precursor lesion (P<0.001). Compared with the drusenoid group, the SDD group did not differ in year 1 (difference, 0.041 mm/year; P=0.43) but grew faster in year 2 (0.306; P<0.001) and year 3 (0.237; P<0.001). AVL group showed faster growth in year 1 (0.396; P<0.001) and year 2 (0.248; P=0.002), but not year 3 (0.060; P=0.57). Differences persisted after adjustment for atrophy characteristics at onset. Parafoveal SDD burden provided no additional information once precursor lesion was accounted for (P=0.12).
CONCLUSION: The study finds distinct temporal trajectories: atrophy arising from drusenoid lesions grows more steadily, whereas from SDD accelerates later, and from AVL grows rapidly early then decelerates. SDD presence elsewhere may be less important than whether the atrophy arose from SDD. The findings may have prognostic implications, representing a stratification variable in clinical trials.},
}
RevDate: 2026-11-10
Associations of Life's Essential 8 with age-related macular degeneration.
The British journal of ophthalmology pii:bjo-2026-330116 [Epub ahead of print].
Additional Links: PMID-43009292
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43009292,
year = {2026},
author = {Jiang, H and Wang, L and Fan, Y and Li, Z and Liu, S and Li, B and Shi, J and Ma, M and Chen, F and Ma, L and Ye, L and Ma, M and Zhang, W},
title = {Associations of Life's Essential 8 with age-related macular degeneration.},
journal = {The British journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1136/bjo-2026-330116},
pmid = {43009292},
issn = {1468-2079},
}
RevDate: 2026-11-12
CmpDate: 2026-11-11
Comparison of morphological and functional parameters after switching therapy from brolucizumab to faricimab in neovascular age-related macular degeneration.
BMC ophthalmology, 26(1):.
BACKGROUND: Brolucizumab, an anti-vascular endothelial growth factor (VEGF) agent, offers extended dosing intervals in neovascular age-related macular degeneration (nAMD) but carries a rare risk of retinal vasculitis. Faricimab, a bispecific antibody targeting VEGF and angiopoietin-2 (Ang-2), maintained efficacy with dosing intervals of up to 16 weeks in the TENAYA and LUCERNE trials and carries a lower reported inflammatory risk. Patients may therefore be switched from brolucizumab to faricimab. This study examines the morphological and functional response after such a switch.
METHODS: Patients with nAMD were included in this retrospective case series. Eligibility required at least three consecutive brolucizumab injections before switching to faricimab. The primary outcome was the change in central retinal thickness (CRT); secondary outcomes were the change in best-corrected visual acuity (VA) and adverse events.
RESULTS: The study included 31 eyes from 28 patients treated with brolucizumab and switched to faricimab. Mean visual acuity (VA) was 0.3 logMAR (Snellen equivalent ~20/40) at visit -3, with no significant change after three brolucizumab injections (0.3 logMAR, ~20/40, p=0.932). After switching to faricimab, mean VA was 0.332 logMAR (~20/40) with no statistically significant difference from the value after three brolucizumab injections (p=0.187). Central retinal thickness (CRT) remained stable before (355.00µm to 347.29µm, p=0.538) and after switching (366.54µm, p=0.190). Of the 11 eyes that were free of fluid before the switch, 10 did not remain dry, and CRT increased significantly (282.9µm to 367.9µm, p=0.013) after extending intervals on average by +2.3 weeks (min 0 to max +5 weeks). However, visual function remained stable (p=0.559). In contrast, two eyes became dry with shorter intervals (-2 weeks), one eye remained dry (+2 weeks) and 18 eyes remained active (-0.5 weeks).
CONCLUSIONS: Overall, morphological and functional parameters remained stable after switching to faricimab, and the safety profile was stable. Because every eye received both agents sequentially and no concurrent brolucizumab control group was included, this was not a head-to-head comparison. The increase in retinal thickness in some cases highlights the need for individualized treatment based on patient response.
Additional Links: PMID-43009871
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43009871,
year = {2026},
author = {Boltz, A and Paster, J and Mehany, S and Vécsei-Marlovits, VP},
title = {Comparison of morphological and functional parameters after switching therapy from brolucizumab to faricimab in neovascular age-related macular degeneration.},
journal = {BMC ophthalmology},
volume = {26},
number = {1},
pages = {},
pmid = {43009871},
issn = {1471-2415},
mesh = {Humans ; Retrospective Studies ; *Visual Acuity/physiology ; Male ; *Angiogenesis Inhibitors/therapeutic use ; Female ; Intravitreal Injections ; *Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage ; Aged ; Tomography, Optical Coherence ; *Wet Macular Degeneration/drug therapy/physiopathology/diagnosis ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Aged, 80 and over ; Drug Substitution ; Retina/pathology ; Fluorescein Angiography ; Follow-Up Studies ; Antibodies, Bispecific ; },
abstract = {BACKGROUND: Brolucizumab, an anti-vascular endothelial growth factor (VEGF) agent, offers extended dosing intervals in neovascular age-related macular degeneration (nAMD) but carries a rare risk of retinal vasculitis. Faricimab, a bispecific antibody targeting VEGF and angiopoietin-2 (Ang-2), maintained efficacy with dosing intervals of up to 16 weeks in the TENAYA and LUCERNE trials and carries a lower reported inflammatory risk. Patients may therefore be switched from brolucizumab to faricimab. This study examines the morphological and functional response after such a switch.
METHODS: Patients with nAMD were included in this retrospective case series. Eligibility required at least three consecutive brolucizumab injections before switching to faricimab. The primary outcome was the change in central retinal thickness (CRT); secondary outcomes were the change in best-corrected visual acuity (VA) and adverse events.
RESULTS: The study included 31 eyes from 28 patients treated with brolucizumab and switched to faricimab. Mean visual acuity (VA) was 0.3 logMAR (Snellen equivalent ~20/40) at visit -3, with no significant change after three brolucizumab injections (0.3 logMAR, ~20/40, p=0.932). After switching to faricimab, mean VA was 0.332 logMAR (~20/40) with no statistically significant difference from the value after three brolucizumab injections (p=0.187). Central retinal thickness (CRT) remained stable before (355.00µm to 347.29µm, p=0.538) and after switching (366.54µm, p=0.190). Of the 11 eyes that were free of fluid before the switch, 10 did not remain dry, and CRT increased significantly (282.9µm to 367.9µm, p=0.013) after extending intervals on average by +2.3 weeks (min 0 to max +5 weeks). However, visual function remained stable (p=0.559). In contrast, two eyes became dry with shorter intervals (-2 weeks), one eye remained dry (+2 weeks) and 18 eyes remained active (-0.5 weeks).
CONCLUSIONS: Overall, morphological and functional parameters remained stable after switching to faricimab, and the safety profile was stable. Because every eye received both agents sequentially and no concurrent brolucizumab control group was included, this was not a head-to-head comparison. The increase in retinal thickness in some cases highlights the need for individualized treatment based on patient response.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Retrospective Studies
*Visual Acuity/physiology
Male
*Angiogenesis Inhibitors/therapeutic use
Female
Intravitreal Injections
*Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage
Aged
Tomography, Optical Coherence
*Wet Macular Degeneration/drug therapy/physiopathology/diagnosis
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Aged, 80 and over
Drug Substitution
Retina/pathology
Fluorescein Angiography
Follow-Up Studies
Antibodies, Bispecific
RevDate: 2026-11-11
CmpDate: 2026-11-11
[Multiple mechanisms and intervention strategies of monocytes/macrophages in ocular diseases].
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 62(11):966-976.
Monocytes/macrophages possess prominent heterogeneity and functional plasticity, and their functional imbalance participates in the initiation and progression of multiple ocular diseases. This review summarizes the roles of monocytes/macrophages in age-related macular degeneration, diabetic retinopathy, high myopia, uveitis and glaucoma. It particularly elaborates their pathogenic mechanisms involving oxidative stress, inflammatory amplification, blood-retinal barrier disruption and pathological neovascularization, alongside their immunomodulatory and tissue-repairing functions. We also outline intervention strategies targeting monocytes/macrophages, including blocking pro-inflammatory recruitment and signaling pathways, inducing anti-inflammatory polarization, and immune reprogramming, which may offer novel ideas for precision therapy of chronic inflammatory ocular diseases.
Additional Links: PMID-43010767
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43010767,
year = {2026},
author = {Pei, YJ and Meng, JQ and Zhu, XJ},
title = {[Multiple mechanisms and intervention strategies of monocytes/macrophages in ocular diseases].},
journal = {[Zhonghua yan ke za zhi] Chinese journal of ophthalmology},
volume = {62},
number = {11},
pages = {966-976},
doi = {10.3760/cma.j.cn112142-20251118-00488},
pmid = {43010767},
issn = {0412-4081},
support = {82271069, 82301188//National Natural Science Foundation of China/ ; },
mesh = {Humans ; *Monocytes ; *Macrophages ; *Eye Diseases ; Animals ; Oxidative Stress ; },
abstract = {Monocytes/macrophages possess prominent heterogeneity and functional plasticity, and their functional imbalance participates in the initiation and progression of multiple ocular diseases. This review summarizes the roles of monocytes/macrophages in age-related macular degeneration, diabetic retinopathy, high myopia, uveitis and glaucoma. It particularly elaborates their pathogenic mechanisms involving oxidative stress, inflammatory amplification, blood-retinal barrier disruption and pathological neovascularization, alongside their immunomodulatory and tissue-repairing functions. We also outline intervention strategies targeting monocytes/macrophages, including blocking pro-inflammatory recruitment and signaling pathways, inducing anti-inflammatory polarization, and immune reprogramming, which may offer novel ideas for precision therapy of chronic inflammatory ocular diseases.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Monocytes
*Macrophages
*Eye Diseases
Animals
Oxidative Stress
RevDate: 2026-11-11
Gut-hormone receptor systems in the eye: Pharmacological, local and putative endocrine signalling.
European journal of ophthalmology [Epub ahead of print].
The neural retina has traditionally been viewed as a downstream target of systemic metabolic disease, yet experimental and clinical evidence suggests that ocular tissues may also respond directly to peptide-hormone signalling. This review critically examines gut-hormone-related receptor systems in the eye across three biologically distinct evidence streams: endogenous circulating gut peptides, pharmacological receptor agonism, and locally synthesised ocular peptides. Physiological retinal access of native gut peptides remains poorly characterised, while receptor localisation is highly dependent on species and detection methodology. Mechanistic evidence is strongest for pharmacological GLP-1 receptor activation and local NPY and ghrelin systems, particularly in relation to neuroprotection, immunomodulation, metabolic and oxidative homeostasis, and neurovascular regulation. Human evidence remains disease-specific: diabetic retinopathy findings vary with glycaemic trajectory and endpoint definition; age-related macular degeneration associations are heterogeneous; glaucoma studies suggest a possible reduction in incidence without establishing protection against progression; and dry-eye evidence remains preliminary. Semaglutide also carries a regulatory safety signal for non-arteritic anterior ischaemic optic neuropathy. Future research should establish physiological ligand access and receptor engagement, validate ocular receptor localisation, characterise retinal and optic-nerve-head microvascular responses, and incorporate prospective ophthalmic phenotyping into metabolic-drug trials. Overall, current evidence supports pharmacological and local ocular peptide-receptor signalling, whereas direct physiological endocrine communication between the gut and eye remains unproven.
Additional Links: PMID-43012562
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43012562,
year = {2026},
author = {Wang, Z and Zich, LW and Li, Y and Liu, Y},
title = {Gut-hormone receptor systems in the eye: Pharmacological, local and putative endocrine signalling.},
journal = {European journal of ophthalmology},
volume = {},
number = {},
pages = {11206721261507148},
doi = {10.1177/11206721261507148},
pmid = {43012562},
issn = {1724-6016},
abstract = {The neural retina has traditionally been viewed as a downstream target of systemic metabolic disease, yet experimental and clinical evidence suggests that ocular tissues may also respond directly to peptide-hormone signalling. This review critically examines gut-hormone-related receptor systems in the eye across three biologically distinct evidence streams: endogenous circulating gut peptides, pharmacological receptor agonism, and locally synthesised ocular peptides. Physiological retinal access of native gut peptides remains poorly characterised, while receptor localisation is highly dependent on species and detection methodology. Mechanistic evidence is strongest for pharmacological GLP-1 receptor activation and local NPY and ghrelin systems, particularly in relation to neuroprotection, immunomodulation, metabolic and oxidative homeostasis, and neurovascular regulation. Human evidence remains disease-specific: diabetic retinopathy findings vary with glycaemic trajectory and endpoint definition; age-related macular degeneration associations are heterogeneous; glaucoma studies suggest a possible reduction in incidence without establishing protection against progression; and dry-eye evidence remains preliminary. Semaglutide also carries a regulatory safety signal for non-arteritic anterior ischaemic optic neuropathy. Future research should establish physiological ligand access and receptor engagement, validate ocular receptor localisation, characterise retinal and optic-nerve-head microvascular responses, and incorporate prospective ophthalmic phenotyping into metabolic-drug trials. Overall, current evidence supports pharmacological and local ocular peptide-receptor signalling, whereas direct physiological endocrine communication between the gut and eye remains unproven.},
}
RevDate: 2026-11-08
CmpDate: 2026-11-08
Engineered regulatory states resolve context-dependent genetics in macular degeneration.
bioRxiv : the preprint server for biology pii:2026.10.09.758047.
The effects of many genes and disease-associated variants remain hidden in standard cellular models, limiting functional interpretation. Here we engineer regulatory states via CRISPR activation of transcription factors (TFs) in human RPE-1 cells, a model for age-related macular degeneration (AMD). Multiome Perturb-seq profiling of single-TF perturbations identified regulators that selectively opened chromatin at AMD GWAS variants inaccessible in resting RPE-1. Priming of partner motifs in chromatin made accessible by single-TF perturbations predicted TF pairs generating emergent transcriptional states in combinatorial Perturb-seq, providing a design principle for selecting informative interactions. Distinct TF pairs also showed variable convergence between polygenic AMD signals and Mendelian retinal disease genes, supporting an omnigenic model shaped by regulatory states. Finally, Mosaic, a chromatin-informed model of TF interaction phenotypes, nominated out-of-sample regulators, including a higher-order combination with experimentally validated emergent effects on AMD-associated programs. Engineered regulatory states thus bring hidden disease biology within experimental reach.
Additional Links: PMID-42999327
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42999327,
year = {2026},
author = {Metzner, E and Guruvayurappan, K and Southard, KM and Ardy, RC and Dey, KK and Norman, TM},
title = {Engineered regulatory states resolve context-dependent genetics in macular degeneration.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.09.758047},
pmid = {42999327},
issn = {2692-8205},
abstract = {The effects of many genes and disease-associated variants remain hidden in standard cellular models, limiting functional interpretation. Here we engineer regulatory states via CRISPR activation of transcription factors (TFs) in human RPE-1 cells, a model for age-related macular degeneration (AMD). Multiome Perturb-seq profiling of single-TF perturbations identified regulators that selectively opened chromatin at AMD GWAS variants inaccessible in resting RPE-1. Priming of partner motifs in chromatin made accessible by single-TF perturbations predicted TF pairs generating emergent transcriptional states in combinatorial Perturb-seq, providing a design principle for selecting informative interactions. Distinct TF pairs also showed variable convergence between polygenic AMD signals and Mendelian retinal disease genes, supporting an omnigenic model shaped by regulatory states. Finally, Mosaic, a chromatin-informed model of TF interaction phenotypes, nominated out-of-sample regulators, including a higher-order combination with experimentally validated emergent effects on AMD-associated programs. Engineered regulatory states thus bring hidden disease biology within experimental reach.},
}
RevDate: 2026-11-09
The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability.
Journal of vitreoretinal diseases [Epub ahead of print].
PURPOSE: To examine the yearly cost of antivascular endothelial growth factor (anti-VEGF) therapy borne by patients and to assess the major contributors to patient cost.
METHODS: A retrospective, cross-sectional cost analysis was conducted of 29 250 insured patients in a single practice receiving anti-VEGF injections over a 21-month period between January 1, 2023, and September 30, 2024. Direct costs to the patient were abstracted, including patient copay and patient-responsible portions of imaging, medication, procedure, and visit costs; medication costs were based on average sales price. Transportation cost and opportunity cost associated with missed work were operationalized to estimate indirect costs, using age-stratified employment rates and median earnings from the United States Bureau of Labor Statistics for both patients and accompanying caregivers.
RESULTS: The mean (±SD) direct cost per visit was $91.72 ± $22.22. Indirect costs per visit varied by indication, with a mean indirect cost per visit of $97.89 for patients with neovascular age-related macular degeneration (AMD) and $164.44 for patients with diabetic macular edema (DME) for a half day of missed work, and $167.98 and $301.09, respectively, for a full day off work. Indirect costs accounted for 45.37% to 74.86% of total patient cost for a half day off, and 58.76% to 84.50% for a full day off. Relative to the baseline of 12 monthly bevacizumab injections received annually (half-day off scenario), the equivalent total patient cost accrued would correspond to a mean annual number of injections of 9.32 and 10.00 for aflibercept 2 mg, 11.09 and 11.35 for aflibercept 8 mg, and 9.05 and 9.78 for faricimab 6 mg in patients with neovascular AMD and patients with DME, respectively.
CONCLUSIONS: Patient cost is driven more by visit frequency and its associated indirect costs than by drug price. Less frequent dosing with a more durable agent can therefore lower the total cost experienced by patients despite a higher acquisition price.
Additional Links: PMID-42999437
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42999437,
year = {2026},
author = {Davis, EC and Murickan, T and Khurram, I and Berkowitz, ST and Williard, C and Thomas, AS},
title = {The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability.},
journal = {Journal of vitreoretinal diseases},
volume = {},
number = {},
pages = {24741264261498875},
pmid = {42999437},
issn = {2474-1272},
abstract = {PURPOSE: To examine the yearly cost of antivascular endothelial growth factor (anti-VEGF) therapy borne by patients and to assess the major contributors to patient cost.
METHODS: A retrospective, cross-sectional cost analysis was conducted of 29 250 insured patients in a single practice receiving anti-VEGF injections over a 21-month period between January 1, 2023, and September 30, 2024. Direct costs to the patient were abstracted, including patient copay and patient-responsible portions of imaging, medication, procedure, and visit costs; medication costs were based on average sales price. Transportation cost and opportunity cost associated with missed work were operationalized to estimate indirect costs, using age-stratified employment rates and median earnings from the United States Bureau of Labor Statistics for both patients and accompanying caregivers.
RESULTS: The mean (±SD) direct cost per visit was $91.72 ± $22.22. Indirect costs per visit varied by indication, with a mean indirect cost per visit of $97.89 for patients with neovascular age-related macular degeneration (AMD) and $164.44 for patients with diabetic macular edema (DME) for a half day of missed work, and $167.98 and $301.09, respectively, for a full day off work. Indirect costs accounted for 45.37% to 74.86% of total patient cost for a half day off, and 58.76% to 84.50% for a full day off. Relative to the baseline of 12 monthly bevacizumab injections received annually (half-day off scenario), the equivalent total patient cost accrued would correspond to a mean annual number of injections of 9.32 and 10.00 for aflibercept 2 mg, 11.09 and 11.35 for aflibercept 8 mg, and 9.05 and 9.78 for faricimab 6 mg in patients with neovascular AMD and patients with DME, respectively.
CONCLUSIONS: Patient cost is driven more by visit frequency and its associated indirect costs than by drug price. Less frequent dosing with a more durable agent can therefore lower the total cost experienced by patients despite a higher acquisition price.},
}
RevDate: 2026-11-08
An update on pharmacotherapies and emerging therapeutic approaches for geographic atrophy.
Expert opinion on pharmacotherapy [Epub ahead of print].
INTRODUCTION: Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of irreversible vision loss. The 2023 FDA approvals of pegcetacoplan and avacincaptad pegol were a milestone, but modest anatomic benefit without demonstrated prespecified functional benefit, increased neovascular conversion, and substantial treatment burden underscore the need for better therapies and more sensitive functional endpoints. The EMA denied pegcetacoplan's marketing authorization and issued an unsupportive provisional opinion on avacincaptad pegol, prompting its application withdrawal.
AREAS COVERED: Based on searches of PubMed, trial registries, regulatory documents, and conference proceedings through September 2026, this review examines real-world experience with approved complement inhibitors; next-generation complement approaches, including C1q inhibition, systemic C5 and C3 suppression, and complement-directed gene therapies; and non-complement strategies targeting inflammation, mitochondrial dysfunction, apoptosis, the visual cycle, and iron homeostasis, with photobiomodulation and cell-based therapies as non-pharmacologic comparators. The strength of evidence is distinguished throughout, and the rationale for multi-target strategies is discussed.
EXPERT OPINION: Current complement inhibitors fall short of ideal clinical utility, with no functional benefit demonstrated on prespecified endpoints and only exploratory, largely post hoc functional signals despite frequent injections. The field is moving toward multi-target strategies, functional endpoints, durable gene therapy platforms, and biomarker-driven patient selection.
Additional Links: PMID-42999938
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42999938,
year = {2026},
author = {Rowe, LW and Guymer, R and Wykoff, CC and Regillo, CD and Ho, AC and Bernstein, PS and Loewenstein, A and Avery, RL and Eliott, D and Ciulla, TA},
title = {An update on pharmacotherapies and emerging therapeutic approaches for geographic atrophy.},
journal = {Expert opinion on pharmacotherapy},
volume = {},
number = {},
pages = {},
doi = {10.1080/14656566.2026.2761125},
pmid = {42999938},
issn = {1744-7666},
abstract = {INTRODUCTION: Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of irreversible vision loss. The 2023 FDA approvals of pegcetacoplan and avacincaptad pegol were a milestone, but modest anatomic benefit without demonstrated prespecified functional benefit, increased neovascular conversion, and substantial treatment burden underscore the need for better therapies and more sensitive functional endpoints. The EMA denied pegcetacoplan's marketing authorization and issued an unsupportive provisional opinion on avacincaptad pegol, prompting its application withdrawal.
AREAS COVERED: Based on searches of PubMed, trial registries, regulatory documents, and conference proceedings through September 2026, this review examines real-world experience with approved complement inhibitors; next-generation complement approaches, including C1q inhibition, systemic C5 and C3 suppression, and complement-directed gene therapies; and non-complement strategies targeting inflammation, mitochondrial dysfunction, apoptosis, the visual cycle, and iron homeostasis, with photobiomodulation and cell-based therapies as non-pharmacologic comparators. The strength of evidence is distinguished throughout, and the rationale for multi-target strategies is discussed.
EXPERT OPINION: Current complement inhibitors fall short of ideal clinical utility, with no functional benefit demonstrated on prespecified endpoints and only exploratory, largely post hoc functional signals despite frequent injections. The field is moving toward multi-target strategies, functional endpoints, durable gene therapy platforms, and biomarker-driven patient selection.},
}
RevDate: 2026-11-09
Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments.
Korean journal of ophthalmology : KJO pii:kjo.2026.0032 [Epub ahead of print].
PURPOSE: To compare short-term anatomical and functional outcomes of intravitreal brolucizumab versus aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD) with thick pigment epithelial detachments (PEDs).
METHODS: This retrospective comparative study included treatment-naïve nAMD eyes with thick PEDs (maximum PED height ≥250 μm) treated with intravitreal aflibercept or brolucizumab between January 2022 and June 2025, with a minimum 6-month follow-up. The primary outcome was anatomical response at Month 6, defined as ≥50% reduction in maximum PED height. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), qualitative OCT features, injection burden, and safety. Longitudinal changes were analyzed using linear mixed-effects models.
RESULTS: Forty-one eyes (aflibercept, n=21; brolucizumab, n=20) were included. Baseline BCVA, CFT, and PED height did not differ significantly between the groups, although SFCT was thicker in the brolucizumab group (P=0.034). Over 6 months, the mean number of injections was significantly lower with brolucizumab (3.05 ± 0.40 vs. 3.86 ± 0.65, P<0.001). Brolucizumab achieved greater reduction in PED height at Month 3 (P=0.014) and Month 6 (P=0.044). In mixed-effects analysis, all anatomical parameters and BCVA improved over time (Ptime<0.001). SFCT demonstrated significant group and interaction effects (Pgroup=0.031; Pint=0.006), whereas PED height and CFT did not. Residual subretinal hyperreflective material was less frequent at Month 3 with brolucizumab (0.0% vs. 23.8%, P=0.048). No intraocular inflammation occurred.
CONCLUSIONS: In treatment-naïve nAMD eyes with thick PEDs, brolucizumab was associated with greater short-term anatomical improvement and a lower injection burden compared with aflibercept, whereas no statistically significant between-group difference was observed in BCVA change. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.
Additional Links: PMID-43001004
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43001004,
year = {2026},
author = {Lee, IG and Kim, HD and Cho, IH and Lee, CH},
title = {Comparison of Aflibercept and Brolucizumab in Treatment-Naïve Neovascular Age-related Macular Degeneration with Thick Pigment Epithelial Detachments.},
journal = {Korean journal of ophthalmology : KJO},
volume = {},
number = {},
pages = {},
doi = {10.3341/kjo.2026.0032},
pmid = {43001004},
issn = {2092-9382},
abstract = {PURPOSE: To compare short-term anatomical and functional outcomes of intravitreal brolucizumab versus aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD) with thick pigment epithelial detachments (PEDs).
METHODS: This retrospective comparative study included treatment-naïve nAMD eyes with thick PEDs (maximum PED height ≥250 μm) treated with intravitreal aflibercept or brolucizumab between January 2022 and June 2025, with a minimum 6-month follow-up. The primary outcome was anatomical response at Month 6, defined as ≥50% reduction in maximum PED height. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), qualitative OCT features, injection burden, and safety. Longitudinal changes were analyzed using linear mixed-effects models.
RESULTS: Forty-one eyes (aflibercept, n=21; brolucizumab, n=20) were included. Baseline BCVA, CFT, and PED height did not differ significantly between the groups, although SFCT was thicker in the brolucizumab group (P=0.034). Over 6 months, the mean number of injections was significantly lower with brolucizumab (3.05 ± 0.40 vs. 3.86 ± 0.65, P<0.001). Brolucizumab achieved greater reduction in PED height at Month 3 (P=0.014) and Month 6 (P=0.044). In mixed-effects analysis, all anatomical parameters and BCVA improved over time (Ptime<0.001). SFCT demonstrated significant group and interaction effects (Pgroup=0.031; Pint=0.006), whereas PED height and CFT did not. Residual subretinal hyperreflective material was less frequent at Month 3 with brolucizumab (0.0% vs. 23.8%, P=0.048). No intraocular inflammation occurred.
CONCLUSIONS: In treatment-naïve nAMD eyes with thick PEDs, brolucizumab was associated with greater short-term anatomical improvement and a lower injection burden compared with aflibercept, whereas no statistically significant between-group difference was observed in BCVA change. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-09
Bilateral Corneal Melting Following High-Voltage Electrical Injury: A Case Report and Review.
Romanian journal of ophthalmology, 70(3):442-448.
Electrical injuries, particularly those involving high-voltage current, can cause extensive damage across multiple organ systems. Although ocular involvement is rare, the eye may develop severe, vision-threatening anterior and posterior segment complications. This report describes an unusual case of bilateral corneal melting following a high-voltage domestic electrical injury in the absence of direct ocular contact or periocular burns. A 65-year-old female presented ten days after injury with progressive bilateral visual loss, photophobia, tearing, and ocular pain. Slit-lamp examination revealed diffuse corneal edema, Descemet's membrane folds, stromal necrosis, and large epithelial defects in both eyes. Fundus visualization was initially obscured. A diagnosis of bilateral corneal melting secondary to electrical trauma was made. The patient was started on systemic corticosteroids, topical fortified antibiotics, and lubricating agents. Despite partial clinical improvement, persistent epithelial defects necessitated bilateral amniotic membrane transplantation. Postoperatively, the ocular surface stabilized, with gradual epithelial healing and symptom resolution. By day 120, bilateral central corneal opacities with superficial neovascularization were observed. Fundus examination, possible after corneal clearing, revealed signs of age-related macular degeneration and mild optic disc pallor. Visual acuity remained at light perception in both eyes due to posterior segment pathology. This case underscores the importance of recognizing rare anterior segment complications such as sterile keratolysis in patients with electrical injuries, even when no facial burns are present. Corneal melting in this context likely results from a combination of ischemia, inflammatory enzyme activity, and neurotrophic dysfunction. Early medical intervention with corticosteroids, combined with surgical management using amniotic membrane grafting, is crucial to preserve anatomical integrity and prevent perforation. Long-term follow-up is critical to identify delayed complications, support ocular healing, and assess posterior segment status. This case contributes to the limited literature on electrical injuries with bilateral corneal involvement.
Additional Links: PMID-43001073
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43001073,
year = {2026},
author = {Choudhary, DS and Garg, T and Kalal, BS},
title = {Bilateral Corneal Melting Following High-Voltage Electrical Injury: A Case Report and Review.},
journal = {Romanian journal of ophthalmology},
volume = {70},
number = {3},
pages = {442-448},
pmid = {43001073},
issn = {2501-2533},
mesh = {Humans ; Female ; Aged ; Visual Acuity ; *Burns, Electric/diagnosis/complications ; *Cornea/pathology ; *Corneal Diseases/etiology/diagnosis ; Eye Burns/diagnosis ; },
abstract = {Electrical injuries, particularly those involving high-voltage current, can cause extensive damage across multiple organ systems. Although ocular involvement is rare, the eye may develop severe, vision-threatening anterior and posterior segment complications. This report describes an unusual case of bilateral corneal melting following a high-voltage domestic electrical injury in the absence of direct ocular contact or periocular burns. A 65-year-old female presented ten days after injury with progressive bilateral visual loss, photophobia, tearing, and ocular pain. Slit-lamp examination revealed diffuse corneal edema, Descemet's membrane folds, stromal necrosis, and large epithelial defects in both eyes. Fundus visualization was initially obscured. A diagnosis of bilateral corneal melting secondary to electrical trauma was made. The patient was started on systemic corticosteroids, topical fortified antibiotics, and lubricating agents. Despite partial clinical improvement, persistent epithelial defects necessitated bilateral amniotic membrane transplantation. Postoperatively, the ocular surface stabilized, with gradual epithelial healing and symptom resolution. By day 120, bilateral central corneal opacities with superficial neovascularization were observed. Fundus examination, possible after corneal clearing, revealed signs of age-related macular degeneration and mild optic disc pallor. Visual acuity remained at light perception in both eyes due to posterior segment pathology. This case underscores the importance of recognizing rare anterior segment complications such as sterile keratolysis in patients with electrical injuries, even when no facial burns are present. Corneal melting in this context likely results from a combination of ischemia, inflammatory enzyme activity, and neurotrophic dysfunction. Early medical intervention with corticosteroids, combined with surgical management using amniotic membrane grafting, is crucial to preserve anatomical integrity and prevent perforation. Long-term follow-up is critical to identify delayed complications, support ocular healing, and assess posterior segment status. This case contributes to the limited literature on electrical injuries with bilateral corneal involvement.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Aged
Visual Acuity
*Burns, Electric/diagnosis/complications
*Cornea/pathology
*Corneal Diseases/etiology/diagnosis
Eye Burns/diagnosis
RevDate: 2026-11-10
CmpDate: 2026-11-09
Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response.
Drug design, development and therapy, 20:646469.
PURPOSE: To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and visual prognosis.
METHODS: This single-center retrospective cohort included 34 nAMD eyes that had received at least three consecutive aflibercept injections at 4-week intervals. Patients followed a 1+pro re nata (PRN) regimen for 12 months post-switch. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, and the prevalence of subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage (SRH) were evaluated. In 13 eyes with baseline SHRM, generalized estimating equations (GEE) were utilized to explore the association of dynamic SHRM height changes and treatment interval adjustments with visual acuity changes.
RESULTS: A total of 34 eyes were included. CMT dropped significantly after the initial faricimab injection (P = 0.0427). SRF prevalence declined markedly at 6 months, with significant PED and IRF prevalence reductions at 12 months. Among the 11 eyes with baseline SRH, the maximum SRH diameter decreased significantly at month 12 (adjusted P = 0.0039). No significant change was detected in BCVA. Median treatment intervals lengthened from 4.5 to 8.0 weeks (P = 0.017). In 13 eyes with baseline SHRM, SHRM reduction was associated with contemporaneous treatment-interval prolongation (B = -3.299 weeks per 100-μm increase; P < 0.001), but not with subsequent injection intervals or concurrent visual-acuity changes.
CONCLUSION: Switching to faricimab was associated with overall anatomical improvements and prolonged treatment intervals among pretreated nAMD eyes, while visual gains remained limited. However, complete anatomical resolution was not achieved in all patients. Dynamic changes in SHRM height may represent an exploratory imaging feature associated with treatment interval changes, however, its prospective predictive value and clinical utility remain to be validated.
Additional Links: PMID-43001148
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43001148,
year = {2026},
author = {Wang, J and Li, F and Wang, Y and Kong, X and Zhou, W},
title = {Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response.},
journal = {Drug design, development and therapy},
volume = {20},
number = {},
pages = {646469},
pmid = {43001148},
issn = {1177-8881},
mesh = {Humans ; *Receptors, Vascular Endothelial Growth Factor/administration & dosage/antagonists & inhibitors/therapeutic use ; *Recombinant Fusion Proteins/administration & dosage/therapeutic use ; Retrospective Studies ; Male ; Female ; *Macular Degeneration/drug therapy ; Aged ; Visual Acuity/drug effects ; Treatment Outcome ; *Angiogenesis Inhibitors/administration & dosage ; Aged, 80 and over ; Middle Aged ; China ; Time Factors ; East Asian People ; Antibodies, Bispecific ; },
abstract = {PURPOSE: To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and visual prognosis.
METHODS: This single-center retrospective cohort included 34 nAMD eyes that had received at least three consecutive aflibercept injections at 4-week intervals. Patients followed a 1+pro re nata (PRN) regimen for 12 months post-switch. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, and the prevalence of subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage (SRH) were evaluated. In 13 eyes with baseline SHRM, generalized estimating equations (GEE) were utilized to explore the association of dynamic SHRM height changes and treatment interval adjustments with visual acuity changes.
RESULTS: A total of 34 eyes were included. CMT dropped significantly after the initial faricimab injection (P = 0.0427). SRF prevalence declined markedly at 6 months, with significant PED and IRF prevalence reductions at 12 months. Among the 11 eyes with baseline SRH, the maximum SRH diameter decreased significantly at month 12 (adjusted P = 0.0039). No significant change was detected in BCVA. Median treatment intervals lengthened from 4.5 to 8.0 weeks (P = 0.017). In 13 eyes with baseline SHRM, SHRM reduction was associated with contemporaneous treatment-interval prolongation (B = -3.299 weeks per 100-μm increase; P < 0.001), but not with subsequent injection intervals or concurrent visual-acuity changes.
CONCLUSION: Switching to faricimab was associated with overall anatomical improvements and prolonged treatment intervals among pretreated nAMD eyes, while visual gains remained limited. However, complete anatomical resolution was not achieved in all patients. Dynamic changes in SHRM height may represent an exploratory imaging feature associated with treatment interval changes, however, its prospective predictive value and clinical utility remain to be validated.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Receptors, Vascular Endothelial Growth Factor/administration & dosage/antagonists & inhibitors/therapeutic use
*Recombinant Fusion Proteins/administration & dosage/therapeutic use
Retrospective Studies
Male
Female
*Macular Degeneration/drug therapy
Aged
Visual Acuity/drug effects
Treatment Outcome
*Angiogenesis Inhibitors/administration & dosage
Aged, 80 and over
Middle Aged
China
Time Factors
East Asian People
Antibodies, Bispecific
RevDate: 2026-11-10
3D corneal and retinal bioprinting: Tissue engineering strategies, translational challenges, and clinical opportunities.
Progress in retinal and eye research, 115:101538 pii:S1350-9462(26)00104-7 [Epub ahead of print].
Three-dimensional bioprinting has emerged as a promising strategy for addressing major unmet needs in ophthalmology, including the global shortage of donor corneal tissue and the absence of restorative therapies for retinal degenerative disease. Advances in biomaterials, stem cell biology, and biofabrication have enabled increasingly sophisticated ocular constructs, ranging from engineered corneal grafts to multicellular retinal models that recapitulate key aspects of native tissue architecture. However, substantial challenges remain in reproducing the optical, mechanical, and biological functions required for clinical translation. This review critically evaluates the current state of corneal and retinal bioprinting through a framework organized around tissue target, fabrication modality, and intended application. Major bioprinting approaches, including extrusion-based, laser-assisted, drop-on-demand, and light-based technologies, are compared with respect to resolution, cell compatibility, scalability, and translational potential. Particular emphasis is placed on the engineering constraints governing construct fidelity, bioink design, tissue integration, and long-term functional performance. Current evidence suggests that corneal and retinal bioprinting have progressed along distinct translational trajectories. Corneal bioprinting has achieved encouraging preclinical outcomes, with one approach entering early clinical evaluation, whereas retinal bioprinting has generated highly informative disease models but remains at an earlier stage of translational development. Across both tissues, the field has increasingly shifted from reproducing individual cellular components toward reconstructing the biological interfaces and multicellular systems that underlie tissue function. Future progress will depend on establishing functional validation frameworks, reproducible manufacturing workflows, and standardized benchmarks to support the clinical development of vision-restoring bioprinted constructs.
Additional Links: PMID-42951099
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42951099,
year = {2026},
author = {Shah, J and Pathuri, S and Sharma, R and Skottman, H and Mörö, A and Karamichos, D and Choi, A and Ong, J and Mehta, JS and Shrivastava, A and Sagoo, M and Berdahl, JP and Pandit, R and Bharti, K},
title = {3D corneal and retinal bioprinting: Tissue engineering strategies, translational challenges, and clinical opportunities.},
journal = {Progress in retinal and eye research},
volume = {115},
number = {},
pages = {101538},
doi = {10.1016/j.preteyeres.2026.101538},
pmid = {42951099},
issn = {1873-1635},
abstract = {Three-dimensional bioprinting has emerged as a promising strategy for addressing major unmet needs in ophthalmology, including the global shortage of donor corneal tissue and the absence of restorative therapies for retinal degenerative disease. Advances in biomaterials, stem cell biology, and biofabrication have enabled increasingly sophisticated ocular constructs, ranging from engineered corneal grafts to multicellular retinal models that recapitulate key aspects of native tissue architecture. However, substantial challenges remain in reproducing the optical, mechanical, and biological functions required for clinical translation. This review critically evaluates the current state of corneal and retinal bioprinting through a framework organized around tissue target, fabrication modality, and intended application. Major bioprinting approaches, including extrusion-based, laser-assisted, drop-on-demand, and light-based technologies, are compared with respect to resolution, cell compatibility, scalability, and translational potential. Particular emphasis is placed on the engineering constraints governing construct fidelity, bioink design, tissue integration, and long-term functional performance. Current evidence suggests that corneal and retinal bioprinting have progressed along distinct translational trajectories. Corneal bioprinting has achieved encouraging preclinical outcomes, with one approach entering early clinical evaluation, whereas retinal bioprinting has generated highly informative disease models but remains at an earlier stage of translational development. Across both tissues, the field has increasingly shifted from reproducing individual cellular components toward reconstructing the biological interfaces and multicellular systems that underlie tissue function. Future progress will depend on establishing functional validation frameworks, reproducible manufacturing workflows, and standardized benchmarks to support the clinical development of vision-restoring bioprinted constructs.},
}
RevDate: 2026-11-07
CmpDate: 2026-11-07
Loss of Farnesoid X Receptor Signaling Promotes Choroidal Neovascularization in Mice.
bioRxiv : the preprint server for biology pii:2026.10.21.760483.
UNLABELLED: Choroidal neovascularization (CNV) is a defining feature of neovascular age-related macular degeneration (nAMD). Although anti-vascular endothelial growth factor (VEGF) therapies suppress neovascular activity, incomplete responses, recurrent leakage, and subretinal fibrosis remain important clinical challenges. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor with anti-inflammatory, anti-fibrotic, and anti-angiogenic functions in other tissues, but its role in CNV is unknown. Analysis of publicly available human transcriptomic data (GSE135092) showed FXR expression in the retinal pigment epithelium (RPE)/choroid and significant downregulation in AMD-affected macular RPE/choroid. To define the role of FXR in CNV, laser photocoagulation was performed in wild-type (WT) and FXR-deficient (FXR [-/-]) mice, with disease progression assessed by in vivo imaging, histology, ex vivo choroidal sprouting, and endothelial cell assays. FXR expression in the RPE/choroid was reduced 14 days after laser injury. Compared with WT mice, FXR [-/-] mice developed larger CNV lesions, more extensive hyperfluorescence on fluorescein angiography, and increased lesion area during disease progression. FXR deficiency also impaired resolution of fibrotic remodeling. In WT mice, α-SMA peaked at day 14 and declined by day 21, whereas collagen I remained low throughout; in FXR [-/-] mice, both collagen I and α-SMA were significantly elevated relative to WT and remained significantly higher than WT at day 21. Consistent with these findings, FXR- deficient choroidal explants exhibited increased vascular sprouting, and FXR [-/-] endothelial cells formed more extensive capillary-like networks. Together, these findings identify FXR as an endogenous regulator of pathological angiogenesis, vascular leakage, mesenchymal activation, and fibrotic remodeling during CNV and provide a rationale for investigating FXR-directed strategies for nAMD.
IMPACT STATEMENT: Neovascular age-related macular degeneration remains limited by recurrent vascular leakage and subretinal fibrosis despite effective VEGF suppression. This study identifies the bile acid-activated nuclear receptor FXR as a previously unrecognized regulator of the angiogenic and fibrotic responses underlying choroidal neovascularization. Integrating human AMD transcriptomic data with genetic, in vivo, ex vivo, and endothelial-cell approaches, we show that FXR expression is reduced in diseased RPE/choroid and that FXR deficiency enhances neovascular growth, vascular leakage, endothelial angiogenic activity, and persistent myofibroblast activation. These findings connect bile acid receptor signaling with RPE/choroidal vascular homeostasis and provide a biological foundation for evaluating FXR-directed approaches as complementary strategies for neovascular AMD.
Additional Links: PMID-42996119
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42996119,
year = {2026},
author = {Harris, C and Nisar, MA and Seth, A and Oxenrider, A and Bailey, B and Seth, G and Martin, PM and Jadeja, RN and Thounaojam, MC},
title = {Loss of Farnesoid X Receptor Signaling Promotes Choroidal Neovascularization in Mice.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.21.760483},
pmid = {42996119},
issn = {2692-8205},
abstract = {UNLABELLED: Choroidal neovascularization (CNV) is a defining feature of neovascular age-related macular degeneration (nAMD). Although anti-vascular endothelial growth factor (VEGF) therapies suppress neovascular activity, incomplete responses, recurrent leakage, and subretinal fibrosis remain important clinical challenges. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor with anti-inflammatory, anti-fibrotic, and anti-angiogenic functions in other tissues, but its role in CNV is unknown. Analysis of publicly available human transcriptomic data (GSE135092) showed FXR expression in the retinal pigment epithelium (RPE)/choroid and significant downregulation in AMD-affected macular RPE/choroid. To define the role of FXR in CNV, laser photocoagulation was performed in wild-type (WT) and FXR-deficient (FXR [-/-]) mice, with disease progression assessed by in vivo imaging, histology, ex vivo choroidal sprouting, and endothelial cell assays. FXR expression in the RPE/choroid was reduced 14 days after laser injury. Compared with WT mice, FXR [-/-] mice developed larger CNV lesions, more extensive hyperfluorescence on fluorescein angiography, and increased lesion area during disease progression. FXR deficiency also impaired resolution of fibrotic remodeling. In WT mice, α-SMA peaked at day 14 and declined by day 21, whereas collagen I remained low throughout; in FXR [-/-] mice, both collagen I and α-SMA were significantly elevated relative to WT and remained significantly higher than WT at day 21. Consistent with these findings, FXR- deficient choroidal explants exhibited increased vascular sprouting, and FXR [-/-] endothelial cells formed more extensive capillary-like networks. Together, these findings identify FXR as an endogenous regulator of pathological angiogenesis, vascular leakage, mesenchymal activation, and fibrotic remodeling during CNV and provide a rationale for investigating FXR-directed strategies for nAMD.
IMPACT STATEMENT: Neovascular age-related macular degeneration remains limited by recurrent vascular leakage and subretinal fibrosis despite effective VEGF suppression. This study identifies the bile acid-activated nuclear receptor FXR as a previously unrecognized regulator of the angiogenic and fibrotic responses underlying choroidal neovascularization. Integrating human AMD transcriptomic data with genetic, in vivo, ex vivo, and endothelial-cell approaches, we show that FXR expression is reduced in diseased RPE/choroid and that FXR deficiency enhances neovascular growth, vascular leakage, endothelial angiogenic activity, and persistent myofibroblast activation. These findings connect bile acid receptor signaling with RPE/choroidal vascular homeostasis and provide a biological foundation for evaluating FXR-directed approaches as complementary strategies for neovascular AMD.},
}
RevDate: 2026-11-10
CmpDate: 2026-11-07
Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework.
Molecular genetics and genomics : MGG, 301(1):.
This study aimed to prioritize potential therapeutic candidates for age-related macular degeneration (AMD) using an integrated multi-omics Mendelian randomization (MR) framework. We performed two-sample MR using 2,816 cis-pQTLs from four proteome-wide association studies to identify AMD-associated plasma proteins. Validation included summary-based MR (SMR), colocalization, protein-protein interaction analysis, pathway enrichment, retinal expression profiling, and druggability assessment. We identified 22 AMD-associated proteins, including both known (e.g., CFB, APOE, C3) and novel candidates (e.g., CTRL, LCAT, TNFRSF10A). Four targets (C3, CTRL, LCAT, TNFRSF10A) were prioritized as Tier 1 candidates based on consistent MR and colocalization evidence. These targets were enriched in complement activation, coagulation, and lipid metabolism pathways. This study proposed 22 potential therapeutic targets for AMD, with C3, CTRL, LCAT, and TNFRSF10A representing high-confidence candidates for further mechanistic and clinical investigation.
Additional Links: PMID-42998155
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42998155,
year = {2026},
author = {Xiang, Z and Huang, W and Zhao, X and Zhou, M and Huang, X and Wang, S},
title = {Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework.},
journal = {Molecular genetics and genomics : MGG},
volume = {301},
number = {1},
pages = {},
pmid = {42998155},
issn = {1617-4623},
support = {10000015Z155080000004//National Clinical Key Specialty Construction Project/ ; 2023YFC2506100//National Key Research and Development Program of China/ ; 82471077//the National Natural Science Foundation of China/ ; SHDC12024138//Shanghai Hospital Development Center Foundation/ ; SHDC22024304-A//Shanghai Municipal Hospital Ophthalmology Specialist Alliance/ ; 2022KY1179//Zhejiang Medicine and Health Science and Technology Project/ ; 2023-Z2//Ningbo Clinical Medical Research Center for Ophthalmology/ ; },
mesh = {Humans ; *Macular Degeneration/genetics/blood/drug therapy/pathology ; *Proteome/genetics ; Multiomics ; *Mendelian Randomization Analysis/methods ; *Blood Proteins/genetics/metabolism ; Lipid Metabolism/genetics ; },
abstract = {This study aimed to prioritize potential therapeutic candidates for age-related macular degeneration (AMD) using an integrated multi-omics Mendelian randomization (MR) framework. We performed two-sample MR using 2,816 cis-pQTLs from four proteome-wide association studies to identify AMD-associated plasma proteins. Validation included summary-based MR (SMR), colocalization, protein-protein interaction analysis, pathway enrichment, retinal expression profiling, and druggability assessment. We identified 22 AMD-associated proteins, including both known (e.g., CFB, APOE, C3) and novel candidates (e.g., CTRL, LCAT, TNFRSF10A). Four targets (C3, CTRL, LCAT, TNFRSF10A) were prioritized as Tier 1 candidates based on consistent MR and colocalization evidence. These targets were enriched in complement activation, coagulation, and lipid metabolism pathways. This study proposed 22 potential therapeutic targets for AMD, with C3, CTRL, LCAT, and TNFRSF10A representing high-confidence candidates for further mechanistic and clinical investigation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Macular Degeneration/genetics/blood/drug therapy/pathology
*Proteome/genetics
Multiomics
*Mendelian Randomization Analysis/methods
*Blood Proteins/genetics/metabolism
Lipid Metabolism/genetics
RevDate: 2026-11-07
Statin Use and Age-related Macular Degeneration: A Systematic Review and Meta-Analysis of Disease Outcomes.
American journal of ophthalmology pii:S0002-9394(26)00615-X [Epub ahead of print].
TOPIC: This systematic review and meta-analysis evaluated the association between statin use and the prevalence, incidence, and progression of age-related macular degeneration (AMD).
CLINICAL RELEVANCE: AMD is a major cause of vision loss in older adults, many of whom receive statins for cardiovascular prevention.
METHODS: We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library through October 2025 for randomized trials and cohort, case-control, and cross-sectional studies with comparators. We assessed risk of bias with tools appropriate to each design and pooled effect measures separately using random-effects models. The protocol was registered in PROSPERO.
RESULTS: Twenty-eight studies included 1,918,120 participants. Pooled odds ratios (ORs) for the prevalence of any, early, and late AMD were 1.03 (95% confidence interval [CI], 0.86-1.24), 1.10 (95% CI, 0.92-1.31), and 0.75 (95% CI, 0.46-1.25), respectively. For incidence of any AMD, the pooled hazard ratio (HR) was 1.04 (95% CI, 0.82-1.31) and the OR was 0.76 (95% CI, 0.43-1.34), with substantial heterogeneity. For neovascular AMD incidence, different study subsets suggested lower hazard (HR, 0.72; 95% CI, 0.60-0.85) and higher risk (risk ratio, 1.31; 95% CI, 1.18-1.44); the OR was inconclusive (0.93; 95% CI, 0.82-1.05). Progression evidence was limited and heterogeneous. Ten of 12 longitudinal nonrandomized studies had serious overall risk of bias.
CONCLUSION: The evidence was of very low certainty and insufficient to establish a protective or harmful effect of statins on AMD. These findings do not support prescribing statins specifically for AMD or discontinuing otherwise indicated therapy.
Additional Links: PMID-42998694
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42998694,
year = {2026},
author = {Magalhães, PLM and Rassi, T and Amaral, DC and Veiga, DM and Oliveira, AKR and Gonzalez, JVP and Silva, LO and Caixeta, GL and Maia, M and Louzada, RN},
title = {Statin Use and Age-related Macular Degeneration: A Systematic Review and Meta-Analysis of Disease Outcomes.},
journal = {American journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.ajo.2026.11.005},
pmid = {42998694},
issn = {1879-1891},
abstract = {TOPIC: This systematic review and meta-analysis evaluated the association between statin use and the prevalence, incidence, and progression of age-related macular degeneration (AMD).
CLINICAL RELEVANCE: AMD is a major cause of vision loss in older adults, many of whom receive statins for cardiovascular prevention.
METHODS: We searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library through October 2025 for randomized trials and cohort, case-control, and cross-sectional studies with comparators. We assessed risk of bias with tools appropriate to each design and pooled effect measures separately using random-effects models. The protocol was registered in PROSPERO.
RESULTS: Twenty-eight studies included 1,918,120 participants. Pooled odds ratios (ORs) for the prevalence of any, early, and late AMD were 1.03 (95% confidence interval [CI], 0.86-1.24), 1.10 (95% CI, 0.92-1.31), and 0.75 (95% CI, 0.46-1.25), respectively. For incidence of any AMD, the pooled hazard ratio (HR) was 1.04 (95% CI, 0.82-1.31) and the OR was 0.76 (95% CI, 0.43-1.34), with substantial heterogeneity. For neovascular AMD incidence, different study subsets suggested lower hazard (HR, 0.72; 95% CI, 0.60-0.85) and higher risk (risk ratio, 1.31; 95% CI, 1.18-1.44); the OR was inconclusive (0.93; 95% CI, 0.82-1.05). Progression evidence was limited and heterogeneous. Ten of 12 longitudinal nonrandomized studies had serious overall risk of bias.
CONCLUSION: The evidence was of very low certainty and insufficient to establish a protective or harmful effect of statins on AMD. These findings do not support prescribing statins specifically for AMD or discontinuing otherwise indicated therapy.},
}
RevDate: 2026-11-08
CmpDate: 2026-11-05
First-in-Human Regulatory T Cell-Derived Exosomes Plus Ranibizumab for Refractory nAMD.
Journal of extracellular vesicles, 15(11):.
Persistent fluid despite intravitreal anti-vascular endothelial growth factor (VEGF) treatment remains common in neovascular age-related macular degeneration (nAMD). Regulatory T cell-derived exosomes (TregExo) have preclinical immunomodulatory activity. To evaluate the safety and maximum tolerated dose (MTD) of intravitreal autologous TregExo plus ranibizumab in refractory nAMD. Design, Setting, and Participants: Single-centre, prospective, open-label phase 1a trial using a 3+3 dose-escalation design at Hebei General Hospital. Four participants with persistent intraretinal or subretinal fluid despite at least 3 consecutive monthly intravitreal anti-VEGF injections were treated. One intravitreal injection of autologous TregExo (planned doses, 0.05, 0.5, or 1.5 mg) coformulated with ranibizumab, 0.5 mg. The primary outcome was safety and MTD determination. Dose-limiting toxicity (DLT) was prespecified as severe sterile intraocular inflammation, sustained intraocular pressure greater than 30 mm Hg, loss of more than 15 ETDRS points, or another serious ocular adverse event within 30 days. Exploratory visual and anatomic outcomes were assessed through day 90. Four participants were treated: 3 at 0.05 mg and 1 at 0.5 mg. No DLT or intraocular inflammation occurred in the 0.05-mg cohort, and intraocular pressure remained stable. Two low-dose participants improved from ETDRS scores of 3 and 9 at baseline to 35 at day 90; Patient 1 had a macular thickness reduction from 318.2 to 253.9 µm. The 0.5-mg participant developed sterile intraocular inflammation with vision loss and a large intraretinal cyst, which resolved after local corticosteroid therapy. Dose escalation was stopped, and 0.05 mg was the protocol-defined MTD. Intravitreal autologous TregExo plus ranibizumab had an identifiable dose ceiling: 0.05 mg was tolerated, whereas 0.5 mg was associated with DLT. Further controlled evaluation of lower-dose TregExo-based adjunctive therapy in refractory nAMD is warranted. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2500095798.
Additional Links: PMID-42988724
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42988724,
year = {2026},
author = {Tian, Y and Qian, Z and Fan, S and Wang, J and Wei, W and Tao, Y},
title = {First-in-Human Regulatory T Cell-Derived Exosomes Plus Ranibizumab for Refractory nAMD.},
journal = {Journal of extracellular vesicles},
volume = {15},
number = {11},
pages = {},
pmid = {42988724},
issn = {2001-3078},
support = {82525020//National Natural Science Foundation of China/ ; 82471081//National Natural Science Foundation of China/ ; T2225021//National Natural Science Foundation of China/ ; 2025YFA1212700//National Key Research and Development Program of China/ ; DFL20220301//Beijing Hospitals Authority's Ascent Program/ ; H2020206650//Natural Science Foundation of Hebei Province/ ; },
mesh = {Humans ; *Ranibizumab/therapeutic use/administration & dosage/pharmacology ; Female ; *T-Lymphocytes, Regulatory/metabolism/immunology ; Male ; Intravitreal Injections ; *Exosomes/metabolism/transplantation ; *Macular Degeneration/drug therapy ; Aged ; *Angiogenesis Inhibitors/administration & dosage/therapeutic use ; Prospective Studies ; Maximum Tolerated Dose ; },
abstract = {Persistent fluid despite intravitreal anti-vascular endothelial growth factor (VEGF) treatment remains common in neovascular age-related macular degeneration (nAMD). Regulatory T cell-derived exosomes (TregExo) have preclinical immunomodulatory activity. To evaluate the safety and maximum tolerated dose (MTD) of intravitreal autologous TregExo plus ranibizumab in refractory nAMD. Design, Setting, and Participants: Single-centre, prospective, open-label phase 1a trial using a 3+3 dose-escalation design at Hebei General Hospital. Four participants with persistent intraretinal or subretinal fluid despite at least 3 consecutive monthly intravitreal anti-VEGF injections were treated. One intravitreal injection of autologous TregExo (planned doses, 0.05, 0.5, or 1.5 mg) coformulated with ranibizumab, 0.5 mg. The primary outcome was safety and MTD determination. Dose-limiting toxicity (DLT) was prespecified as severe sterile intraocular inflammation, sustained intraocular pressure greater than 30 mm Hg, loss of more than 15 ETDRS points, or another serious ocular adverse event within 30 days. Exploratory visual and anatomic outcomes were assessed through day 90. Four participants were treated: 3 at 0.05 mg and 1 at 0.5 mg. No DLT or intraocular inflammation occurred in the 0.05-mg cohort, and intraocular pressure remained stable. Two low-dose participants improved from ETDRS scores of 3 and 9 at baseline to 35 at day 90; Patient 1 had a macular thickness reduction from 318.2 to 253.9 µm. The 0.5-mg participant developed sterile intraocular inflammation with vision loss and a large intraretinal cyst, which resolved after local corticosteroid therapy. Dose escalation was stopped, and 0.05 mg was the protocol-defined MTD. Intravitreal autologous TregExo plus ranibizumab had an identifiable dose ceiling: 0.05 mg was tolerated, whereas 0.5 mg was associated with DLT. Further controlled evaluation of lower-dose TregExo-based adjunctive therapy in refractory nAMD is warranted. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2500095798.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Ranibizumab/therapeutic use/administration & dosage/pharmacology
Female
*T-Lymphocytes, Regulatory/metabolism/immunology
Male
Intravitreal Injections
*Exosomes/metabolism/transplantation
*Macular Degeneration/drug therapy
Aged
*Angiogenesis Inhibitors/administration & dosage/therapeutic use
Prospective Studies
Maximum Tolerated Dose
RevDate: 2026-11-07
CmpDate: 2026-11-06
Central-field stimulus thresholds in age-related macular degeneration: Associations with visual function and retinal structure.
Advances in ophthalmology practice and research, 6(4):355-362.
BACKGROUND: To evaluate the central-field stimulus threshold (CST) values in patients with age-related macular degeneration (AMD) and investigate the relationship between CST values and conventional visual function assessments, as well as retinal anatomical parameters, thereby exploring the role of CST in assessing anti-vascular endothelial growth factor (VEGF) therapy.
METHODS: Forty patients (eighty eyes) with AMD were included in the analysis. All patients underwent complete ophthalmic examination, including slit-lamp examination, fundus examination, intraocular pressure measurement, Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), fundus photography, optical coherence tomography (OCT), OCT angiography, microperimetry (MP), and CST testing. Linear mixed-effects models and generalized linear mixed models were employed to analyze the correlations between CST and BCVA, MP, OCT features, and choroidal neovascularization (CNV) area, as well as changes in CST following anti-VEGF therapy.
RESULTS: Compared to normal eyes, neovascular AMD (nAMD) eyes exhibited higher CST values for white (-47.02 ± 9.02 vs. -51.09 ± 3.61 dB), blue (-52.50 ± 14.46 vs. -60.28 ± 8.60 dB), and red (-30.22 ± 8.21 vs. -36.24 ± 6.41 dB) stimuli. Approximately 39% of nAMD eyes exhibited cone-mediated vision under scotopic conditions. In nAMD eyes, BCVA was negatively correlated with blue and white CST, indicating that better BCVA was associated with higher central retinal light sensitivity. Red and blue CST were positively correlated with center retinal thickness (CRT) and CNV area (All P < 0.05). In the thicker CRT group, the blue-red CST difference decreased from -18.03 ± 10.01 dB to -22.85 ± 2.22 dB after 1 month of anti-VEGF treatment (P = 0.047), 9 of 14 eyes were cone-mediated at baseline, which decreased to 3 eyes after three months of treatment.
CONCLUSIONS: CST assessment revealed that both cone and rod were affected in nAMD eyes. CST was correlated with CRT and CNV area. In some nAMD patients, severe rod dysfunction leads to a shift to cone-mediated vision under scotopic conditions, but anti-VEGF therapy may ameliorate this phenomenon. These findings suggest that CST assesses the visual function of AMD patients from a more microscopic, cellular functional standpoint, which may be beneficial for monitoring AMD progression and evaluating the treatment efficacy.
Additional Links: PMID-42991158
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42991158,
year = {2026},
author = {Chen, Y and Bo, Q and Liu, W and Wang, H and Liu, Z and Zhang, H and Chen, J and Sun, J and Jia, H and Gong, Y and Li, T and Sun, X},
title = {Central-field stimulus thresholds in age-related macular degeneration: Associations with visual function and retinal structure.},
journal = {Advances in ophthalmology practice and research},
volume = {6},
number = {4},
pages = {355-362},
pmid = {42991158},
issn = {2667-3762},
abstract = {BACKGROUND: To evaluate the central-field stimulus threshold (CST) values in patients with age-related macular degeneration (AMD) and investigate the relationship between CST values and conventional visual function assessments, as well as retinal anatomical parameters, thereby exploring the role of CST in assessing anti-vascular endothelial growth factor (VEGF) therapy.
METHODS: Forty patients (eighty eyes) with AMD were included in the analysis. All patients underwent complete ophthalmic examination, including slit-lamp examination, fundus examination, intraocular pressure measurement, Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), fundus photography, optical coherence tomography (OCT), OCT angiography, microperimetry (MP), and CST testing. Linear mixed-effects models and generalized linear mixed models were employed to analyze the correlations between CST and BCVA, MP, OCT features, and choroidal neovascularization (CNV) area, as well as changes in CST following anti-VEGF therapy.
RESULTS: Compared to normal eyes, neovascular AMD (nAMD) eyes exhibited higher CST values for white (-47.02 ± 9.02 vs. -51.09 ± 3.61 dB), blue (-52.50 ± 14.46 vs. -60.28 ± 8.60 dB), and red (-30.22 ± 8.21 vs. -36.24 ± 6.41 dB) stimuli. Approximately 39% of nAMD eyes exhibited cone-mediated vision under scotopic conditions. In nAMD eyes, BCVA was negatively correlated with blue and white CST, indicating that better BCVA was associated with higher central retinal light sensitivity. Red and blue CST were positively correlated with center retinal thickness (CRT) and CNV area (All P < 0.05). In the thicker CRT group, the blue-red CST difference decreased from -18.03 ± 10.01 dB to -22.85 ± 2.22 dB after 1 month of anti-VEGF treatment (P = 0.047), 9 of 14 eyes were cone-mediated at baseline, which decreased to 3 eyes after three months of treatment.
CONCLUSIONS: CST assessment revealed that both cone and rod were affected in nAMD eyes. CST was correlated with CRT and CNV area. In some nAMD patients, severe rod dysfunction leads to a shift to cone-mediated vision under scotopic conditions, but anti-VEGF therapy may ameliorate this phenomenon. These findings suggest that CST assesses the visual function of AMD patients from a more microscopic, cellular functional standpoint, which may be beneficial for monitoring AMD progression and evaluating the treatment efficacy.},
}
RevDate: 2026-11-07
Longitudinal Systemic C-Reactive Protein and Risk of Progression to Advanced Age-Related Macular Degeneration.
Journal of vitreoretinal diseases [Epub ahead of print].
PURPOSE: To assess whether longitudinally measured systemic high-sensitivity C-reactive protein levels are associated with time to progression to any advanced age-related macular degeneration (AMD) or AMD phenotypes in a cohort of subjects with intermediate AMD (iAMD).
METHODS: Medical records were obtained from subjects in the University of Colorado AMD Registry (enrolled 2014-2023) with at least 1 month of follow-up. Cox proportional hazards models were used to calculate hazard ratios (HRs) from joint models estimating the association between longitudinally measured systemic high-sensitivity C-reactive protein and time to progression to advanced AMD.
RESULTS: A total of 428 subjects with iAMD were enrolled. During the 1828 person-years of follow-up, 18% of subjects showed progression to geographic atrophy (GA), and 14% had progression to neovascular AMD. Analyzed as a continuous variable, high-sensitivity C-reactive protein levels (mg/L) were not associated with time to progression to any advanced AMD (HR, 1.13, 95% credible interval [95% CrI], 0.57 to 2.23; P = .71), time to progression to GA (HR, 1.21, 95% CrI, 0.44 to 3.27; P = .71), or time to progression to neovascular AMD (HR, 1.03, 95% CrI, 0.43 to 2.50; P = .95). Examined as a dichotomous variable by decile, high-sensitivity C-reactive protein was not associated with progression to any advanced AMD for any dichotomization threshold assessed.
CONCLUSIONS: The findings suggest that longitudinally measured systemic high-sensitivity C-reactive protein is not a useful biomarker for the timing of progression from iAMD to advanced AMD phenotypes.
Additional Links: PMID-42991377
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42991377,
year = {2026},
author = {Grove, NC and Lynch, AM and Wagner, BD and Holers, VM and Gnanaraj, R and Lisker-Cervantes, A and Patnaik, JL and de Carlo Forest, TE and Auer, EA and Mathias, MT and Manoharan, N and Mandava, N and Palestine, AG},
title = {Longitudinal Systemic C-Reactive Protein and Risk of Progression to Advanced Age-Related Macular Degeneration.},
journal = {Journal of vitreoretinal diseases},
volume = {},
number = {},
pages = {24741264261498852},
pmid = {42991377},
issn = {2474-1272},
support = {R01 EY032456/EY/NEI NIH HHS/United States ; UL1 TR002535/TR/NCATS NIH HHS/United States ; UM1 TR004399/TR/NCATS NIH HHS/United States ; },
abstract = {PURPOSE: To assess whether longitudinally measured systemic high-sensitivity C-reactive protein levels are associated with time to progression to any advanced age-related macular degeneration (AMD) or AMD phenotypes in a cohort of subjects with intermediate AMD (iAMD).
METHODS: Medical records were obtained from subjects in the University of Colorado AMD Registry (enrolled 2014-2023) with at least 1 month of follow-up. Cox proportional hazards models were used to calculate hazard ratios (HRs) from joint models estimating the association between longitudinally measured systemic high-sensitivity C-reactive protein and time to progression to advanced AMD.
RESULTS: A total of 428 subjects with iAMD were enrolled. During the 1828 person-years of follow-up, 18% of subjects showed progression to geographic atrophy (GA), and 14% had progression to neovascular AMD. Analyzed as a continuous variable, high-sensitivity C-reactive protein levels (mg/L) were not associated with time to progression to any advanced AMD (HR, 1.13, 95% credible interval [95% CrI], 0.57 to 2.23; P = .71), time to progression to GA (HR, 1.21, 95% CrI, 0.44 to 3.27; P = .71), or time to progression to neovascular AMD (HR, 1.03, 95% CrI, 0.43 to 2.50; P = .95). Examined as a dichotomous variable by decile, high-sensitivity C-reactive protein was not associated with progression to any advanced AMD for any dichotomization threshold assessed.
CONCLUSIONS: The findings suggest that longitudinally measured systemic high-sensitivity C-reactive protein is not a useful biomarker for the timing of progression from iAMD to advanced AMD phenotypes.},
}
RevDate: 2026-11-09
CmpDate: 2026-11-06
Fas Ligand enhances vessel maturation and inhibits vascular leakage associated with age-related macular degeneration.
Frontiers in immunology, 17:1898554.
INTRODUCTION: Age-related macular degeneration (AMD), results from choroidal neovascularization (CNV), retinal edema and loss of photoreceptors. Previous studies suggest that Fas Ligand (FasL) on retinal pigment epithelial cells inhibits CNV by inducing apoptosis of infiltrating Fas+ vascular endothelial cells. However, membrane-bound FasL (mFasL) can be cleaved by metalloproteinases to release a soluble fragment (sFasL) and the two isoforms have distinct functions. mFasL induces apoptosis and inflammation while sFasL has been shown to promote cell activation, cell survival, cell proliferation, and cell migration. In this current study, we use a genetic approach to prevent cleavage of mFasL in order to determine the extent to which sFasL and/or mFasL contribute to vascular leakage in a mouse model of laser-induced CNV.
METHODS: To distinguish the role of mFasL from sFasL in regulating CNV and vascular leakage, we used a 532 nm laser to induce CNV in three types of mice: (i) wild-type (WT) FasL[WT/WT] mice that express low levels of mFasL and high levels of sFasL, (ii) homozygous FasL[ΔCS/ΔCS] mice that express greater than normal levels of mFasL and no sFasL, and (iii) heterozygous FasL[ΔCS/WT] mice that express greater than normal levels of mFasL and less than normal levels of sFasL.
RESULTS: Unexpectedly, CNV size and the area of vascular leakage were comparable in homozygous FasL[ΔCS/ΔCS] and WT mice. However, heterozygous FasL[ΔCS/WT] mice developed significantly less vascular leakage and showed accelerated neovessel maturation that depended on the expression of the Fas receptor in LysM-positive myeloid cells. Moreover, the protective phenotype observed in heterozygous FasL[ΔCS/WT] mice correlated with increased retinal expression of PDGFRb and TGFβ1, reduced retinal expression of VEGFA, and increased expression of PEDF, which is known to inhibit VEGF-induced vascular permeability and promote vessel normalization.
DISCUSSION: Overall, these data indicate that FasL-mediated protection from CNV depends on expression of both sFasL and mFasL. Moreover, the accelerated neovessel maturation observed in heterozygous FasL[ΔCS/WT] mice depends on Fas signaling in LysM-positive myeloid cells and is highly dependent on the extent of FasL cleavage, identifying Fas ligand cleavage as a potential therapeutic strategy to promote neovessel maturation and prevent vascular leakage in wet AMD.
Additional Links: PMID-42991796
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42991796,
year = {2026},
author = {Koirala, A and Marshak-Rothstein, A and Ksander, BR and Gregory-Ksander, M},
title = {Fas Ligand enhances vessel maturation and inhibits vascular leakage associated with age-related macular degeneration.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1898554},
pmid = {42991796},
issn = {1664-3224},
support = {P30 EY003790/EY/NEI NIH HHS/United States ; R01 AR055634/AR/NIAMS NIH HHS/United States ; R21 EY022433/EY/NEI NIH HHS/United States ; },
mesh = {Animals ; *Fas Ligand Protein/metabolism/genetics ; *Macular Degeneration/metabolism/pathology ; Mice ; *Choroidal Neovascularization/metabolism/pathology/etiology ; *Capillary Permeability ; Disease Models, Animal ; Mice, Inbred C57BL ; Mice, Knockout ; },
abstract = {INTRODUCTION: Age-related macular degeneration (AMD), results from choroidal neovascularization (CNV), retinal edema and loss of photoreceptors. Previous studies suggest that Fas Ligand (FasL) on retinal pigment epithelial cells inhibits CNV by inducing apoptosis of infiltrating Fas+ vascular endothelial cells. However, membrane-bound FasL (mFasL) can be cleaved by metalloproteinases to release a soluble fragment (sFasL) and the two isoforms have distinct functions. mFasL induces apoptosis and inflammation while sFasL has been shown to promote cell activation, cell survival, cell proliferation, and cell migration. In this current study, we use a genetic approach to prevent cleavage of mFasL in order to determine the extent to which sFasL and/or mFasL contribute to vascular leakage in a mouse model of laser-induced CNV.
METHODS: To distinguish the role of mFasL from sFasL in regulating CNV and vascular leakage, we used a 532 nm laser to induce CNV in three types of mice: (i) wild-type (WT) FasL[WT/WT] mice that express low levels of mFasL and high levels of sFasL, (ii) homozygous FasL[ΔCS/ΔCS] mice that express greater than normal levels of mFasL and no sFasL, and (iii) heterozygous FasL[ΔCS/WT] mice that express greater than normal levels of mFasL and less than normal levels of sFasL.
RESULTS: Unexpectedly, CNV size and the area of vascular leakage were comparable in homozygous FasL[ΔCS/ΔCS] and WT mice. However, heterozygous FasL[ΔCS/WT] mice developed significantly less vascular leakage and showed accelerated neovessel maturation that depended on the expression of the Fas receptor in LysM-positive myeloid cells. Moreover, the protective phenotype observed in heterozygous FasL[ΔCS/WT] mice correlated with increased retinal expression of PDGFRb and TGFβ1, reduced retinal expression of VEGFA, and increased expression of PEDF, which is known to inhibit VEGF-induced vascular permeability and promote vessel normalization.
DISCUSSION: Overall, these data indicate that FasL-mediated protection from CNV depends on expression of both sFasL and mFasL. Moreover, the accelerated neovessel maturation observed in heterozygous FasL[ΔCS/WT] mice depends on Fas signaling in LysM-positive myeloid cells and is highly dependent on the extent of FasL cleavage, identifying Fas ligand cleavage as a potential therapeutic strategy to promote neovessel maturation and prevent vascular leakage in wet AMD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Fas Ligand Protein/metabolism/genetics
*Macular Degeneration/metabolism/pathology
Mice
*Choroidal Neovascularization/metabolism/pathology/etiology
*Capillary Permeability
Disease Models, Animal
Mice, Inbred C57BL
Mice, Knockout
RevDate: 2026-11-06
Early macular dryness after four loading injections of faricimab was associated with reduced two-year treatment burden in treatment-naïve neovascular age-related macular degeneration.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Epub ahead of print].
PURPOSE: To investigate the association of complete macular dryness after four loading injections of faricimab with treatment burden and dosing intervals over two years in treatment-naïve neovascular age-related macular degeneration (nAMD).
METHODS: This retrospective consecutive case series included treatment-naïve nAMD eyes treated with four monthly loading intravitreal injections of faricimab followed by a treat-and-extend (TAE) regimen in which treatment intervals were adjusted in 2-week increments according to disease activity. Eyes were classified according to complete absence of intraretinal and subretinal fluid after the fourth injection. The primary outcome was the cumulative number of faricimab injections during 2 years. Secondary outcomes included year-1 and year-2 injection numbers and treatment intervals.
RESULTS: Ninety-one eyes were included. Complete macular dryness after the fourth injection (Week 16) was achieved in 73 eyes (80.2%), which required significantly fewer injections during two years than eyes with persistent fluid (median [interquartile ranges; 25th - 75th percentiles]), 11 [10-12] vs. 14 [12-14.75]; P < 0.001). The dry group also required fewer injections during year 2 (3 [3-4] vs. 5 [4-5]; P = 0.001) and had longer treatment intervals at 2 years (16 [14-16] vs. 12 [10-12] weeks; P < 0.001). In multivariable analyses, Week-16 dryness remained independently associated with fewer cumulative injections and longer treatment intervals.
CONCLUSIONS: Complete macular dryness after four loading injections of faricimab was associated with lower injection burden and longer treatment intervals over two years. Assessment of optical coherence tomography fluid status after loading may help inform individualized TAE management in nAMD.
Additional Links: PMID-42995256
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42995256,
year = {2026},
author = {Hikichi, T},
title = {Early macular dryness after four loading injections of faricimab was associated with reduced two-year treatment burden in treatment-naïve neovascular age-related macular degeneration.},
journal = {Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie},
volume = {},
number = {},
pages = {},
pmid = {42995256},
issn = {1435-702X},
abstract = {PURPOSE: To investigate the association of complete macular dryness after four loading injections of faricimab with treatment burden and dosing intervals over two years in treatment-naïve neovascular age-related macular degeneration (nAMD).
METHODS: This retrospective consecutive case series included treatment-naïve nAMD eyes treated with four monthly loading intravitreal injections of faricimab followed by a treat-and-extend (TAE) regimen in which treatment intervals were adjusted in 2-week increments according to disease activity. Eyes were classified according to complete absence of intraretinal and subretinal fluid after the fourth injection. The primary outcome was the cumulative number of faricimab injections during 2 years. Secondary outcomes included year-1 and year-2 injection numbers and treatment intervals.
RESULTS: Ninety-one eyes were included. Complete macular dryness after the fourth injection (Week 16) was achieved in 73 eyes (80.2%), which required significantly fewer injections during two years than eyes with persistent fluid (median [interquartile ranges; 25th - 75th percentiles]), 11 [10-12] vs. 14 [12-14.75]; P < 0.001). The dry group also required fewer injections during year 2 (3 [3-4] vs. 5 [4-5]; P = 0.001) and had longer treatment intervals at 2 years (16 [14-16] vs. 12 [10-12] weeks; P < 0.001). In multivariable analyses, Week-16 dryness remained independently associated with fewer cumulative injections and longer treatment intervals.
CONCLUSIONS: Complete macular dryness after four loading injections of faricimab was associated with lower injection burden and longer treatment intervals over two years. Assessment of optical coherence tomography fluid status after loading may help inform individualized TAE management in nAMD.},
}
RevDate: 2026-11-05
Combined Versus Monotherapy Anti-Complement and Anti-Vascular Endothelial Growth Factor Intravitreal Injections for Age-Related Macular Degeneration: Safety Outcomes in the Real World.
Ophthalmology. Retina pii:S2468-6530(26)00566-X [Epub ahead of print].
PURPOSE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the established treatment for neovascular AMD (nAMD), while anti-complement therapy was recently approved for the treatment of geographic atrophy (GA). This study compared safety outcomes with combined anti-VEGF and anti-complement therapy with those of each monotherapy in real-world, routine clinical practice.
DESIGN: Retrospective, consecutive cohort study.
PARTICIPANTS: All eyes receiving ≥1 intravitreal anti-VEGF and/or anti-complement therapy injection(s) with ≥30 days of follow-up.
METHODS: This study utilized a large electronic medical record (EMR) database from a US consortium of retina practices. Eyes were categorized into Monotherapy (MT) or Dual Therapy (DT) cohorts. The MT cohort was sub-divided into eyes receiving anti-VEGF MT for nAMD and those receiving anti-complement MT for GA. The DT cohort, comprised of eyes receiving both agents, was stratified by treatment sequence: anti-VEGF initiated first (anti-VEGF/complement DT) or anti-complement initiated first (anti-complement/VEGF DT).
MAIN OUTCOME MEASURES: Incidences of endophthalmitis, retinal vasculitis, retinitis and vision loss of ≥15 letters in the setting of intraocular inflammation (IOI) other than endophthalmitis, retinal vasculitis, or retinitis occurring within 21 days of any injection. Secondary outcomes included rates of uveitis, vitritis, and retinal detachment occurring within 21 days of intravitreal injection as well as changes in best recorded visual acuity (BRVA) and intraocular pressure (IOP).
RESULTS: Across 54,983 eyes with a mean patient age of 82.1 ± 9.0 years, 1,103,299 intravitreal injections (1,068,545 anti-VEGF; 34,754 anti-complement) were administered. Anti-VEGF MT accounted for 83.5% (n=45,940) of eyes and anti-complement MT 12.3% (n=6,751), while 4.2% (n=2,292) received DT. Overall adverse event rates were low per 10,000 injections: endophthalmitis (1.21), retinal vasculitis (0.03), retinitis (0.03), intraocular inflammation with ≥15-letter vision loss (0.05). Among 277 patients involving 340 eyes who received at least one same-day dual treatment, event rates per 10,000 injections were 4.66 for endophthalmitis (n = 1), 0 for retinal vasculitis, and 4.66 for retinitis (n = 1). In comparison, among eyes receiving non-same-day DT injections, rates were 0.91 for endophthalmitis (n = 6), 0.15 for retinal vasculitis (n = 1), and 0 for retinitis. BRVA declined over time in all cohorts and no cohort demonstrated sustained IOP elevation.
CONCLUSION: In this analysis of outcomes from routine clinical practice, dual anti-VEGF and anti-complement therapy was not associated with higher overall rates of serious ocular adverse events compared with monotherapy. Serious ocular adverse events were rare across all treatment strategies. Additional larger and prospective analyses are warranted to further characterize the safety of combined intravitreal injections in clinical practice.
Additional Links: PMID-42988264
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42988264,
year = {2026},
author = {Esmaeilkhanian, H and Dorflinger, C and Wang, C and Storey, PP and Al-Khersan, H and Fan, KC and Minaker, S and MacCumber, M and Quinn, K and Holcomb, D and Wykoff, CC and Wood, EH},
title = {Combined Versus Monotherapy Anti-Complement and Anti-Vascular Endothelial Growth Factor Intravitreal Injections for Age-Related Macular Degeneration: Safety Outcomes in the Real World.},
journal = {Ophthalmology. Retina},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.oret.2026.10.016},
pmid = {42988264},
issn = {2468-6530},
abstract = {PURPOSE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the established treatment for neovascular AMD (nAMD), while anti-complement therapy was recently approved for the treatment of geographic atrophy (GA). This study compared safety outcomes with combined anti-VEGF and anti-complement therapy with those of each monotherapy in real-world, routine clinical practice.
DESIGN: Retrospective, consecutive cohort study.
PARTICIPANTS: All eyes receiving ≥1 intravitreal anti-VEGF and/or anti-complement therapy injection(s) with ≥30 days of follow-up.
METHODS: This study utilized a large electronic medical record (EMR) database from a US consortium of retina practices. Eyes were categorized into Monotherapy (MT) or Dual Therapy (DT) cohorts. The MT cohort was sub-divided into eyes receiving anti-VEGF MT for nAMD and those receiving anti-complement MT for GA. The DT cohort, comprised of eyes receiving both agents, was stratified by treatment sequence: anti-VEGF initiated first (anti-VEGF/complement DT) or anti-complement initiated first (anti-complement/VEGF DT).
MAIN OUTCOME MEASURES: Incidences of endophthalmitis, retinal vasculitis, retinitis and vision loss of ≥15 letters in the setting of intraocular inflammation (IOI) other than endophthalmitis, retinal vasculitis, or retinitis occurring within 21 days of any injection. Secondary outcomes included rates of uveitis, vitritis, and retinal detachment occurring within 21 days of intravitreal injection as well as changes in best recorded visual acuity (BRVA) and intraocular pressure (IOP).
RESULTS: Across 54,983 eyes with a mean patient age of 82.1 ± 9.0 years, 1,103,299 intravitreal injections (1,068,545 anti-VEGF; 34,754 anti-complement) were administered. Anti-VEGF MT accounted for 83.5% (n=45,940) of eyes and anti-complement MT 12.3% (n=6,751), while 4.2% (n=2,292) received DT. Overall adverse event rates were low per 10,000 injections: endophthalmitis (1.21), retinal vasculitis (0.03), retinitis (0.03), intraocular inflammation with ≥15-letter vision loss (0.05). Among 277 patients involving 340 eyes who received at least one same-day dual treatment, event rates per 10,000 injections were 4.66 for endophthalmitis (n = 1), 0 for retinal vasculitis, and 4.66 for retinitis (n = 1). In comparison, among eyes receiving non-same-day DT injections, rates were 0.91 for endophthalmitis (n = 6), 0.15 for retinal vasculitis (n = 1), and 0 for retinitis. BRVA declined over time in all cohorts and no cohort demonstrated sustained IOP elevation.
CONCLUSION: In this analysis of outcomes from routine clinical practice, dual anti-VEGF and anti-complement therapy was not associated with higher overall rates of serious ocular adverse events compared with monotherapy. Serious ocular adverse events were rare across all treatment strategies. Additional larger and prospective analyses are warranted to further characterize the safety of combined intravitreal injections in clinical practice.},
}
RevDate: 2026-11-05
Fluid fluctuation and visual outcomes in neovascular age-related macular degeneration: A systematic review and meta-analysis.
Survey of ophthalmology pii:S0039-6257(26)00157-8 [Epub ahead of print].
Fluctuation in retinal thickness and fluid during anti-vascular endothelial growrh factor (VEGF) therapy has emerged as a candidate prognostic biomarker in neovascular age-related macular degeneration (nAMD), but the evidence is heterogeneous and has not been quantitatively synthesized. We searched PubMed/MEDLINE, Scopus, and Web of Science from inception to December, 2025, for studies reporting retinal fluid or thickness fluctuation metrics and best-corrected visual acuity (BCVA) outcomes in eyes receiving anti-VEGF therapy for nAMD, including both observational studies and post hoc analyses of randomized trials. Between-group mean differences (MDs) in BCVA change were pooled using random-effects models, stratified by study design and OCT parameter, and certainty of evidence was assessed using GRADE. Seventeen studies comprising 19 reports and 9,873 eyes were included. Among observational studies at 24 months, eyes in the highest fluctuation category had significantly smaller BCVA gains than those in the lowest for every parameter examined: intraretinal fluid (MD -7.00 letters, 95% CI -10.27 to -3.72), subretinal fluid (-5.02, -8.09 to -1.95), pigment epithelial detachment (-8.41, -14.54 to -2.27), total fluid (-9.42, -12.69 to -6.15), and central subfield thickness (-10.56, -14.40 to -6.73), with low to moderate heterogeneity (I[2] 0-42.6%). Among post hoc analyses of randomized trials at 24 months, the pooled difference was -6.02 letters (-8.72 to -3.32), with substantial heterogeneity (I[2] = 77.2%) that leave-one-out analysis showed did not alter the direction or significance of the estimate. Greater fluctuation was additionally associated with approximately twice the odds of macular fibrosis and atrophy. Certainty of evidence was low to very low for most fluid compartments, limited principally by the non-randomized nature of the exposure and by the absence of a standardized definition of fluctuation across studies. Temporal anatomical stability, rather than the presence of fluid at any single visit, may therefore carry prognostic information beyond conventional measures of disease activity, though prospective evaluation using a common metric is required before stability can be adopted as a treatment target.
Additional Links: PMID-42988275
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42988275,
year = {2026},
author = {Ferreira, A and Reiter, GS and Vieira, RJ and Papafotiou, E and Lume, M and Furtado, MJ and Udaondo, P},
title = {Fluid fluctuation and visual outcomes in neovascular age-related macular degeneration: A systematic review and meta-analysis.},
journal = {Survey of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.survophthal.2026.11.003},
pmid = {42988275},
issn = {1879-3304},
abstract = {Fluctuation in retinal thickness and fluid during anti-vascular endothelial growrh factor (VEGF) therapy has emerged as a candidate prognostic biomarker in neovascular age-related macular degeneration (nAMD), but the evidence is heterogeneous and has not been quantitatively synthesized. We searched PubMed/MEDLINE, Scopus, and Web of Science from inception to December, 2025, for studies reporting retinal fluid or thickness fluctuation metrics and best-corrected visual acuity (BCVA) outcomes in eyes receiving anti-VEGF therapy for nAMD, including both observational studies and post hoc analyses of randomized trials. Between-group mean differences (MDs) in BCVA change were pooled using random-effects models, stratified by study design and OCT parameter, and certainty of evidence was assessed using GRADE. Seventeen studies comprising 19 reports and 9,873 eyes were included. Among observational studies at 24 months, eyes in the highest fluctuation category had significantly smaller BCVA gains than those in the lowest for every parameter examined: intraretinal fluid (MD -7.00 letters, 95% CI -10.27 to -3.72), subretinal fluid (-5.02, -8.09 to -1.95), pigment epithelial detachment (-8.41, -14.54 to -2.27), total fluid (-9.42, -12.69 to -6.15), and central subfield thickness (-10.56, -14.40 to -6.73), with low to moderate heterogeneity (I[2] 0-42.6%). Among post hoc analyses of randomized trials at 24 months, the pooled difference was -6.02 letters (-8.72 to -3.32), with substantial heterogeneity (I[2] = 77.2%) that leave-one-out analysis showed did not alter the direction or significance of the estimate. Greater fluctuation was additionally associated with approximately twice the odds of macular fibrosis and atrophy. Certainty of evidence was low to very low for most fluid compartments, limited principally by the non-randomized nature of the exposure and by the absence of a standardized definition of fluctuation across studies. Temporal anatomical stability, rather than the presence of fluid at any single visit, may therefore carry prognostic information beyond conventional measures of disease activity, though prospective evaluation using a common metric is required before stability can be adopted as a treatment target.},
}
RevDate: 2026-11-05
Risk of age-related macular degeneration: population-attributable fractions in 600 000 individuals without genetic information or baseline ocular phenotypes from two contemporary population-based studies.
BMJ open ophthalmology, 11(4): pii:bmjophth-2026-003039.
Additional Links: PMID-42988534
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42988534,
year = {2026},
author = {Beheshti, SO and Larsen, LM and Nordestgaard, BG and Afzal, S},
title = {Risk of age-related macular degeneration: population-attributable fractions in 600 000 individuals without genetic information or baseline ocular phenotypes from two contemporary population-based studies.},
journal = {BMJ open ophthalmology},
volume = {11},
number = {4},
pages = {},
doi = {10.1136/bmjophth-2026-003039},
pmid = {42988534},
issn = {2397-3269},
}
RevDate: 2026-11-04
CmpDate: 2026-11-04
A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization.
Proceedings of the National Academy of Sciences of the United States of America, 123(45):e2613631123.
Wet age-related macular degeneration (AMD), a leading cause of irreversible vision loss, is driven by pathological choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor (anti-VEGF) therapies remain the clinical standard, their utility is constrained by incomplete responses in nearly 50% of patients and off-target risks-such as geographic atrophy-stemming from non-specific VEGF blockade. Here, we identify a robust correlation between vascular cell adhesion molecule-1 (VCAM-1) and VEGF/VEGF receptor (VEGFR) expression in aqueous humor from AMD patients and in murine CNV models. Thus, we engineered a tetravalent bispecific protein, RHV, by functionalizing an L-rhamnulose-1-phosphate aldolase scaffold with peptides that selectively bind VCAM-1 and the VEGFR on neovessels. The tetravalent design confers high apparent affinity, enhancing pathological endothelial targeting while sparing healthy retinal vasculature. RHV induces concurrent internalization and lysosomal degradation of both VCAM-1 and VEGFR via a head-to-tail binding mode, leading to sustained inhibition of the VEGF/VEGFR, PI3K/AKT and Apelin/APJ signaling pathways. In murine CNV models, a single intravitreal injection of RHV exhibits superior ocular retention and lesion penetration, achieving therapeutic efficacy comparable to aflibercept [a ligand-trap fusion protein for VEGF-A, VEGF-B and placental growth factor (PIGF)] at one-quarter of the molar dose. This dual-receptor degradation-based strategy represents a targeted and durable approach for treating ocular neovascularization.
Additional Links: PMID-42981038
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42981038,
year = {2026},
author = {Zhang, J and Du, M and Ge, L and Cao, Y and Jiang, J and Yin, X and Chen, G and Wang, Q},
title = {A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization.},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
volume = {123},
number = {45},
pages = {e2613631123},
doi = {10.1073/pnas.2613631123},
pmid = {42981038},
issn = {1091-6490},
support = {XDB1480000 XDB0520301//the Strategic Priority Research Program of Chinese Academy of Sciences/ ; 2024YFA1803400//the National Key Research and Development Program/ ; 22127808 22177128 22174158//the National Natural Science Foundation of China/ ; BK20232046 BK20243004//the Basic Research Program of Jiangsu/ ; SYG2024080 SSD2025001//the Science and Technology Project of Suzhou/ ; SSD2024103//the Suzhou Basic Research Pilot Project/ ; },
mesh = {*Choroidal Neovascularization/drug therapy/metabolism/pathology ; Animals ; *Vascular Cell Adhesion Molecule-1/metabolism ; Humans ; Mice ; *Receptors, Vascular Endothelial Growth Factor/metabolism ; Proteolysis/drug effects ; Macular Degeneration/drug therapy/metabolism ; Disease Models, Animal ; Mice, Inbred C57BL ; Vascular Endothelial Growth Factor A/metabolism ; },
abstract = {Wet age-related macular degeneration (AMD), a leading cause of irreversible vision loss, is driven by pathological choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor (anti-VEGF) therapies remain the clinical standard, their utility is constrained by incomplete responses in nearly 50% of patients and off-target risks-such as geographic atrophy-stemming from non-specific VEGF blockade. Here, we identify a robust correlation between vascular cell adhesion molecule-1 (VCAM-1) and VEGF/VEGF receptor (VEGFR) expression in aqueous humor from AMD patients and in murine CNV models. Thus, we engineered a tetravalent bispecific protein, RHV, by functionalizing an L-rhamnulose-1-phosphate aldolase scaffold with peptides that selectively bind VCAM-1 and the VEGFR on neovessels. The tetravalent design confers high apparent affinity, enhancing pathological endothelial targeting while sparing healthy retinal vasculature. RHV induces concurrent internalization and lysosomal degradation of both VCAM-1 and VEGFR via a head-to-tail binding mode, leading to sustained inhibition of the VEGF/VEGFR, PI3K/AKT and Apelin/APJ signaling pathways. In murine CNV models, a single intravitreal injection of RHV exhibits superior ocular retention and lesion penetration, achieving therapeutic efficacy comparable to aflibercept [a ligand-trap fusion protein for VEGF-A, VEGF-B and placental growth factor (PIGF)] at one-quarter of the molar dose. This dual-receptor degradation-based strategy represents a targeted and durable approach for treating ocular neovascularization.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Choroidal Neovascularization/drug therapy/metabolism/pathology
Animals
*Vascular Cell Adhesion Molecule-1/metabolism
Humans
Mice
*Receptors, Vascular Endothelial Growth Factor/metabolism
Proteolysis/drug effects
Macular Degeneration/drug therapy/metabolism
Disease Models, Animal
Mice, Inbred C57BL
Vascular Endothelial Growth Factor A/metabolism
RevDate: 2026-11-07
CmpDate: 2026-11-04
Lipidomic and transcriptomic remodeling underlies early retinal pathogenesis in dry age-related macular degeneration.
Cell death & disease, 17(1):.
Dry age-related macular degeneration (AMD) is initiated by retinal pigment epithelium (RPE) dysfunction, yet early metabolic mechanisms linking RPE injury to photoreceptor dysfunction remain unclear. Using a physiologically relevant mouse model, we performed cell-type-resolved lipidomic and transcriptomic profiling with ultrastructural analyses. RPE-specific loss of Chloride Intracellular Channel 4 (CLIC4) induced coordinated lipid remodeling and transcriptional rewiring compromising RPE-photoreceptor lipid homeostasis. Both RPE and neural retina exhibited shifts toward very-long-chain unsaturated phospholipids and ceramides, while mutant RPE also accumulated saturated very-long-chain ceramides and cholesterol, particularly in females, favoring drusen deposition. Strikingly, RPE and rods mounted divergent responses: RPE activated compensatory mechanisms, whereas rods exhibited transcriptomic and ultrastructural evidence of bioenergetic suppression, mitochondrial structural abnormalities, and mitochondria-derived oxidative damage, establishing a feed-forward stress cycle extending beyond canonical rod-RPE carbon-energy coupling. These findings underscore rod mitochondrial structural integrity as a potential early biomarker, positioning disrupted lipid recycling as a targetable axis in dry AMD pathogenesis.
Additional Links: PMID-42982791
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42982791,
year = {2026},
author = {Roy, N and Chuang, JZ and Chen, TH and Sun, Y and Allen, DE and Kautzmann, MI and Bhattacharjee, S and Lee, MP and McIntire, LBJ and Bazan, NG and Sung, CH},
title = {Lipidomic and transcriptomic remodeling underlies early retinal pathogenesis in dry age-related macular degeneration.},
journal = {Cell death & disease},
volume = {17},
number = {1},
pages = {},
pmid = {42982791},
issn = {2041-4889},
support = {EY005121//U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI)/ ; R01 EY005121/EY/NEI NIH HHS/United States ; R01 EY029428/EY/NEI NIH HHS/United States ; EY029428//U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI)/ ; R01 EY032966/EY/NEI NIH HHS/United States ; EY032966//U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI)/ ; },
mesh = {Animals ; *Macular Degeneration/genetics/pathology/metabolism ; *Lipidomics/methods ; Mice ; Female ; *Transcriptome/genetics ; *Retinal Pigment Epithelium/metabolism/pathology/ultrastructure ; Mitochondria/metabolism ; Oxidative Stress ; Chloride Channels/metabolism/genetics ; },
abstract = {Dry age-related macular degeneration (AMD) is initiated by retinal pigment epithelium (RPE) dysfunction, yet early metabolic mechanisms linking RPE injury to photoreceptor dysfunction remain unclear. Using a physiologically relevant mouse model, we performed cell-type-resolved lipidomic and transcriptomic profiling with ultrastructural analyses. RPE-specific loss of Chloride Intracellular Channel 4 (CLIC4) induced coordinated lipid remodeling and transcriptional rewiring compromising RPE-photoreceptor lipid homeostasis. Both RPE and neural retina exhibited shifts toward very-long-chain unsaturated phospholipids and ceramides, while mutant RPE also accumulated saturated very-long-chain ceramides and cholesterol, particularly in females, favoring drusen deposition. Strikingly, RPE and rods mounted divergent responses: RPE activated compensatory mechanisms, whereas rods exhibited transcriptomic and ultrastructural evidence of bioenergetic suppression, mitochondrial structural abnormalities, and mitochondria-derived oxidative damage, establishing a feed-forward stress cycle extending beyond canonical rod-RPE carbon-energy coupling. These findings underscore rod mitochondrial structural integrity as a potential early biomarker, positioning disrupted lipid recycling as a targetable axis in dry AMD pathogenesis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Macular Degeneration/genetics/pathology/metabolism
*Lipidomics/methods
Mice
Female
*Transcriptome/genetics
*Retinal Pigment Epithelium/metabolism/pathology/ultrastructure
Mitochondria/metabolism
Oxidative Stress
Chloride Channels/metabolism/genetics
RevDate: 2026-11-05
Feasibility of applying generative AI to create managed care pharmacy formulary reviews.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists pii:9013082 [Epub ahead of print].
PURPOSE: Formulary reviews are used with other data sources and clinical judgement to support formulary strategies, such as placement for existing and new-to-market drugs. We describe the pharmacy resident user experience and assessed the feasibility of using clinical and research-focused generative artificial (genAI) tools in a managed care setting for creating formulary reviews for 2 complex and rare diseases: multiple sclerosis and age-related macular degeneration. This allowed genAI feasibility assessment for disease states with less well-defined guidelines and fewer data sources from which to draw information.
SUMMARY: Users reported a steeper learning curve with research-specific genAI systems compared with pharmacy-focused tools. Users noted pharmacy-focused genAI tools may produce more current drug pipeline information, relative to research-focused AI systems. Prompt engineering, the skill of creating effective prompts to elicit accurate information from genAI models, also contributed to the quality of the evidence produced, regardless of the tool used. The pharmacists noted time savings when utilizing AI compared with a completely manual data generation process involving individual searches of PubMed, business reports, FDA websites, and pharmaceutical company-related information sources.
CONCLUSION: Pharmacists need adequate time and training to optimize prompt techniques to produce quality health- and medication-related information and must be educated on potential downsides of genAI such as inaccurate or incomplete results. With currently available tools, all generated output required careful human fact checking. With continued use and accumulating experience, the pharmacist may become more efficient over time with genAI support for formulary reviews.
Additional Links: PMID-42985849
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42985849,
year = {2026},
author = {Mahan, M and Fronizer, L and Exantus, S and Poonawalla, I and Dixon, S and Rastegar, J},
title = {Feasibility of applying generative AI to create managed care pharmacy formulary reviews.},
journal = {American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
volume = {},
number = {},
pages = {},
doi = {10.1093/ajhp/zxag373},
pmid = {42985849},
issn = {1535-2900},
abstract = {PURPOSE: Formulary reviews are used with other data sources and clinical judgement to support formulary strategies, such as placement for existing and new-to-market drugs. We describe the pharmacy resident user experience and assessed the feasibility of using clinical and research-focused generative artificial (genAI) tools in a managed care setting for creating formulary reviews for 2 complex and rare diseases: multiple sclerosis and age-related macular degeneration. This allowed genAI feasibility assessment for disease states with less well-defined guidelines and fewer data sources from which to draw information.
SUMMARY: Users reported a steeper learning curve with research-specific genAI systems compared with pharmacy-focused tools. Users noted pharmacy-focused genAI tools may produce more current drug pipeline information, relative to research-focused AI systems. Prompt engineering, the skill of creating effective prompts to elicit accurate information from genAI models, also contributed to the quality of the evidence produced, regardless of the tool used. The pharmacists noted time savings when utilizing AI compared with a completely manual data generation process involving individual searches of PubMed, business reports, FDA websites, and pharmaceutical company-related information sources.
CONCLUSION: Pharmacists need adequate time and training to optimize prompt techniques to produce quality health- and medication-related information and must be educated on potential downsides of genAI such as inaccurate or incomplete results. With currently available tools, all generated output required careful human fact checking. With continued use and accumulating experience, the pharmacist may become more efficient over time with genAI support for formulary reviews.},
}
RevDate: 2026-11-05
Occurrence, progression and risk factors of macular atrophy in neovascular age-related macular degeneration according to neovascularization subtypes.
Acta ophthalmologica [Epub ahead of print].
OBJECTIVE: To assess the occurrence, risk factors, and progression of macular atrophy (MA) according to macular neovascularization (MNV) subtype in neovascular AMD (nAMD).
METHODS: This multicentre retrospective observational cohort study included 416 eyes with nAMD, followed for at least 12 months and treated with anti-VEGF. MA was measured annually on near-infrared imaging. Occurrence and risk factors were analysed by MNV subtype using Kaplan-Meier survival and Cox regression models. Atrophy enlargement rate was assessed in mm[2]/year and after applying square root transformation. MNV subtypes were divided into subepithelial (Type 1), intraretinal (Type 3) and MNV with subretinal component (Type 2 and mixed Type 1+2).
RESULTS: Over a mean follow-up of 55.4 ± 22.9 months, 47.4% of eyes developed or presented with MA, with the highest prevalence in Type 3 MNV (82%). Kaplan-Meier analysis confirmed a significantly greater risk in Type 3 lesions (p < 0.0001). Independent risk factors included Type 3 MNV, subretinal drusenoid deposits, thinner choroid and fewer visits with subretinal fluid. After multivariable adjustment, the cumulative number of anti-VEGF injections was not significantly associated with MA occurrence. The mean MA enlargement rate was 1.0 ± 1.1 mm[2]/year overall, ranging from 0.9 ± 1.1 mm[2]/year in Types 1 to 1.5 ± 1.1 mm[2]/year in MNV with subretinal component, p = 0.002.
CONCLUSIONS: Type 3 MNV carries the highest risk of MA, underscoring the need for careful monitoring, whereas MA progression was faster in lesions with a subretinal component. No independent association between cumulative anti-VEGF injection number and MA occurrence was observed; however, this finding should be interpreted cautiously given the potential for confounding by disease activity, MNV subtype, treatment regimen and follow-up intensity.
Additional Links: PMID-42986005
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42986005,
year = {2026},
author = {Moulin, A and Zeender, G and Rizzuto, P and Gascon, P and Allaix, K and Feldman, A and De Bats, F and Wolff, B and Pradat, P and Desmangles, P and Kodjikian, L and Mathis, T},
title = {Occurrence, progression and risk factors of macular atrophy in neovascular age-related macular degeneration according to neovascularization subtypes.},
journal = {Acta ophthalmologica},
volume = {},
number = {},
pages = {},
doi = {10.1111/aos.70263},
pmid = {42986005},
issn = {1755-3768},
abstract = {OBJECTIVE: To assess the occurrence, risk factors, and progression of macular atrophy (MA) according to macular neovascularization (MNV) subtype in neovascular AMD (nAMD).
METHODS: This multicentre retrospective observational cohort study included 416 eyes with nAMD, followed for at least 12 months and treated with anti-VEGF. MA was measured annually on near-infrared imaging. Occurrence and risk factors were analysed by MNV subtype using Kaplan-Meier survival and Cox regression models. Atrophy enlargement rate was assessed in mm[2]/year and after applying square root transformation. MNV subtypes were divided into subepithelial (Type 1), intraretinal (Type 3) and MNV with subretinal component (Type 2 and mixed Type 1+2).
RESULTS: Over a mean follow-up of 55.4 ± 22.9 months, 47.4% of eyes developed or presented with MA, with the highest prevalence in Type 3 MNV (82%). Kaplan-Meier analysis confirmed a significantly greater risk in Type 3 lesions (p < 0.0001). Independent risk factors included Type 3 MNV, subretinal drusenoid deposits, thinner choroid and fewer visits with subretinal fluid. After multivariable adjustment, the cumulative number of anti-VEGF injections was not significantly associated with MA occurrence. The mean MA enlargement rate was 1.0 ± 1.1 mm[2]/year overall, ranging from 0.9 ± 1.1 mm[2]/year in Types 1 to 1.5 ± 1.1 mm[2]/year in MNV with subretinal component, p = 0.002.
CONCLUSIONS: Type 3 MNV carries the highest risk of MA, underscoring the need for careful monitoring, whereas MA progression was faster in lesions with a subretinal component. No independent association between cumulative anti-VEGF injection number and MA occurrence was observed; however, this finding should be interpreted cautiously given the potential for confounding by disease activity, MNV subtype, treatment regimen and follow-up intensity.},
}
RevDate: 2026-11-05
CmpDate: 2026-11-04
Glucagon-Like Peptide-1 Receptor Agonists and the Eye: Ocular Safety, Retinal Outcomes, and Clinical Implications.
Journal of Korean medical science, 41(42):e345.
Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity, but rapidly expanding use has generated concern about ocular adverse events. In Korea, newly established national health insurance reimbursement criteria for injectable semaglutide (Ozempic prefilled pen) took effect on February 1, 2026; as use among eligible patients may expand, proportionate ophthalmic preparedness is timely. This structured narrative review evaluates randomized trials, systematic reviews, large pharmacoepidemiologic studies, mechanistic investigations, and regulatory assessments through June 30, 2026. The evidence does not support a single class-wide syndrome of ocular toxicity. The most coherent retinal signal is early worsening of diabetic retinopathy during rapid glycemic improvement, particularly in eyes with substantial pre-existing disease; available trial and real-world evidence does not demonstrate a uniform sustained toxic effect. Nonarteritic anterior ischemic optic neuropathy is a rare but clinically important semaglutide safety signal. Multiple observational studies and regulatory action justify vigilance, although effect estimates remain heterogeneous and the absolute risk is low. Evidence for neovascular age-related macular degeneration is conflicting, whereas reported associations with retinal vein occlusion and glaucoma remain exploratory. For retina specialists, management should be phenotype based: identify active or advanced diabetic retinopathy, avoid delaying indicated retinal treatment, document the timing and trajectory of metabolic change, and urgently evaluate sudden painless visual loss or field defects. This approach preserves the substantial systemic benefits of incretin therapy while improving recognition of uncommon but consequential ocular events.
Additional Links: PMID-42978139
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42978139,
year = {2026},
author = {Yeo, GE and Kim, J},
title = {Glucagon-Like Peptide-1 Receptor Agonists and the Eye: Ocular Safety, Retinal Outcomes, and Clinical Implications.},
journal = {Journal of Korean medical science},
volume = {41},
number = {42},
pages = {e345},
pmid = {42978139},
issn = {1598-6357},
support = {BDCHA RND2025-010//CHA Bundang Medical Center/Korea ; },
mesh = {Humans ; *Glucagon-Like Peptide-1 Receptor Agonists ; *Glucagon-Like Peptides/adverse effects/therapeutic use ; Semaglutide ; Diabetic Retinopathy ; *Diabetes Mellitus, Type 2/drug therapy ; *Hypoglycemic Agents/adverse effects/therapeutic use ; *Retina/drug effects/pathology ; Glucagon-Like Peptide-1 Receptor/metabolism ; },
abstract = {Glucagon-like peptide-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity, but rapidly expanding use has generated concern about ocular adverse events. In Korea, newly established national health insurance reimbursement criteria for injectable semaglutide (Ozempic prefilled pen) took effect on February 1, 2026; as use among eligible patients may expand, proportionate ophthalmic preparedness is timely. This structured narrative review evaluates randomized trials, systematic reviews, large pharmacoepidemiologic studies, mechanistic investigations, and regulatory assessments through June 30, 2026. The evidence does not support a single class-wide syndrome of ocular toxicity. The most coherent retinal signal is early worsening of diabetic retinopathy during rapid glycemic improvement, particularly in eyes with substantial pre-existing disease; available trial and real-world evidence does not demonstrate a uniform sustained toxic effect. Nonarteritic anterior ischemic optic neuropathy is a rare but clinically important semaglutide safety signal. Multiple observational studies and regulatory action justify vigilance, although effect estimates remain heterogeneous and the absolute risk is low. Evidence for neovascular age-related macular degeneration is conflicting, whereas reported associations with retinal vein occlusion and glaucoma remain exploratory. For retina specialists, management should be phenotype based: identify active or advanced diabetic retinopathy, avoid delaying indicated retinal treatment, document the timing and trajectory of metabolic change, and urgently evaluate sudden painless visual loss or field defects. This approach preserves the substantial systemic benefits of incretin therapy while improving recognition of uncommon but consequential ocular events.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Glucagon-Like Peptide-1 Receptor Agonists
*Glucagon-Like Peptides/adverse effects/therapeutic use
Semaglutide
Diabetic Retinopathy
*Diabetes Mellitus, Type 2/drug therapy
*Hypoglycemic Agents/adverse effects/therapeutic use
*Retina/drug effects/pathology
Glucagon-Like Peptide-1 Receptor/metabolism
RevDate: 2026-11-04
Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration.
Korean journal of ophthalmology : KJO pii:kjo.2026.0051 [Epub ahead of print].
OBJECTIVES: To evaluate the three-year long-term efficacy, treatment durability, and safety of switching to brolucizumab in patients with neovascular age-related macular degeneration (nAMD) who were refractory to previous anti-vascular endothelial growth factor (anti-VEGF) agents in a real-world setting.
METHODS: This retrospective study included nAMD patients who switched to brolucizumab between July 2021 and November 2022. Clinical outcomes were evaluated based on changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the presence of retinal fluid, as well as changes in annual injection frequency and treatment intervals. Safety outcomes, including intraocular inflammation (IOI), were also assessed.
RESULTS: A total of 123 patients were initially reviewed. After excluding patients who did not complete the 3-year follow-up or met exclusion criteria, 47 eyes of 47 patients were included in the final efficacy analysis. Mean BCVA significantly improved from 0.33 ± 0.24 logMAR at baseline to 0.27 ± 0.20 logMAR at 3 years (p < 0.05). Mean CMT demonstrated a significant and sustained reduction from 333.36 ± 136.05 µm at baseline to 232.06 ± 68.90 µm at 3 years (p < 0.001). By the end of the 3-year period, 70.2% of patients successfully achieved an extended treatment interval of ≥16 weeks. IOI was observed in 3.3% of patients but was manageable, with no cases of retinal vasculitis or retinal vascular occlusion observed.
CONCLUSIONS: Switching to brolucizumab provided maintained visual and anatomical improvements with extended treatment intervals over 3 years. The safety profile was consistent with previous reports, and IOI events were manageable in a real-world setting.
Additional Links: PMID-42978379
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42978379,
year = {2026},
author = {Lee, S and Sun, HJ and Lee, SJ and Choi, KS},
title = {Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration.},
journal = {Korean journal of ophthalmology : KJO},
volume = {},
number = {},
pages = {},
doi = {10.3341/kjo.2026.0051},
pmid = {42978379},
issn = {2092-9382},
abstract = {OBJECTIVES: To evaluate the three-year long-term efficacy, treatment durability, and safety of switching to brolucizumab in patients with neovascular age-related macular degeneration (nAMD) who were refractory to previous anti-vascular endothelial growth factor (anti-VEGF) agents in a real-world setting.
METHODS: This retrospective study included nAMD patients who switched to brolucizumab between July 2021 and November 2022. Clinical outcomes were evaluated based on changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the presence of retinal fluid, as well as changes in annual injection frequency and treatment intervals. Safety outcomes, including intraocular inflammation (IOI), were also assessed.
RESULTS: A total of 123 patients were initially reviewed. After excluding patients who did not complete the 3-year follow-up or met exclusion criteria, 47 eyes of 47 patients were included in the final efficacy analysis. Mean BCVA significantly improved from 0.33 ± 0.24 logMAR at baseline to 0.27 ± 0.20 logMAR at 3 years (p < 0.05). Mean CMT demonstrated a significant and sustained reduction from 333.36 ± 136.05 µm at baseline to 232.06 ± 68.90 µm at 3 years (p < 0.001). By the end of the 3-year period, 70.2% of patients successfully achieved an extended treatment interval of ≥16 weeks. IOI was observed in 3.3% of patients but was manageable, with no cases of retinal vasculitis or retinal vascular occlusion observed.
CONCLUSIONS: Switching to brolucizumab provided maintained visual and anatomical improvements with extended treatment intervals over 3 years. The safety profile was consistent with previous reports, and IOI events were manageable in a real-world setting.},
}
RevDate: 2026-11-04
CmpDate: 2026-11-04
Metabolomic Signatures of Healthy Dietary Patterns Associated With Lower Risk of Age-Related Macular Degeneration.
Investigative ophthalmology & visual science, 67(13):11.
PURPOSE: The purpose of this study was to evaluate the association of metabolomic signatures reflecting adherence and metabolic response to dietary patterns with prevalence and structural severity of age-related macular degeneration (AMD).
METHODS: In this cross-sectional study of 1008 eyes from 504 participants, metabolomic profiles in plasma and urine were measured by liquid chromatography-tandem mass spectrometry. Previously derived signatures for eight dietary patterns-including the Alternate Mediterranean diet (AMED), Dietary Approaches to Stop Hypertension (DASH), plant-based diet indices (PDIs), and two mechanism-based diets including Empirical Dietary Inflammatory Pattern (EDIP) and Empirical Dietary Index for Hyperinsulinemia (EDIH)-were evaluated for association with AMD using linear mixed models and Mendelian randomization (MR).
RESULTS: Each signature (38-66 metabolites) correlated with its dietary pattern score (Pearson r = 0.16-0.30). Per SD increase in plasma signatures of four healthy dietary patterns (AMED, DASH, PDI, and healthy PDI [hPDI]) were associated with 12% to 16% lower odds of AMD and reduced severity, whereas the unhealthy PDI (uPDI) signature was associated with 13% higher odds and greater severity (false discovery rate [FDR] < 0.05). DASH showed the strongest inverse association with AMD and with atrophy, hyper-reflective foci, and ellipsoid-zone disruption (β = -0.808 to -0.613). Further MR analyses found that genetically instrumented signatures of DASH and Alternate Health Eating Index (AHEI)-2010 were inversely associated with AMD, whereas the EDIP signature was positively associated.
CONCLUSIONS: Metabolomic signatures of healthy dietary patterns are associated with lower odds and reduced structural severity of AMD. Further longitudinal studies are warranted to validate these findings.
Additional Links: PMID-42980359
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42980359,
year = {2026},
author = {Kang, H and Yun, H and Xu, S and Li, J and Mendez, K and Lains, I and Nigalye, A and Katz, R and Sourirajan, K and Bhat, R and Kozak, G and Choi, H and Bannerman, A and Alvarez, RA and Wu, D and Kim, IK and Miller, JB and Vavvas, DG and Miller, JW and Lasky-Su, J and Liang, L and Husain, D},
title = {Metabolomic Signatures of Healthy Dietary Patterns Associated With Lower Risk of Age-Related Macular Degeneration.},
journal = {Investigative ophthalmology & visual science},
volume = {67},
number = {13},
pages = {11},
doi = {10.1167/iovs.67.13.11},
pmid = {42980359},
issn = {1552-5783},
mesh = {Humans ; Female ; Cross-Sectional Studies ; *Macular Degeneration/metabolism/epidemiology/prevention & control ; *Metabolomics/methods ; Aged ; Male ; *Diet, Healthy ; Tandem Mass Spectrometry ; Risk Factors ; Chromatography, Liquid ; Biomarkers ; Dietary Approaches To Stop Hypertension ; Middle Aged ; Diet, Mediterranean ; },
abstract = {PURPOSE: The purpose of this study was to evaluate the association of metabolomic signatures reflecting adherence and metabolic response to dietary patterns with prevalence and structural severity of age-related macular degeneration (AMD).
METHODS: In this cross-sectional study of 1008 eyes from 504 participants, metabolomic profiles in plasma and urine were measured by liquid chromatography-tandem mass spectrometry. Previously derived signatures for eight dietary patterns-including the Alternate Mediterranean diet (AMED), Dietary Approaches to Stop Hypertension (DASH), plant-based diet indices (PDIs), and two mechanism-based diets including Empirical Dietary Inflammatory Pattern (EDIP) and Empirical Dietary Index for Hyperinsulinemia (EDIH)-were evaluated for association with AMD using linear mixed models and Mendelian randomization (MR).
RESULTS: Each signature (38-66 metabolites) correlated with its dietary pattern score (Pearson r = 0.16-0.30). Per SD increase in plasma signatures of four healthy dietary patterns (AMED, DASH, PDI, and healthy PDI [hPDI]) were associated with 12% to 16% lower odds of AMD and reduced severity, whereas the unhealthy PDI (uPDI) signature was associated with 13% higher odds and greater severity (false discovery rate [FDR] < 0.05). DASH showed the strongest inverse association with AMD and with atrophy, hyper-reflective foci, and ellipsoid-zone disruption (β = -0.808 to -0.613). Further MR analyses found that genetically instrumented signatures of DASH and Alternate Health Eating Index (AHEI)-2010 were inversely associated with AMD, whereas the EDIP signature was positively associated.
CONCLUSIONS: Metabolomic signatures of healthy dietary patterns are associated with lower odds and reduced structural severity of AMD. Further longitudinal studies are warranted to validate these findings.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Cross-Sectional Studies
*Macular Degeneration/metabolism/epidemiology/prevention & control
*Metabolomics/methods
Aged
Male
*Diet, Healthy
Tandem Mass Spectrometry
Risk Factors
Chromatography, Liquid
Biomarkers
Dietary Approaches To Stop Hypertension
Middle Aged
Diet, Mediterranean
RevDate: 2026-11-02
CmpDate: 2026-11-02
Association of Thyroid Autoimmunity With Age-Related Macular Degeneration in U.S. Adults.
Translational vision science & technology, 15(11):3.
PURPOSE: To investigate the associations of thyroid autoimmunity, assessed by thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), with prevalent age-related macular degeneration (AMD) in U.S. adults, and to explore whether genetic liabilities to Hashimoto thyroiditis (HT) and Graves' disease (GD) were associated with AMD risk using two-sample Mendelian randomization (MR).
METHODS: This cross-sectional study included 2967 adults aged 40 years or older from the 2007-2008 National Health and Nutrition Examination Survey. Survey-weighted logistic regression models included TPOAb and TgAb positivity simultaneously. Two-sample MR analyses were exploratory.
RESULTS: Among 2967 participants, 234 had AMD, corresponding to a weighted prevalence of 6.6% (95% confidence interval [CI], 5.6%-7.9%). In the mutually adjusted observational model, TgAb positivity was associated with higher odds of prevalent AMD (odds ratio [OR], 2.02; 95% CI, 1.13-3.61; P = 0.022), whereas TPOAb positivity was not associated with AMD (OR, 0.93; 95% CI, 0.63-1.37; P = 0.676). Exploratory MR analyses suggested a possible association between genetic liability to HT and AMD (OR, 1.14; 95% CI, 1.01-1.29; P = 0.033), whereas evidence for GD was less consistent.
CONCLUSIONS: TgAb positivity was associated with prevalent AMD. The cross-sectional design and the nonidentical exposures assessed in the observational and MR analyses preclude causal inference.
TRANSLATIONAL RELEVANCE: Thyroglobulin antibody positivity was associated with prevalent AMD and may reflect a systemic immune phenotype warranting prospective investigation.
Additional Links: PMID-42969572
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42969572,
year = {2026},
author = {Chen, X and Zhang, J and Wong, TY and Huang, L and Wang, YX},
title = {Association of Thyroid Autoimmunity With Age-Related Macular Degeneration in U.S. Adults.},
journal = {Translational vision science & technology},
volume = {15},
number = {11},
pages = {3},
doi = {10.1167/tvst.15.11.3},
pmid = {42969572},
issn = {2164-2591},
mesh = {Humans ; Female ; Cross-Sectional Studies ; *Macular Degeneration/immunology/epidemiology/genetics ; United States/epidemiology ; Autoantibodies/blood/immunology ; Male ; Middle Aged ; Adult ; *Autoimmunity/immunology ; Aged ; Nutrition Surveys ; Thyroglobulin/immunology ; Prevalence ; *Thyroid Gland/immunology ; Hashimoto Disease/immunology/epidemiology ; Graves Disease/immunology/epidemiology ; Iodide Peroxidase/immunology ; },
abstract = {PURPOSE: To investigate the associations of thyroid autoimmunity, assessed by thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), with prevalent age-related macular degeneration (AMD) in U.S. adults, and to explore whether genetic liabilities to Hashimoto thyroiditis (HT) and Graves' disease (GD) were associated with AMD risk using two-sample Mendelian randomization (MR).
METHODS: This cross-sectional study included 2967 adults aged 40 years or older from the 2007-2008 National Health and Nutrition Examination Survey. Survey-weighted logistic regression models included TPOAb and TgAb positivity simultaneously. Two-sample MR analyses were exploratory.
RESULTS: Among 2967 participants, 234 had AMD, corresponding to a weighted prevalence of 6.6% (95% confidence interval [CI], 5.6%-7.9%). In the mutually adjusted observational model, TgAb positivity was associated with higher odds of prevalent AMD (odds ratio [OR], 2.02; 95% CI, 1.13-3.61; P = 0.022), whereas TPOAb positivity was not associated with AMD (OR, 0.93; 95% CI, 0.63-1.37; P = 0.676). Exploratory MR analyses suggested a possible association between genetic liability to HT and AMD (OR, 1.14; 95% CI, 1.01-1.29; P = 0.033), whereas evidence for GD was less consistent.
CONCLUSIONS: TgAb positivity was associated with prevalent AMD. The cross-sectional design and the nonidentical exposures assessed in the observational and MR analyses preclude causal inference.
TRANSLATIONAL RELEVANCE: Thyroglobulin antibody positivity was associated with prevalent AMD and may reflect a systemic immune phenotype warranting prospective investigation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Cross-Sectional Studies
*Macular Degeneration/immunology/epidemiology/genetics
United States/epidemiology
Autoantibodies/blood/immunology
Male
Middle Aged
Adult
*Autoimmunity/immunology
Aged
Nutrition Surveys
Thyroglobulin/immunology
Prevalence
*Thyroid Gland/immunology
Hashimoto Disease/immunology/epidemiology
Graves Disease/immunology/epidemiology
Iodide Peroxidase/immunology
RevDate: 2026-11-05
Cell-cycle regulatory responses in retinal degeneration: From post-mitotic homeostasis to cell-state transitions and fate decisions.
Experimental eye research, 274:111309 pii:S0014-4835(26)00465-3 [Epub ahead of print].
Cell-cycle regulatory perturbations are increasingly implicated in retinal degeneration, yet their biological significance varies fundamentally across retinal cell types because proliferative competence differs between terminally differentiated neurons and proliferation-capable retinal populations. While retinal neurons normally maintain permanent cell-cycle exit, Müller glia, microglia, retinal pigment epithelial (RPE) cells, endothelial cells, and pericytes retain varying capacities for quiescence, proliferation, and injury-induced reactivation. Consequently, alterations in cyclins, cyclin-dependent kinases (CDKs), RB-E2F signaling, DNA replication machinery, or checkpoint regulators may represent distinct biological states depending on cellular context. In this review, we examine cell-cycle perturbations across inherited retinal diseases (IRDs), age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal gliosis and inflammation, and retinal organoid models. We critically assess current evidence for neuronal cell-cycle re-entry and propose a practical evidence hierarchy that distinguishes pathway activation, neuronal localization, progression through cell-cycle phases, cell-type-specific causality, and longitudinal cellular fate. We argue that many reported findings reflect incomplete or ambiguous evidence and should not be equated with bona fide neuronal cell-cycle re-entry. We further propose a fate-bifurcation model in which cellular outcomes are determined by the depth and duration of cell-cycle engagement together with cell identity, checkpoint integrity, CDK inhibitor activity, DNA damage burden, metabolic state, and microenvironment cues. Under this framework, limited or checkpoint-restrained engagement may support transient neuronal adaptation or survival, whereas sustained activation may promote senescence-like states, and deeper progression under inadequate checkpoint control may contribute to neuronal dysfunction and death. In proliferation-competent retinal compartments, related pathways may instead drive gliosis, immune expansion, epithelial remodeling, angiogenesis, or senescence. By integrating evidence across retinal diseases and cell types, this state-based framework provides a unified interpretation of apparently conflicting observations and offers a conceptual foundation for developing cell-type- and state-specific therapeutic strategies for retinal degeneration.
Additional Links: PMID-42971418
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42971418,
year = {2026},
author = {Du, W and Ma, R and Hong, Y and Chen, Y and Huang, L and Xiao, L and Tang, L and Chen, D},
title = {Cell-cycle regulatory responses in retinal degeneration: From post-mitotic homeostasis to cell-state transitions and fate decisions.},
journal = {Experimental eye research},
volume = {274},
number = {},
pages = {111309},
doi = {10.1016/j.exer.2026.111309},
pmid = {42971418},
issn = {1096-0007},
abstract = {Cell-cycle regulatory perturbations are increasingly implicated in retinal degeneration, yet their biological significance varies fundamentally across retinal cell types because proliferative competence differs between terminally differentiated neurons and proliferation-capable retinal populations. While retinal neurons normally maintain permanent cell-cycle exit, Müller glia, microglia, retinal pigment epithelial (RPE) cells, endothelial cells, and pericytes retain varying capacities for quiescence, proliferation, and injury-induced reactivation. Consequently, alterations in cyclins, cyclin-dependent kinases (CDKs), RB-E2F signaling, DNA replication machinery, or checkpoint regulators may represent distinct biological states depending on cellular context. In this review, we examine cell-cycle perturbations across inherited retinal diseases (IRDs), age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal gliosis and inflammation, and retinal organoid models. We critically assess current evidence for neuronal cell-cycle re-entry and propose a practical evidence hierarchy that distinguishes pathway activation, neuronal localization, progression through cell-cycle phases, cell-type-specific causality, and longitudinal cellular fate. We argue that many reported findings reflect incomplete or ambiguous evidence and should not be equated with bona fide neuronal cell-cycle re-entry. We further propose a fate-bifurcation model in which cellular outcomes are determined by the depth and duration of cell-cycle engagement together with cell identity, checkpoint integrity, CDK inhibitor activity, DNA damage burden, metabolic state, and microenvironment cues. Under this framework, limited or checkpoint-restrained engagement may support transient neuronal adaptation or survival, whereas sustained activation may promote senescence-like states, and deeper progression under inadequate checkpoint control may contribute to neuronal dysfunction and death. In proliferation-competent retinal compartments, related pathways may instead drive gliosis, immune expansion, epithelial remodeling, angiogenesis, or senescence. By integrating evidence across retinal diseases and cell types, this state-based framework provides a unified interpretation of apparently conflicting observations and offers a conceptual foundation for developing cell-type- and state-specific therapeutic strategies for retinal degeneration.},
}
RevDate: 2026-11-02
Geographic atrophy growth rates in the Amish population: findings from the Amish eye study.
The British journal of ophthalmology pii:bjo-2026-330584 [Epub ahead of print].
Additional Links: PMID-42971759
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42971759,
year = {2026},
author = {Nittala, MG and Quarta, A and Verma, A and Velaga, SB and Huang, J and Chujo, S and Forte, P and Abbasgolidazeh, R and Sivilotti, F and Stambolian, D and Pericak-Vance, MA and Haines, JL and Sadda, S},
title = {Geographic atrophy growth rates in the Amish population: findings from the Amish eye study.},
journal = {The British journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1136/bjo-2026-330584},
pmid = {42971759},
issn = {1468-2079},
}
RevDate: 2026-11-02
The Royal College of Ophthalmologists' National Ophthalmology Database: report 15, severe vision loss following cataract surgery.
Eye (London, England) [Epub ahead of print].
BACKGROUND/OBJECTIVES: To investigate rates of severe vision loss post-cataract surgery.
SUBJECTS/METHODS: Post-cataract severe vision loss (SVL) was defined as a loss of ≥0.60 LogMAR between preoperative presenting visual acuity and postoperative visual acuity. The term 'legally blind' was used for eyes with a corrected visual acuity worse than 1.30 LogMAR. Between 2010 and 2024, there were 1,750,553 eligible operations performed on 1,217,267 patients by 3766 surgeons from 132 centres supplying data to the Royal College of Ophthalmologists National Ophthalmology Database Cataract Audit.
RESULTS: Severe vision loss was recorded in 3723 (0.21%) eyes, including 3 eyes (2 patients) from 2 718 immediate sequential bilateral cataract surgery (ISBCS) eyes. The highest observed SVL rate was 10.68% for eyes recorded as left aphakic after surgery and the second highest observed SVL rate (3.32%) was when posterior capsular rupture occurred. The SVL rate was higher than the overall rate for eyes with previous intravitreal injections (0.76%), eyes with optic nerve or central nervous system problems (0.74%), age-related macular degeneration (0.52%), previous vitrectomy surgery (0.49%), diabetic retinopathy (0.45%), glaucoma (0.42%) or corneal pathology (0.33%). Of 1,642,386 (93.8%) eyes that were not preoperatively legally blind, 2731 (0.2%) were postoperatively legally blind. Of these, 2294 (84.0%) eyes experienced severe vision loss.
CONCLUSIONS: Severe vision loss from any cause following cataract surgery occurs infrequently. However, it has a higher prevalence in eyes left aphakic, when PCR occurs and for certain ocular comorbidities.
Additional Links: PMID-42972053
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42972053,
year = {2026},
author = {Ramsden, CM and Norridge, CFE and Mamtora, S and Donachie, PHJ and Buchan, JC},
title = {The Royal College of Ophthalmologists' National Ophthalmology Database: report 15, severe vision loss following cataract surgery.},
journal = {Eye (London, England)},
volume = {},
number = {},
pages = {},
pmid = {42972053},
issn = {1476-5454},
abstract = {BACKGROUND/OBJECTIVES: To investigate rates of severe vision loss post-cataract surgery.
SUBJECTS/METHODS: Post-cataract severe vision loss (SVL) was defined as a loss of ≥0.60 LogMAR between preoperative presenting visual acuity and postoperative visual acuity. The term 'legally blind' was used for eyes with a corrected visual acuity worse than 1.30 LogMAR. Between 2010 and 2024, there were 1,750,553 eligible operations performed on 1,217,267 patients by 3766 surgeons from 132 centres supplying data to the Royal College of Ophthalmologists National Ophthalmology Database Cataract Audit.
RESULTS: Severe vision loss was recorded in 3723 (0.21%) eyes, including 3 eyes (2 patients) from 2 718 immediate sequential bilateral cataract surgery (ISBCS) eyes. The highest observed SVL rate was 10.68% for eyes recorded as left aphakic after surgery and the second highest observed SVL rate (3.32%) was when posterior capsular rupture occurred. The SVL rate was higher than the overall rate for eyes with previous intravitreal injections (0.76%), eyes with optic nerve or central nervous system problems (0.74%), age-related macular degeneration (0.52%), previous vitrectomy surgery (0.49%), diabetic retinopathy (0.45%), glaucoma (0.42%) or corneal pathology (0.33%). Of 1,642,386 (93.8%) eyes that were not preoperatively legally blind, 2731 (0.2%) were postoperatively legally blind. Of these, 2294 (84.0%) eyes experienced severe vision loss.
CONCLUSIONS: Severe vision loss from any cause following cataract surgery occurs infrequently. However, it has a higher prevalence in eyes left aphakic, when PCR occurs and for certain ocular comorbidities.},
}
RevDate: 2026-11-03
Post-ovipositional staging series of the foveate, gold-dust day gecko, Phelsuma laticauda (Gekkota: Squamata).
Developmental dynamics : an official publication of the American Association of Anatomists [Epub ahead of print].
BACKGROUND: Disorders affecting the fovea, a specialized pit in the human retina necessary for high acuity vision, represent a significant healthcare burden across the globe. Degenerative diseases (e.g., macular degeneration) and developmental conditions (e.g., albinism and aniridia) affecting the fovea can lead to irreversible, central vision loss. These conditions are challenging to study because commonly used laboratory animal models lack a fovea. Many day geckos have a fovea and are easy to care for, however, they lack a complete embryonic staging series.
RESULTS: We established a breeding colony of the gold-dust day gecko, Phelsuma laticauda, and generated post-ovipositional embryonic staging series chronicling changes in body and eye morphology throughout gestation.
CONCLUSIONS: P. laticauda undergoes early asymmetric ocular remodeling and the prospective foveal region transiently elongates and retracts during the final third of embryonic development, a progression consistent with other foveate lizards and humans. These findings support day geckos as a promising model for understanding foveal development and potentially relevant disease pathways.
Additional Links: PMID-42972847
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42972847,
year = {2026},
author = {Wegerski, AE and Griffing, AH and Murr, CE and Gamble, T and Brooks, BP and Hufnagel, RB and Rasys, AM},
title = {Post-ovipositional staging series of the foveate, gold-dust day gecko, Phelsuma laticauda (Gekkota: Squamata).},
journal = {Developmental dynamics : an official publication of the American Association of Anatomists},
volume = {},
number = {},
pages = {},
doi = {10.1002/dvdy.70194},
pmid = {42972847},
issn = {1097-0177},
support = {/NH/NIH HHS/United States ; },
abstract = {BACKGROUND: Disorders affecting the fovea, a specialized pit in the human retina necessary for high acuity vision, represent a significant healthcare burden across the globe. Degenerative diseases (e.g., macular degeneration) and developmental conditions (e.g., albinism and aniridia) affecting the fovea can lead to irreversible, central vision loss. These conditions are challenging to study because commonly used laboratory animal models lack a fovea. Many day geckos have a fovea and are easy to care for, however, they lack a complete embryonic staging series.
RESULTS: We established a breeding colony of the gold-dust day gecko, Phelsuma laticauda, and generated post-ovipositional embryonic staging series chronicling changes in body and eye morphology throughout gestation.
CONCLUSIONS: P. laticauda undergoes early asymmetric ocular remodeling and the prospective foveal region transiently elongates and retracts during the final third of embryonic development, a progression consistent with other foveate lizards and humans. These findings support day geckos as a promising model for understanding foveal development and potentially relevant disease pathways.},
}
RevDate: 2026-11-03
[Uveitis masquerade syndrome: diagnostic pitfalls and clinical implications].
Die Ophthalmologie [Epub ahead of print].
Uveitis masquerade syndrome (UMS) is an important differential diagnosis of steroid-refractory uveitis; primary vitreoretinal lymphoma (PVRL) is the most frequent malignant cause. This article reports on 3 patients aged 56, 63 and 75 years who were initially misdiagnosed with posterior uveitis and treated unsuccessfully with corticosteroids. Sub-retinal pigment epithelium (RPE) infiltrates partly mimicked macular degeneration. Multimodal imaging, biopsy and molecular analyses confirmed an intraocular lymphoma and two cases involved the central nervous system. The cases highlight the warning signs and the value of interdisciplinary collaboration.
Additional Links: PMID-42975577
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42975577,
year = {2026},
author = {Muhamed, M and Becker, AL and Helal Birjandi, A and Book, B and Hufendiek, K and Brockmann, D and Framme, C and Bechrakis, NE and Sokolenko, EA},
title = {[Uveitis masquerade syndrome: diagnostic pitfalls and clinical implications].},
journal = {Die Ophthalmologie},
volume = {},
number = {},
pages = {},
pmid = {42975577},
issn = {2731-7218},
abstract = {Uveitis masquerade syndrome (UMS) is an important differential diagnosis of steroid-refractory uveitis; primary vitreoretinal lymphoma (PVRL) is the most frequent malignant cause. This article reports on 3 patients aged 56, 63 and 75 years who were initially misdiagnosed with posterior uveitis and treated unsuccessfully with corticosteroids. Sub-retinal pigment epithelium (RPE) infiltrates partly mimicked macular degeneration. Multimodal imaging, biopsy and molecular analyses confirmed an intraocular lymphoma and two cases involved the central nervous system. The cases highlight the warning signs and the value of interdisciplinary collaboration.},
}
RevDate: 2026-11-03
Association of Estimated Glucose Disposal Rate and Risk of Age-Related Macular Degeneration: Evidence from the UK Biobank.
Current eye research [Epub ahead of print].
PURPOSE: The association between insulin resistance (IR) and age-related macular degeneration (AMD) risk remains unclear. This study examined the impact of estimated glucose disposal rate (eGDR), an IR indicator, on AMD development and explored the potential mediating role of systemic inflammation.
METHODS: This prospective cohort study included 429,844 participants from the UK Biobank with available eGDR data and no AMD at baseline. Cox proportional hazard models were used to evaluate the eGDR-AMD association, while restricted cubic spline (RCS) plots were employed to investigate the shape of this relationship. Exploratory mediation analysis was conducted to examine the contribution of systemic inflammatory markers to the association.
RESULTS: During a median follow-up of 13.4 years, 6,828 individuals developed AMD. Higher eGDR was linked to a 13% reduced AMD risk per standard deviation increase (HR: 0.87; 95% CI: 0.84-0.91; p < 0.001), with an L-shaped relationship observed (P-overall < 0.001; P-non-linear = 0.013). Systemic inflammatory markers (C-reactive protein, neutrophils, neutrophil-lymphocyte ratio, systemic immune-inflammatory index) mediated only a small proportion (0.3%-6.6%) of the eGDR-AMD association.
CONCLUSION: Higher eGDR, as a surrogate marker of IR, is associated with a modestly lower risk of incident AMD, with systemic inflammation explaining only a small proportion of this association. Any mechanistic interpretation or clinical implication of this observational association requires further validation in future studies.
Additional Links: PMID-42977491
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42977491,
year = {2026},
author = {Huang, Y and Zhu, X and Zhang, X and Zhang, Z and Jiang, Y and Wu, X and Gu, Z and Huang, X and Chen, H and Zheng, Z},
title = {Association of Estimated Glucose Disposal Rate and Risk of Age-Related Macular Degeneration: Evidence from the UK Biobank.},
journal = {Current eye research},
volume = {},
number = {},
pages = {1-7},
doi = {10.1080/02713683.2026.2745491},
pmid = {42977491},
issn = {1460-2202},
abstract = {PURPOSE: The association between insulin resistance (IR) and age-related macular degeneration (AMD) risk remains unclear. This study examined the impact of estimated glucose disposal rate (eGDR), an IR indicator, on AMD development and explored the potential mediating role of systemic inflammation.
METHODS: This prospective cohort study included 429,844 participants from the UK Biobank with available eGDR data and no AMD at baseline. Cox proportional hazard models were used to evaluate the eGDR-AMD association, while restricted cubic spline (RCS) plots were employed to investigate the shape of this relationship. Exploratory mediation analysis was conducted to examine the contribution of systemic inflammatory markers to the association.
RESULTS: During a median follow-up of 13.4 years, 6,828 individuals developed AMD. Higher eGDR was linked to a 13% reduced AMD risk per standard deviation increase (HR: 0.87; 95% CI: 0.84-0.91; p < 0.001), with an L-shaped relationship observed (P-overall < 0.001; P-non-linear = 0.013). Systemic inflammatory markers (C-reactive protein, neutrophils, neutrophil-lymphocyte ratio, systemic immune-inflammatory index) mediated only a small proportion (0.3%-6.6%) of the eGDR-AMD association.
CONCLUSION: Higher eGDR, as a surrogate marker of IR, is associated with a modestly lower risk of incident AMD, with systemic inflammation explaining only a small proportion of this association. Any mechanistic interpretation or clinical implication of this observational association requires further validation in future studies.},
}
RevDate: 2026-11-01
Psychiatry of ophthalmology: Proposing the ophthalmo-psychiatric disorders framework.
Survey of ophthalmology pii:S0039-6257(26)00154-2 [Epub ahead of print].
We propose the ophthalmo-psychiatric disorders (OPD) framework as an organizing clinical and research model at the interface of vision science and mental health, and to synthesize, with wording calibrated to evidence strength, bidirectional relationships between ophthalmic disease, visual function, and psychiatric states. Visual impairment and common mental disorders co-distribute globally, with adults with vision loss showing roughly two-to three-fold higher prevalence of depressive and anxiety symptoms than visually normal peers. Elevated psychiatric comorbidity across glaucoma, dry eye disease, and age-related macular degeneration is supported by systematic reviews and meta-analyses, as is the benefit of psychological and stepped-care intervention. Mechanistic claims are weaker: hypothalamic-pituitary-adrenal and autonomic dysregulation, inflammation, circadian disruption, central sensitization, and retinal neurodegeneration remain candidate pathways resting largely on cross-sectional data, and retinal findings in severe mental illness are group-level associations confounded by lifestyle, metabolic, medication, and imaging factors. The eye and the mind are anatomically and physiologically connected. The concept of OPD provides a pragmatic biopsychosocial framework that moves beyond an "organic versus non-organic (functional)" dichotomy and highlights the clinical intersection of the 2 fields. Progress will depend on interdisciplinary training, longitudinal research with harmonized definitions, and culturally sensitive implementation of eye-mind care.
Additional Links: PMID-42967564
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42967564,
year = {2026},
author = {Rojas-Barragan, JA and Montoya-Corral, JL and Agnihotri, A and Lee, E and Weinstein, BL and Lee, AG},
title = {Psychiatry of ophthalmology: Proposing the ophthalmo-psychiatric disorders framework.},
journal = {Survey of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.survophthal.2026.10.012},
pmid = {42967564},
issn = {1879-3304},
abstract = {We propose the ophthalmo-psychiatric disorders (OPD) framework as an organizing clinical and research model at the interface of vision science and mental health, and to synthesize, with wording calibrated to evidence strength, bidirectional relationships between ophthalmic disease, visual function, and psychiatric states. Visual impairment and common mental disorders co-distribute globally, with adults with vision loss showing roughly two-to three-fold higher prevalence of depressive and anxiety symptoms than visually normal peers. Elevated psychiatric comorbidity across glaucoma, dry eye disease, and age-related macular degeneration is supported by systematic reviews and meta-analyses, as is the benefit of psychological and stepped-care intervention. Mechanistic claims are weaker: hypothalamic-pituitary-adrenal and autonomic dysregulation, inflammation, circadian disruption, central sensitization, and retinal neurodegeneration remain candidate pathways resting largely on cross-sectional data, and retinal findings in severe mental illness are group-level associations confounded by lifestyle, metabolic, medication, and imaging factors. The eye and the mind are anatomically and physiologically connected. The concept of OPD provides a pragmatic biopsychosocial framework that moves beyond an "organic versus non-organic (functional)" dichotomy and highlights the clinical intersection of the 2 fields. Progress will depend on interdisciplinary training, longitudinal research with harmonized definitions, and culturally sensitive implementation of eye-mind care.},
}
RevDate: 2026-11-03
CmpDate: 2026-11-01
Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.
Journal of materials science. Materials in medicine, 37(1):.
Wet age-related macular degeneration (Wet AMD) is a major cause of vision loss and has been linked to abnormal choroidal neovascularization (CNV). Current therapies require frequent intravitreal injections, which leads to poor patient adherence. Herein, this study was designed to investigate rapamycin-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles, which represent a sustained-release drug delivery system for wet AMD. The Rap@CS/PLGA NPs were synthesized using emulsion solvent evaporation, followed by coating with chitosan. The obtained Rap@CS/PLGA NPs exhibited a size of 265.9 ± 6.30 nm and encapsulation efficiency (EE) of 60.30 ± 1.20%. The drug release profile showed a biphasic pattern with reduced initial burst release (6 ± 0.6%) followed by sustained release (46 ± 4.1%) over 72 h, which indicates improved delivery control. In vitro cytotoxicity on ARPE and HUVEC cells showed minimal toxicity, with more than 85% viability at dosages up to 100 μg/mL. In vivo anti-angiogenic assays using the chick chorioallantoic membrane (CAM) model showed that the Rap@CS/PLGA group (13 ± 3 vessels) significantly reduced the vessel formation vs Rap (26 ± 2 vessels), confirming superior anti-angiogenic effects. Moreover, the laser-induced CNV mouse model, Rap@CS/PLGA NPs, significantly reduced levels of inflammatory cytokine (TNF-α and IL-6) and restored antioxidant enzyme (SOD, CAT). This showed that protection against oxidative stress in CNV-affected tissue promotes angiogenic gene expression (VEGFA, CCL2), while preserving retinal structure. These findings propose that Rap@CS/PLGA NPs can effectively and control drug delivery for wet-AMD with long-lasting efficacy.
Additional Links: PMID-42967969
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42967969,
year = {2026},
author = {Hu, Y and Wei, L and Yang, H and Sun, J and Li, D and Liu, Q},
title = {Rapamycin-loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential wet age-related macular degeneration treatment: an in vivo study.},
journal = {Journal of materials science. Materials in medicine},
volume = {37},
number = {1},
pages = {},
pmid = {42967969},
issn = {1573-4838},
mesh = {*Chitosan/chemistry ; *Nanoparticles/chemistry ; *Sirolimus/administration & dosage/chemistry ; Animals ; *Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Humans ; Choroidal Neovascularization/drug therapy ; *Wet Macular Degeneration/drug therapy ; Polyglycolic Acid/chemistry ; Human Umbilical Vein Endothelial Cells ; Chorioallantoic Membrane ; Drug Delivery Systems ; Lactic Acid/chemistry ; Drug Liberation ; *Macular Degeneration/drug therapy ; Drug Carriers/chemistry ; },
abstract = {Wet age-related macular degeneration (Wet AMD) is a major cause of vision loss and has been linked to abnormal choroidal neovascularization (CNV). Current therapies require frequent intravitreal injections, which leads to poor patient adherence. Herein, this study was designed to investigate rapamycin-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles, which represent a sustained-release drug delivery system for wet AMD. The Rap@CS/PLGA NPs were synthesized using emulsion solvent evaporation, followed by coating with chitosan. The obtained Rap@CS/PLGA NPs exhibited a size of 265.9 ± 6.30 nm and encapsulation efficiency (EE) of 60.30 ± 1.20%. The drug release profile showed a biphasic pattern with reduced initial burst release (6 ± 0.6%) followed by sustained release (46 ± 4.1%) over 72 h, which indicates improved delivery control. In vitro cytotoxicity on ARPE and HUVEC cells showed minimal toxicity, with more than 85% viability at dosages up to 100 μg/mL. In vivo anti-angiogenic assays using the chick chorioallantoic membrane (CAM) model showed that the Rap@CS/PLGA group (13 ± 3 vessels) significantly reduced the vessel formation vs Rap (26 ± 2 vessels), confirming superior anti-angiogenic effects. Moreover, the laser-induced CNV mouse model, Rap@CS/PLGA NPs, significantly reduced levels of inflammatory cytokine (TNF-α and IL-6) and restored antioxidant enzyme (SOD, CAT). This showed that protection against oxidative stress in CNV-affected tissue promotes angiogenic gene expression (VEGFA, CCL2), while preserving retinal structure. These findings propose that Rap@CS/PLGA NPs can effectively and control drug delivery for wet-AMD with long-lasting efficacy.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Chitosan/chemistry
*Nanoparticles/chemistry
*Sirolimus/administration & dosage/chemistry
Animals
*Polylactic Acid-Polyglycolic Acid Copolymer/chemistry
Humans
Choroidal Neovascularization/drug therapy
*Wet Macular Degeneration/drug therapy
Polyglycolic Acid/chemistry
Human Umbilical Vein Endothelial Cells
Chorioallantoic Membrane
Drug Delivery Systems
Lactic Acid/chemistry
Drug Liberation
*Macular Degeneration/drug therapy
Drug Carriers/chemistry
RevDate: 2026-11-01
Dry, but not wet, age-related macular degeneration increases Alzheimer's disease risk: Findings from a multidimensional analysis.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundAge-related macular degeneration (AMD) and Alzheimer's disease (AD) share pathophysiological features along the eye-brain axis, but epidemiological, molecular, and causal evidence has not been systematically integrated.ObjectiveTo determine whether AMD, particularly its dry subtype, is causally associated with AD by integrating global epidemiological, bibliometric, molecular, and genetic evidence.MethodsWe analyzed Global Burden of Disease 2021 data, performed a bibliometric analysis, explored shared molecular targets using GeneCards and STRING, and conducted bidirectional two-sample Mendelian randomization (MR) using genome-wide association study summary statistics.ResultsFrom 1990 to 2021, AMD and AD prevalence rose in parallel and peaked in high socio-demographic index regions. Bibliometric analysis of 498 publications showed increasing attention to cellular senescence and MR. Bioinformatics identified 241 shared genes between dry AMD and AD, enriched in complement cascades, MAPK/PI3K-Akt signaling, and lipid metabolism. MR showed that dry AMD causally increased AD risk (OR = 1.14, 95% CI: 1.06-1.24, p = 0.0005), whereas overall AMD showed no causal effect and reverse causality was absent.ConclusionsDry AMD, but not AMD overall, is a causal risk factor for AD, providing genetic support for the eye-brain axis hypothesis. Shared pathways, particularly complement dysregulation, may inform risk stratification and therapeutic development.
Additional Links: PMID-42968295
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42968295,
year = {2026},
author = {Yang, L and Zeng, J and Ding, Y and Li, L},
title = {Dry, but not wet, age-related macular degeneration increases Alzheimer's disease risk: Findings from a multidimensional analysis.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261502863},
doi = {10.1177/13872877261502863},
pmid = {42968295},
issn = {1875-8908},
abstract = {BackgroundAge-related macular degeneration (AMD) and Alzheimer's disease (AD) share pathophysiological features along the eye-brain axis, but epidemiological, molecular, and causal evidence has not been systematically integrated.ObjectiveTo determine whether AMD, particularly its dry subtype, is causally associated with AD by integrating global epidemiological, bibliometric, molecular, and genetic evidence.MethodsWe analyzed Global Burden of Disease 2021 data, performed a bibliometric analysis, explored shared molecular targets using GeneCards and STRING, and conducted bidirectional two-sample Mendelian randomization (MR) using genome-wide association study summary statistics.ResultsFrom 1990 to 2021, AMD and AD prevalence rose in parallel and peaked in high socio-demographic index regions. Bibliometric analysis of 498 publications showed increasing attention to cellular senescence and MR. Bioinformatics identified 241 shared genes between dry AMD and AD, enriched in complement cascades, MAPK/PI3K-Akt signaling, and lipid metabolism. MR showed that dry AMD causally increased AD risk (OR = 1.14, 95% CI: 1.06-1.24, p = 0.0005), whereas overall AMD showed no causal effect and reverse causality was absent.ConclusionsDry AMD, but not AMD overall, is a causal risk factor for AD, providing genetic support for the eye-brain axis hypothesis. Shared pathways, particularly complement dysregulation, may inform risk stratification and therapeutic development.},
}
RevDate: 2026-11-02
CmpDate: 2026-11-02
Geographic Atrophy in Age-Related Macular Degeneration Is Associated With Distinct T-Cell Differentiation Profile.
Investigative ophthalmology & visual science, 67(13):3.
PURPOSE: Increasing age is the strongest risk factor in developing AMD. Growing evidence suggests that systemic immunosenescence is implicated in its pathogenesis. This study aims to characterize age-related T-cell differentiation in late-stage AMD by comparing patients with geographic atrophy (GA) and neovascular AMD (nAMD) to a shared healthy control group.
METHODS: Patients with GA or nAMD were recruited from an outpatient AMD-clinic. Individuals with immunological disease, cancer or use of immune-modulating medication were excluded. Blood samples from all participants were stained with monoclonal antibodies and analyzed with flow cytometry to assess T-cell subsets (naive, central memory [CM], effector memory [EM], and effector memory with CD45ra+ [EMRA]) and expression of the age-associated costimulatory markers (CD27, CD28, and CD56).
RESULTS: One hundred twenty-eight patients were included in this study. Patients with GA demonstrated significantly higher levels of CD8+CD28-EM T cells (P = 0.038) and significantly lower levels of CD4+CD56+CM T cells (P = 0.021) compared with healthy controls. Patients with nAMD showed significantly higher levels of naive CD4+CD56+ and CD4+CD56+CM T cells (P = 0.008 and P = 0.008) compared to patients with GA.
CONCLUSIONS: Patients with GA demonstrated an increased proportion of CD8+CD28- EM T cells, a finding similar to other infectious, autoimmune, and neurodegenerative disorders. The increased expression of CD56+ T cells in patients with nAMD supports CD56 having a potential role in angiogenic regulation. Contrarily, we suggest the reduced CD56 expression in patients with GA might contribute to GA pathogenesis.
Additional Links: PMID-42969567
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42969567,
year = {2026},
author = {Hartelius, AB and Thomsen, AK and Subhi, Y and Sørensen, TL and Nielsen, MK},
title = {Geographic Atrophy in Age-Related Macular Degeneration Is Associated With Distinct T-Cell Differentiation Profile.},
journal = {Investigative ophthalmology & visual science},
volume = {67},
number = {13},
pages = {3},
doi = {10.1167/iovs.67.13.3},
pmid = {42969567},
issn = {1552-5783},
mesh = {Humans ; Female ; Male ; Flow Cytometry ; *Geographic Atrophy/immunology/pathology ; Aged ; *Macular Degeneration/immunology/pathology ; *Cell Differentiation ; Aged, 80 and over ; *T-Lymphocyte Subsets/immunology ; Middle Aged ; CD56 Antigen/metabolism ; *T-Lymphocytes/immunology ; },
abstract = {PURPOSE: Increasing age is the strongest risk factor in developing AMD. Growing evidence suggests that systemic immunosenescence is implicated in its pathogenesis. This study aims to characterize age-related T-cell differentiation in late-stage AMD by comparing patients with geographic atrophy (GA) and neovascular AMD (nAMD) to a shared healthy control group.
METHODS: Patients with GA or nAMD were recruited from an outpatient AMD-clinic. Individuals with immunological disease, cancer or use of immune-modulating medication were excluded. Blood samples from all participants were stained with monoclonal antibodies and analyzed with flow cytometry to assess T-cell subsets (naive, central memory [CM], effector memory [EM], and effector memory with CD45ra+ [EMRA]) and expression of the age-associated costimulatory markers (CD27, CD28, and CD56).
RESULTS: One hundred twenty-eight patients were included in this study. Patients with GA demonstrated significantly higher levels of CD8+CD28-EM T cells (P = 0.038) and significantly lower levels of CD4+CD56+CM T cells (P = 0.021) compared with healthy controls. Patients with nAMD showed significantly higher levels of naive CD4+CD56+ and CD4+CD56+CM T cells (P = 0.008 and P = 0.008) compared to patients with GA.
CONCLUSIONS: Patients with GA demonstrated an increased proportion of CD8+CD28- EM T cells, a finding similar to other infectious, autoimmune, and neurodegenerative disorders. The increased expression of CD56+ T cells in patients with nAMD supports CD56 having a potential role in angiogenic regulation. Contrarily, we suggest the reduced CD56 expression in patients with GA might contribute to GA pathogenesis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
Male
Flow Cytometry
*Geographic Atrophy/immunology/pathology
Aged
*Macular Degeneration/immunology/pathology
*Cell Differentiation
Aged, 80 and over
*T-Lymphocyte Subsets/immunology
Middle Aged
CD56 Antigen/metabolism
*T-Lymphocytes/immunology
RevDate: 2026-11-02
CmpDate: 2026-10-31
High-Resolution OCT of Basal Laminar Deposit Phenotypes and Retinal Pigment Epithelium Morphologic Changes in Age-Related Macular Degeneration.
Ophthalmology science, 6(12):101415.
PURPOSE: To characterize the high-resolution OCT phenotype of basal laminar deposit (BLamD) and the codistribution of retinal pigment epithelium (RPE) morphologic changes in patients with age-related macular degeneration (AMD).
DESIGN: Cross-sectional observational study.
PARTICIPANTS: Thirty-one eyes from 19 patients (10 female, 9 male; mean age 85.6 ± 5.5 years) with AMD and OCT-visible BLamD.
METHODS: Structural high-resolution OCT B-scans were systematically graded for BLamD phenotype (persistent, scalloped, and outer retinal corrugations), RPE morphologic changes (spiky RPE and intraretinal hyperreflective foci [IHRF]), foveal involvement, and additional features (hypocore drusen, subretinal drusenoid deposits [SDDs], and soft drusen), including geographic atrophy (GA), complete RPE and outer retinal atrophy (cRORA), and incomplete RPE and outer retinal atrophy.
MAIN OUTCOME MEASURES: Prevalence and co-occurrence of BLamD and RPE phenotypic features stratified by foveal status.
RESULTS: Of the 117 screened patients with AMD, 19 (16.2%) had OCT-visible BLamD, contributing 31 eyes: 28 with cRORA, 1 with incomplete RPE and outer retinal atrophy, and 2 without OCT-defined atrophy. Persistent BLamD was the most prevalent finding (28/31, 90.3%), followed by scalloped BLamD and IHRF (both 21/31, 67.7%) and spiky RPE (18/31, 58.1%). All 31 eyes exhibited ≥1 RPE-BLamD complex abnormality, and 27/31 eyes (87.1%) demonstrated ≥2 concurrent features. Outer retinal corrugations were identified in 4/31 eyes (12.9%) and were exclusively present in eyes without spiky RPE (4/13, 30.8% vs. 0/18, 0%). Foveal-spared GA eyes showed higher prevalences of spiky RPE (9/14, 64.3% vs. 6/14, 42.9%) and IHRF (11/14, 78.6% vs. 7/14, 50.0%) compared with foveal-involved eyes. Eyes lacking persistent BLamD (3/31, 9.7%) paradoxically showed all spiky RPE, scalloped BLamD, and IHRF. Additional findings included hypocore drusen in 8/31 eyes (25.8%), SDD in 31/31 eyes (100%), and soft drusen in 4/31 eyes (12.9%).
CONCLUSIONS: In BLamD-associated GA, persistent and scalloped BLamD, spiky RPE, IHRF, and outer retinal corrugations showed variable patterns of co-occurrence. Spiky RPE and IHRF were more frequent in foveal-sparing than in foveal-involved eyes, although the significance of this observation requires longitudinal validation. These findings support the integration of BLamD morphologic subtyping and RPE phenotyping into clinical and trial-based assessments of advanced AMD, with potential implications for patient selection and monitoring in the era of approved complement inhibition therapies.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Additional Links: PMID-42964701
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42964701,
year = {2026},
author = {Quarta, A and Chujo, S and Forte, P and Feo, A and Huang, J and Abbasgholizadeh, R and Sivilotti, F and Soylu, C and Lee, S and Corradetti, G and Sarraf, D and Sadda, SR},
title = {High-Resolution OCT of Basal Laminar Deposit Phenotypes and Retinal Pigment Epithelium Morphologic Changes in Age-Related Macular Degeneration.},
journal = {Ophthalmology science},
volume = {6},
number = {12},
pages = {101415},
pmid = {42964701},
issn = {2666-9145},
abstract = {PURPOSE: To characterize the high-resolution OCT phenotype of basal laminar deposit (BLamD) and the codistribution of retinal pigment epithelium (RPE) morphologic changes in patients with age-related macular degeneration (AMD).
DESIGN: Cross-sectional observational study.
PARTICIPANTS: Thirty-one eyes from 19 patients (10 female, 9 male; mean age 85.6 ± 5.5 years) with AMD and OCT-visible BLamD.
METHODS: Structural high-resolution OCT B-scans were systematically graded for BLamD phenotype (persistent, scalloped, and outer retinal corrugations), RPE morphologic changes (spiky RPE and intraretinal hyperreflective foci [IHRF]), foveal involvement, and additional features (hypocore drusen, subretinal drusenoid deposits [SDDs], and soft drusen), including geographic atrophy (GA), complete RPE and outer retinal atrophy (cRORA), and incomplete RPE and outer retinal atrophy.
MAIN OUTCOME MEASURES: Prevalence and co-occurrence of BLamD and RPE phenotypic features stratified by foveal status.
RESULTS: Of the 117 screened patients with AMD, 19 (16.2%) had OCT-visible BLamD, contributing 31 eyes: 28 with cRORA, 1 with incomplete RPE and outer retinal atrophy, and 2 without OCT-defined atrophy. Persistent BLamD was the most prevalent finding (28/31, 90.3%), followed by scalloped BLamD and IHRF (both 21/31, 67.7%) and spiky RPE (18/31, 58.1%). All 31 eyes exhibited ≥1 RPE-BLamD complex abnormality, and 27/31 eyes (87.1%) demonstrated ≥2 concurrent features. Outer retinal corrugations were identified in 4/31 eyes (12.9%) and were exclusively present in eyes without spiky RPE (4/13, 30.8% vs. 0/18, 0%). Foveal-spared GA eyes showed higher prevalences of spiky RPE (9/14, 64.3% vs. 6/14, 42.9%) and IHRF (11/14, 78.6% vs. 7/14, 50.0%) compared with foveal-involved eyes. Eyes lacking persistent BLamD (3/31, 9.7%) paradoxically showed all spiky RPE, scalloped BLamD, and IHRF. Additional findings included hypocore drusen in 8/31 eyes (25.8%), SDD in 31/31 eyes (100%), and soft drusen in 4/31 eyes (12.9%).
CONCLUSIONS: In BLamD-associated GA, persistent and scalloped BLamD, spiky RPE, IHRF, and outer retinal corrugations showed variable patterns of co-occurrence. Spiky RPE and IHRF were more frequent in foveal-sparing than in foveal-involved eyes, although the significance of this observation requires longitudinal validation. These findings support the integration of BLamD morphologic subtyping and RPE phenotyping into clinical and trial-based assessments of advanced AMD, with potential implications for patient selection and monitoring in the era of approved complement inhibition therapies.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.},
}
RevDate: 2026-10-31
Cognitive decline: A 10-year prospective study in glaucoma, diabetic retinopathy, and age-related macular degeneration.
Archivos de la Sociedad Espanola de Oftalmologia pii:S2173-5794(26)00241-0 [Epub ahead of print].
OBJECTIVE: To evaluate the longitudinal association of glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD) with 10-year cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score <26, as well as to determine the predictive value of self-perceived visual function and retinal structural biomarkers for cognitive impairment. The 25-item Visual Function Questionnaire (VFQ-25) assesses self-perceived visual functioning and its impact on vision-related activities and quality of life. The Mini-Mental State Examination (MMSE) is a global cognitive screening test assessing domains including orientation, registration and recall, attention/calculation, and language, whereas the MoCA assesses a broader range of cognitive domains, including executive functions, visuospatial abilities, attention, memory, language, and orientation. Because some MMSE and, particularly, MoCA tasks involve visual or visuospatial components, performance may be influenced by visual impairment; both tests may also be influenced by educational level.
PATIENTS AND METHODS: This monocentric prospective observational study included 360 adults aged ≥60 years (90 participants per group and 90 matched controls) followed for 10 years. Demographic, vascular, and psychosocial variables, best-corrected binocular visual acuity, VFQ-25 (25-item Visual Function Questionnaire), MMSE (Mini-Mental State Examination), and MoCA scores were collected. Retinal structure was assessed using swept-source OCT, including retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) measurements. Evaluations were performed at baseline, 5 years, and 10 years. Adjusted Cox models, multivariate logistic regression, and longitudinal mixed-effects models were applied. No stratification of glaucoma or diabetic retinopathy according to clinical severity or stage was performed.
RESULTS: Cognitive impairment was more frequent in DR (54%), glaucoma (52%), and AMD (49%) compared with controls (27%) (p < 0.001). All ocular diseases remained independently associated with cognitive impairment after multivariate adjustment, with the highest risk observed in DR (HR 2.05). Higher VFQ-25 scores were associated with a lower risk of cognitive impairment, whereas GCIPL thinning showed an independent association with increased risk. However, participants with ocular disease had lower educational attainment, a higher prevalence of depression, and a higher comorbidity index at baseline than controls, and these baseline differences may contribute to the observed associations.
CONCLUSIONS: Chronic ocular diseases are associated with a higher 10-year risk of cognitive impairment. These findings should nevertheless be interpreted cautiously because of baseline imbalances in education, depression, and comorbidity, the potential influence of visual impairment on cognitive testing, the lack of severity stratification for glaucoma and DR, and the possibility of residual confounding and reverse causality. Self-perceived visual function and retinal structural biomarkers may represent indicators of neurocognitive vulnerability in aging.
Additional Links: PMID-42966472
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42966472,
year = {2026},
author = {Asensio-Sánchez, VM and Gómez-González, A and Frontela, A and Martín-Prieto, A and Pérez, VA and De-Miguel, M},
title = {Cognitive decline: A 10-year prospective study in glaucoma, diabetic retinopathy, and age-related macular degeneration.},
journal = {Archivos de la Sociedad Espanola de Oftalmologia},
volume = {},
number = {},
pages = {502673},
doi = {10.1016/j.oftale.2026.502673},
pmid = {42966472},
issn = {2173-5794},
abstract = {OBJECTIVE: To evaluate the longitudinal association of glaucoma, diabetic retinopathy (DR), and age-related macular degeneration (AMD) with 10-year cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score <26, as well as to determine the predictive value of self-perceived visual function and retinal structural biomarkers for cognitive impairment. The 25-item Visual Function Questionnaire (VFQ-25) assesses self-perceived visual functioning and its impact on vision-related activities and quality of life. The Mini-Mental State Examination (MMSE) is a global cognitive screening test assessing domains including orientation, registration and recall, attention/calculation, and language, whereas the MoCA assesses a broader range of cognitive domains, including executive functions, visuospatial abilities, attention, memory, language, and orientation. Because some MMSE and, particularly, MoCA tasks involve visual or visuospatial components, performance may be influenced by visual impairment; both tests may also be influenced by educational level.
PATIENTS AND METHODS: This monocentric prospective observational study included 360 adults aged ≥60 years (90 participants per group and 90 matched controls) followed for 10 years. Demographic, vascular, and psychosocial variables, best-corrected binocular visual acuity, VFQ-25 (25-item Visual Function Questionnaire), MMSE (Mini-Mental State Examination), and MoCA scores were collected. Retinal structure was assessed using swept-source OCT, including retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) measurements. Evaluations were performed at baseline, 5 years, and 10 years. Adjusted Cox models, multivariate logistic regression, and longitudinal mixed-effects models were applied. No stratification of glaucoma or diabetic retinopathy according to clinical severity or stage was performed.
RESULTS: Cognitive impairment was more frequent in DR (54%), glaucoma (52%), and AMD (49%) compared with controls (27%) (p < 0.001). All ocular diseases remained independently associated with cognitive impairment after multivariate adjustment, with the highest risk observed in DR (HR 2.05). Higher VFQ-25 scores were associated with a lower risk of cognitive impairment, whereas GCIPL thinning showed an independent association with increased risk. However, participants with ocular disease had lower educational attainment, a higher prevalence of depression, and a higher comorbidity index at baseline than controls, and these baseline differences may contribute to the observed associations.
CONCLUSIONS: Chronic ocular diseases are associated with a higher 10-year risk of cognitive impairment. These findings should nevertheless be interpreted cautiously because of baseline imbalances in education, depression, and comorbidity, the potential influence of visual impairment on cognitive testing, the lack of severity stratification for glaucoma and DR, and the possibility of residual confounding and reverse causality. Self-perceived visual function and retinal structural biomarkers may represent indicators of neurocognitive vulnerability in aging.},
}
RevDate: 2026-10-31
Hydraulic Permeability of Retinal and Subretinal Layers: Experimental Quantification and Computational Modeling.
Experimental eye research pii:S0014-4835(26)00453-7 [Epub ahead of print].
Alterations in retinal tissue permeability are a hallmark of several ocular pathologies, including diabetic retinopathy and age-related macular degeneration. Although permeability plays a crucial role in maintaining retinal homeostasis, previously reported values vary widely due to differences in animal models, tissue preparation, and experimental configurations. In the present study, the hydraulic permeability of porcine retinal and subretinal layers was quantitatively characterized using a custom Ussing chamber, a two-component system for measuring trans-tissue fluid flow, enabling controlled physiological pressures. Tissue isolation was verified by scanning electron microscopy, which allowed identification of the targeted ocular layers based on their characteristic surface morphology. Neuroretina, BrM-choroid, and RPE-BrM-choroid samples were analyzed, and the effect of tissue fixation was systematically evaluated. Additional experiments were performed on fixed retina to investigate the pressure-permeability relationship. To complement the experimental measurements, a COMSOL Multiphysics model of fluid transport across the ocular layers was developed. The model reproduced the experimental configuration and incorporated experimentally determined transport properties together with tissue mechanical properties to (i) evaluate possible setup-induced artefacts, (ii) verify the analytical estimation of RPE permeability, and (iii) investigate the influence of strain-dependent retinal permeability on fluid transport across the tissue complex. Fixation with 4% formalin did not significantly alter retinal permeability while improving measurement reproducibility. The neuroretina exhibited relatively high intrinsic permeability (∼10[-14] m[2]), consistent with its elevated metabolic demand, whereas the RPE-BrM-Choroid complex displayed markedly lower permeability, (∼10[-17] m[2]), reflecting the barrier function of the outer blood-retina barrier. Numerical simulations indicated that the overall hydraulic response is dominated by the RPE-BrM-Choroid complex, while retinal strain-dependent permeability had a negligible influence on the predicted fluid transport, despite the dependence of the permeability-strain relationship on the adopted mechanical assumptions. Overall, this study provides an integrated experimental-computational framework for quantifying retinal and ocular tissue permeability. The proposed approach reduces variability associated with previous methodologies and supports the use of the porcine retina as a biologically relevant model for human tissue. These results provide physiologically relevant parameters for investigating fluid regulation, blood-retina barrier dysfunction, and ocular drug transport.
Additional Links: PMID-42966530
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42966530,
year = {2026},
author = {Tripputi, R and Bertolo, D and Bianchi, E and Pandolfi, AM and Albani, D and Giordano, C and Boschetti, F},
title = {Hydraulic Permeability of Retinal and Subretinal Layers: Experimental Quantification and Computational Modeling.},
journal = {Experimental eye research},
volume = {},
number = {},
pages = {111297},
doi = {10.1016/j.exer.2026.111297},
pmid = {42966530},
issn = {1096-0007},
abstract = {Alterations in retinal tissue permeability are a hallmark of several ocular pathologies, including diabetic retinopathy and age-related macular degeneration. Although permeability plays a crucial role in maintaining retinal homeostasis, previously reported values vary widely due to differences in animal models, tissue preparation, and experimental configurations. In the present study, the hydraulic permeability of porcine retinal and subretinal layers was quantitatively characterized using a custom Ussing chamber, a two-component system for measuring trans-tissue fluid flow, enabling controlled physiological pressures. Tissue isolation was verified by scanning electron microscopy, which allowed identification of the targeted ocular layers based on their characteristic surface morphology. Neuroretina, BrM-choroid, and RPE-BrM-choroid samples were analyzed, and the effect of tissue fixation was systematically evaluated. Additional experiments were performed on fixed retina to investigate the pressure-permeability relationship. To complement the experimental measurements, a COMSOL Multiphysics model of fluid transport across the ocular layers was developed. The model reproduced the experimental configuration and incorporated experimentally determined transport properties together with tissue mechanical properties to (i) evaluate possible setup-induced artefacts, (ii) verify the analytical estimation of RPE permeability, and (iii) investigate the influence of strain-dependent retinal permeability on fluid transport across the tissue complex. Fixation with 4% formalin did not significantly alter retinal permeability while improving measurement reproducibility. The neuroretina exhibited relatively high intrinsic permeability (∼10[-14] m[2]), consistent with its elevated metabolic demand, whereas the RPE-BrM-Choroid complex displayed markedly lower permeability, (∼10[-17] m[2]), reflecting the barrier function of the outer blood-retina barrier. Numerical simulations indicated that the overall hydraulic response is dominated by the RPE-BrM-Choroid complex, while retinal strain-dependent permeability had a negligible influence on the predicted fluid transport, despite the dependence of the permeability-strain relationship on the adopted mechanical assumptions. Overall, this study provides an integrated experimental-computational framework for quantifying retinal and ocular tissue permeability. The proposed approach reduces variability associated with previous methodologies and supports the use of the porcine retina as a biologically relevant model for human tissue. These results provide physiologically relevant parameters for investigating fluid regulation, blood-retina barrier dysfunction, and ocular drug transport.},
}
RevDate: 2026-11-01
Why Homocysteine Gets No Respect How That Adversely Impacts the Health of American Seniors.
Additional Links: PMID-42967519
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42967519,
year = {2026},
author = {Eiser, AR},
title = {Why Homocysteine Gets No Respect How That Adversely Impacts the Health of American Seniors.},
journal = {The American journal of medicine},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.amjmed.2026.10.036},
pmid = {42967519},
issn = {1555-7162},
}
RevDate: 2026-10-30
CmpDate: 2026-10-30
Who Benefits from Web Content Reading Services? Insights from Workshops with People with Reading Difficulties.
Studies in health technology and informatics, 341:297-304.
We ran two workshops in a preliminary investigation into who can benefit from content reading services. Workshop participants were people with age-related macular degeneration and people with aphasia. Through discussions, testing of services, creating personas, and a survey, we found that there are groups that would benefit from content reading services that normally do not use screen readers. This shows this service would be a useful tool in a universal design solution. We introduce the concept of digital tipping point for when demands from digital services go beyond a person's own abilities and need additional support.
Additional Links: PMID-42960794
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42960794,
year = {2026},
author = {Stølen, V and Schulz, T and Fuglerud, KS},
title = {Who Benefits from Web Content Reading Services? Insights from Workshops with People with Reading Difficulties.},
journal = {Studies in health technology and informatics},
volume = {341},
number = {},
pages = {297-304},
doi = {10.3233/SHTI261060},
pmid = {42960794},
issn = {1879-8365},
mesh = {Humans ; *Internet ; *Dyslexia/rehabilitation ; *Reading ; *Persons with Disabilities ; },
abstract = {We ran two workshops in a preliminary investigation into who can benefit from content reading services. Workshop participants were people with age-related macular degeneration and people with aphasia. Through discussions, testing of services, creating personas, and a survey, we found that there are groups that would benefit from content reading services that normally do not use screen readers. This shows this service would be a useful tool in a universal design solution. We introduce the concept of digital tipping point for when demands from digital services go beyond a person's own abilities and need additional support.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Internet
*Dyslexia/rehabilitation
*Reading
*Persons with Disabilities
RevDate: 2026-10-30
Submacular Hemorrhage Requiring Procedural Intervention During Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Japan: The JTY Three-Center Real-World Incidence Study.
Retina (Philadelphia, Pa.) pii:00006982-990000000-01570 [Epub ahead of print].
PURPOSE: To estimate the incidence and clinical characteristics of submacular hemorrhage (SMH) requiring procedural intervention during anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in a Japanese multicenter real-world setting, with exploratory comparison according to the preceding anti-VEGF agent.
METHODS: This multicenter retrospective real-world incidence study reviewed surgical records from three Japanese centers to identify SMH requiring gas injection or vitrectomy during ongoing anti-VEGF treatment. The denominator was the total number of anti-VEGF injections for nAMD during the same period. Incidence per 1,000 injections and site-adjusted incidence rate ratios (IRRs) were estimated using quasi-Poisson regression.
RESULTS: Among 47,358 injections, 54 SMH events requiring procedural intervention were identified (1.14 per 1,000 injections). Median final BCVA after procedural treatment was 1.00 logMAR (Snellen equivalent, 20/200), compared with 0.46 logMAR before SMH (approximately 20/60). PCV accounted for 39 events (72.2%), and prior SMH was documented in 12 eyes (22.2%). Crude incidence was 2.20 for ranibizumab, 1.09 for brolucizumab, 1.08 for aflibercept, and 0.24 for faricimab. Using aflibercept as the reference, IRRs were 1.83 for ranibizumab (95% confidence interval [CI], 0.73-4.59; P = 0.195), 0.91 for brolucizumab (95% CI, 0.25-3.28; P = 0.883), and 0.20 for faricimab (95% CI, 0.01-3.16; P = 0.251).
CONCLUSIONS: SMH requiring procedural intervention during anti-VEGF therapy for nAMD was uncommon but visually severe; among affected eyes, PCV accounted for 72.2% of events. Exploratory drug-specific analyses did not demonstrate significant adjusted differences among anti-VEGF agents. Future patient-level studies should evaluate subtype-specific incidence, hemorrhagic recurrence, and polyp-directed treatment strategies in PCV-rich populations.
Additional Links: PMID-42961146
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42961146,
year = {2026},
author = {Inoda, S and Takahashi, H and Azuma, K and Terao, R and Saeki, Y and Inoue, T and Hirono, K and Ichikawa, T and Maruyama-Inoue, M and Kaburaki, T and Yanagi, Y},
title = {Submacular Hemorrhage Requiring Procedural Intervention During Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Japan: The JTY Three-Center Real-World Incidence Study.},
journal = {Retina (Philadelphia, Pa.)},
volume = {},
number = {},
pages = {},
doi = {10.1097/IAE.0000000000005044},
pmid = {42961146},
issn = {1539-2864},
abstract = {PURPOSE: To estimate the incidence and clinical characteristics of submacular hemorrhage (SMH) requiring procedural intervention during anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in a Japanese multicenter real-world setting, with exploratory comparison according to the preceding anti-VEGF agent.
METHODS: This multicenter retrospective real-world incidence study reviewed surgical records from three Japanese centers to identify SMH requiring gas injection or vitrectomy during ongoing anti-VEGF treatment. The denominator was the total number of anti-VEGF injections for nAMD during the same period. Incidence per 1,000 injections and site-adjusted incidence rate ratios (IRRs) were estimated using quasi-Poisson regression.
RESULTS: Among 47,358 injections, 54 SMH events requiring procedural intervention were identified (1.14 per 1,000 injections). Median final BCVA after procedural treatment was 1.00 logMAR (Snellen equivalent, 20/200), compared with 0.46 logMAR before SMH (approximately 20/60). PCV accounted for 39 events (72.2%), and prior SMH was documented in 12 eyes (22.2%). Crude incidence was 2.20 for ranibizumab, 1.09 for brolucizumab, 1.08 for aflibercept, and 0.24 for faricimab. Using aflibercept as the reference, IRRs were 1.83 for ranibizumab (95% confidence interval [CI], 0.73-4.59; P = 0.195), 0.91 for brolucizumab (95% CI, 0.25-3.28; P = 0.883), and 0.20 for faricimab (95% CI, 0.01-3.16; P = 0.251).
CONCLUSIONS: SMH requiring procedural intervention during anti-VEGF therapy for nAMD was uncommon but visually severe; among affected eyes, PCV accounted for 72.2% of events. Exploratory drug-specific analyses did not demonstrate significant adjusted differences among anti-VEGF agents. Future patient-level studies should evaluate subtype-specific incidence, hemorrhagic recurrence, and polyp-directed treatment strategies in PCV-rich populations.},
}
RevDate: 2026-10-30
Association Between Trends in Geographic Atrophy Growth and Age-related Macular Degeneration Drusen Phenotype.
Ophthalmic surgery, lasers & imaging retina [Epub ahead of print].
BACKGROUND AND OBJECTIVE: The purpose of this study was to characterize the association between geographic atrophy (GA) growth and age-related macular degeneration (AMD) drusen phenotype.
PATIENTS AND METHODS: This retrospective cohort study included 59 eyes from 47 patients over 55 years with GA, followed for up to 5 years. Eyes with poor-quality imaging, irregular follow-up, or exudation were excluded. Based on multimodal retinal imaging, eyes were classified into three groups: Group 1 (reticular pseudodrusen [RPD]), Group 2 (large soft drusen [LSD]), and Group 3 (mixed RPD and LSD). Fundus autofluorescence (FAF) images were analyzed from baseline to 60 months. GA lesion area and growth rate were measured semi-automatically using Region-Finder (Heidelberg Engineering) and compared across groups over time.
RESULTS: The mean baseline GA area was 1.2 ± 0.8 mm[2]. The overall mean GA growth rate was 1.5 ± 0.9 mm[2]/year. Group 1 (RPD) showed the fastest progression at 2.56 ± 1.09 mm[2]/year, significantly higher than Group 2 (LSD, 1.02 ± 0.80 mm[2]/year) and Group 3 (1.10 ± 0.81 mm[2]/year) (P < .005). No significant difference was observed between Groups 2 and 3 (P = .28). These differences remained consistent at months 12, 24, 36, 48, and 60.
CONCLUSION: GA progression is significantly faster in eyes with pure RPD phenotype. Mixed phenotype behaves similarly to LSD, supporting phenotype-specific monitoring and treatment strategies.
Additional Links: PMID-42961327
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42961327,
year = {2026},
author = {Schneider, A and Capuano, V and Ghobril, AB and Semoun, O and Jung, C and Wang, XX and Amoroso, F and Oubraham, H and Mehanna, CJ and Miere, A and Souied, EH},
title = {Association Between Trends in Geographic Atrophy Growth and Age-related Macular Degeneration Drusen Phenotype.},
journal = {Ophthalmic surgery, lasers & imaging retina},
volume = {},
number = {},
pages = {1-8},
doi = {10.3928/23258160-20260930-01},
pmid = {42961327},
issn = {2325-8179},
abstract = {BACKGROUND AND OBJECTIVE: The purpose of this study was to characterize the association between geographic atrophy (GA) growth and age-related macular degeneration (AMD) drusen phenotype.
PATIENTS AND METHODS: This retrospective cohort study included 59 eyes from 47 patients over 55 years with GA, followed for up to 5 years. Eyes with poor-quality imaging, irregular follow-up, or exudation were excluded. Based on multimodal retinal imaging, eyes were classified into three groups: Group 1 (reticular pseudodrusen [RPD]), Group 2 (large soft drusen [LSD]), and Group 3 (mixed RPD and LSD). Fundus autofluorescence (FAF) images were analyzed from baseline to 60 months. GA lesion area and growth rate were measured semi-automatically using Region-Finder (Heidelberg Engineering) and compared across groups over time.
RESULTS: The mean baseline GA area was 1.2 ± 0.8 mm[2]. The overall mean GA growth rate was 1.5 ± 0.9 mm[2]/year. Group 1 (RPD) showed the fastest progression at 2.56 ± 1.09 mm[2]/year, significantly higher than Group 2 (LSD, 1.02 ± 0.80 mm[2]/year) and Group 3 (1.10 ± 0.81 mm[2]/year) (P < .005). No significant difference was observed between Groups 2 and 3 (P = .28). These differences remained consistent at months 12, 24, 36, 48, and 60.
CONCLUSION: GA progression is significantly faster in eyes with pure RPD phenotype. Mixed phenotype behaves similarly to LSD, supporting phenotype-specific monitoring and treatment strategies.},
}
RevDate: 2026-10-30
Real-World Outcomes with Aflibercept 8 mg in Patients with Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) - Retrospective Single-Center Data Analysis.
Ophthalmology and therapy [Epub ahead of print].
INTRODUCTION: This work aims to evaluate real-world functional and anatomical outcomes following intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) treated under routine clinical conditions. We assessed functional and anatomical outcomes, treatment intervals, and subgroup effects by prior treatment status and sex over 12 months.
METHODS: This retrospective, single-center, non-interventional study included adult patients with nAMD or DME treated with aflibercept 8 mg in routine clinical practice between February 2024 and May 2026. Primary outcomes were changes in best-corrected visual acuity (BCVA; logMAR) and central subfield retinal thickness (CST; µm) from baseline to 3-, 6-, and 12-month follow-up. Secondary analyses included subgroup comparisons according to treatment status (treatment-naïve vs. pretreated) and sex, as well as evaluation of injection frequency and treatment intervals. Moreover, therapies before switching to aflibercept 8 mg were evaluated.
RESULTS: A total of 113 patients (138 eyes) were included. Median BCVA remained stable in nAMD (0.398 logMAR) and DME (0.301 logMAR) throughout the 12-month follow-up (p > 0.025). Median CST decreased in both disease groups (nAMD: - 22.0 µm; DME: - 10.0 µm), with significant reductions observed at months 3 and 6 in nAMD and at month 6 in DME (p < 0.025). Treatment intervals increased significantly in both indications (p < 0.05). Subgroup analyses for nAMD showed no significant differences in sex, but significantly greater anatomical improvement in treatment-naïve eyes than in previously treated eyes. One case of mild sterile intraocular inflammation was observed and resolved without permanent visual impairment.
CONCLUSIONS: The findings suggest that aflibercept 8 mg provides effective disease control with maintained visual outcomes and significant anatomical improvements in women and men with nAMD and DME, including a predominantly previously treated population, in routine clinical practice. Longer-term real-world studies are required to confirm durability of these findings.
Additional Links: PMID-42961684
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42961684,
year = {2026},
author = {Messerschmidt-Roth, A and Winter, J and Schulze, S},
title = {Real-World Outcomes with Aflibercept 8 mg in Patients with Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) - Retrospective Single-Center Data Analysis.},
journal = {Ophthalmology and therapy},
volume = {},
number = {},
pages = {},
pmid = {42961684},
issn = {2193-8245},
abstract = {INTRODUCTION: This work aims to evaluate real-world functional and anatomical outcomes following intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) treated under routine clinical conditions. We assessed functional and anatomical outcomes, treatment intervals, and subgroup effects by prior treatment status and sex over 12 months.
METHODS: This retrospective, single-center, non-interventional study included adult patients with nAMD or DME treated with aflibercept 8 mg in routine clinical practice between February 2024 and May 2026. Primary outcomes were changes in best-corrected visual acuity (BCVA; logMAR) and central subfield retinal thickness (CST; µm) from baseline to 3-, 6-, and 12-month follow-up. Secondary analyses included subgroup comparisons according to treatment status (treatment-naïve vs. pretreated) and sex, as well as evaluation of injection frequency and treatment intervals. Moreover, therapies before switching to aflibercept 8 mg were evaluated.
RESULTS: A total of 113 patients (138 eyes) were included. Median BCVA remained stable in nAMD (0.398 logMAR) and DME (0.301 logMAR) throughout the 12-month follow-up (p > 0.025). Median CST decreased in both disease groups (nAMD: - 22.0 µm; DME: - 10.0 µm), with significant reductions observed at months 3 and 6 in nAMD and at month 6 in DME (p < 0.025). Treatment intervals increased significantly in both indications (p < 0.05). Subgroup analyses for nAMD showed no significant differences in sex, but significantly greater anatomical improvement in treatment-naïve eyes than in previously treated eyes. One case of mild sterile intraocular inflammation was observed and resolved without permanent visual impairment.
CONCLUSIONS: The findings suggest that aflibercept 8 mg provides effective disease control with maintained visual outcomes and significant anatomical improvements in women and men with nAMD and DME, including a predominantly previously treated population, in routine clinical practice. Longer-term real-world studies are required to confirm durability of these findings.},
}
RevDate: 2026-11-01
CmpDate: 2026-10-30
Integration of biomarkers in common retinal neurodegenerative diseases: a comprehensive review.
Mammalian genome : official journal of the International Mammalian Genome Society, 37(1):.
Retinal neurodegenerative diseases (RNDs) are major causes of irreversible vision loss worldwide. RNDs majorly include age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. Despite their distinct etiologies, these conditions share convergent mechanisms of retinovascular ischemia, neuronal apoptosis, and chronic inflammation. Physiologically, the retina and optic nerve are direct extensions of the central nervous system, sharing embryological origin, glial architecture, and neurodegenerative mechanisms with the brain, positioning them as an accessible model system for studying both ocular and systemic neurodegeneration. The growing field of ocular biomarkers thus offers objective, quantifiable endpoints for early detection, disease monitoring, and therapeutic evaluation of RNDs by bridging structural, functional, molecular, and genetic dimensions of retinal health. This narrative review synthesizes peer-reviewed literature published between January 2015 and May 2026, identified through PubMed, Scopus, and Web of Science, on ocular biomarkers in AMD, DR, and glaucoma. Eligible studies reported original clinical or translational research assessing imaging, functional, molecular, or genomic biomarkers with quantitative associations to disease diagnosis, prognosis, or treatment response. Biomarker evidence is organized by domain to enable cross-disease comparison and integration, and each major biomarker is graded by clinical maturity, distinguishing routine clinical use, research validation, use as a clinical trial endpoint, and regulatory acceptance. Optical coherence tomography-derived retinal nerve fiber layer thickness in glaucoma and geographic atrophy area on fundus autofluorescence in AMD are the most established biomarkers in clinical care and trials, whereas disorganization of retinal inner layers and vessel density in DR, and dark adaptation and ellipsoid zone integrity in AMD, are well supported in research settings but not yet standardized for routine clinical use. Ocular biomarkers are reshaping precision ophthalmology, offering reproducible measures for diagnosis, prognosis, and therapeutic monitoring across retinal diseases. While several structural and functional biomarkers are nearing clinical adoption, standardized acquisition protocols, external validation, and regulatory qualification remain critical next steps. Integration of multimodal imaging, molecular analytics, and artificial intelligence-driven modeling holds promise for a unified, biomarker-based framework for early detection and individualized management of retinal neurodegeneration. Retinal biomarkers therefore carry dual relevance: they characterize disease within the eye and increasingly serve as accessible surrogates for central nervous system neurodegenerative processes, with broader implications for the field of neurodegenerative disease research.
Additional Links: PMID-42961700
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42961700,
year = {2026},
author = {Fazal, ZZ and Stroumza, JR and Patel, SH and Uy, FRC and Ali, H and Khan, H and Goldberg, JL and Sepah, YJ},
title = {Integration of biomarkers in common retinal neurodegenerative diseases: a comprehensive review.},
journal = {Mammalian genome : official journal of the International Mammalian Genome Society},
volume = {37},
number = {1},
pages = {},
pmid = {42961700},
issn = {1432-1777},
support = {P30EY026877/EY/NEI NIH HHS/United States ; 343614//Research to Prevent Blindness/ ; },
mesh = {Humans ; *Biomarkers/metabolism ; *Neurodegenerative Diseases/diagnosis/genetics/metabolism/pathology ; Animals ; Glaucoma/genetics/diagnosis/metabolism/pathology ; *Retinal Diseases/diagnosis/metabolism/genetics ; Retina/metabolism/pathology ; *Macular Degeneration/genetics/diagnosis/metabolism/pathology ; *Diabetic Retinopathy/genetics/diagnosis/metabolism/pathology ; },
abstract = {Retinal neurodegenerative diseases (RNDs) are major causes of irreversible vision loss worldwide. RNDs majorly include age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. Despite their distinct etiologies, these conditions share convergent mechanisms of retinovascular ischemia, neuronal apoptosis, and chronic inflammation. Physiologically, the retina and optic nerve are direct extensions of the central nervous system, sharing embryological origin, glial architecture, and neurodegenerative mechanisms with the brain, positioning them as an accessible model system for studying both ocular and systemic neurodegeneration. The growing field of ocular biomarkers thus offers objective, quantifiable endpoints for early detection, disease monitoring, and therapeutic evaluation of RNDs by bridging structural, functional, molecular, and genetic dimensions of retinal health. This narrative review synthesizes peer-reviewed literature published between January 2015 and May 2026, identified through PubMed, Scopus, and Web of Science, on ocular biomarkers in AMD, DR, and glaucoma. Eligible studies reported original clinical or translational research assessing imaging, functional, molecular, or genomic biomarkers with quantitative associations to disease diagnosis, prognosis, or treatment response. Biomarker evidence is organized by domain to enable cross-disease comparison and integration, and each major biomarker is graded by clinical maturity, distinguishing routine clinical use, research validation, use as a clinical trial endpoint, and regulatory acceptance. Optical coherence tomography-derived retinal nerve fiber layer thickness in glaucoma and geographic atrophy area on fundus autofluorescence in AMD are the most established biomarkers in clinical care and trials, whereas disorganization of retinal inner layers and vessel density in DR, and dark adaptation and ellipsoid zone integrity in AMD, are well supported in research settings but not yet standardized for routine clinical use. Ocular biomarkers are reshaping precision ophthalmology, offering reproducible measures for diagnosis, prognosis, and therapeutic monitoring across retinal diseases. While several structural and functional biomarkers are nearing clinical adoption, standardized acquisition protocols, external validation, and regulatory qualification remain critical next steps. Integration of multimodal imaging, molecular analytics, and artificial intelligence-driven modeling holds promise for a unified, biomarker-based framework for early detection and individualized management of retinal neurodegeneration. Retinal biomarkers therefore carry dual relevance: they characterize disease within the eye and increasingly serve as accessible surrogates for central nervous system neurodegenerative processes, with broader implications for the field of neurodegenerative disease research.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Biomarkers/metabolism
*Neurodegenerative Diseases/diagnosis/genetics/metabolism/pathology
Animals
Glaucoma/genetics/diagnosis/metabolism/pathology
*Retinal Diseases/diagnosis/metabolism/genetics
Retina/metabolism/pathology
*Macular Degeneration/genetics/diagnosis/metabolism/pathology
*Diabetic Retinopathy/genetics/diagnosis/metabolism/pathology
RevDate: 2026-11-02
CmpDate: 2026-10-31
Systematic review of atropine cost-effectiveness in childhood myopia management.
Frontiers in pharmacology, 17:1836579.
BACKGROUND: Childhood myopia is a global public health concern, with rising prevalence and a significant economic burden due to complications like retinal detachment and macular degeneration. Low-dose atropine (LDA) range 0.01%-0.05% is a clinically effective intervention for slowing myopia progression. However, its economic value remains under-evaluated across diverse settings.
METHODS AND FINDINGS: We conducted a systematic review following PRISMA guidelines and registered in PROSPERO (CRD420251009680) to assess the cost-effectiveness of atropine for myopia management in children. Four model-based economic evaluations met the inclusion criteria, from Hong Kong, New Zealand, Australia/China and France/United Kingdom. Two studies used Markov cohort state-transition models while two employed a cohort decision-analytic model with probabilistic simulation of refractive outcomes. All four economic evaluations adopted a societal perspective; each applied a 3% annual discount rate to costs in their analyses and reported sensitivity analyses around discounting. Time horizons ranged from 5 years for incident myopia to lifetime horizons capturing myopia complications and vision impairment. Across economic models, LDA was consistently found to be cost-effective or cost-saving compared with standard care. Reported incremental cost-effectiveness ratios (ICERs) included approximately NZ$1,590 per quality-adjusted life year (QALY) gained in a New Zealand Markov cost-utility model, and USD 220-275 per diopter spherical equivalent reduction in a 5-year Hong Kong cost-effectiveness analysis. Evidence from high- and middle-income settings indicates that low-dose atropine is a cost-effective strategy, particularly when long-term progression to high myopia and its associated complications is considered. In European settings, low-dose atropine demonstrated a favorable cost profile compared with standard correction in children at higher risk of myopia progression, with consistent findings of cost-neutrality or cost savings when downstream costs of high myopia were included.
CONCLUSION: Studies demonstrate favourable economic value using diverse metrics, including cost per diopter reduction, cost ratios, and cost-utility estimates, rather than uniformly reported ICERs. Greater economic benefits are observed over longer time horizons, largely driven by the avoidance of high myopia-related complications and associated costs.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251009680, identifier PROSPERO CRD420251009680.
Additional Links: PMID-42964589
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42964589,
year = {2026},
author = {Sui, CF and Ng, CH and Soh, YC and Lee, KS and Hermansyah, A and Ming, LC},
title = {Systematic review of atropine cost-effectiveness in childhood myopia management.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1836579},
pmid = {42964589},
issn = {1663-9812},
abstract = {BACKGROUND: Childhood myopia is a global public health concern, with rising prevalence and a significant economic burden due to complications like retinal detachment and macular degeneration. Low-dose atropine (LDA) range 0.01%-0.05% is a clinically effective intervention for slowing myopia progression. However, its economic value remains under-evaluated across diverse settings.
METHODS AND FINDINGS: We conducted a systematic review following PRISMA guidelines and registered in PROSPERO (CRD420251009680) to assess the cost-effectiveness of atropine for myopia management in children. Four model-based economic evaluations met the inclusion criteria, from Hong Kong, New Zealand, Australia/China and France/United Kingdom. Two studies used Markov cohort state-transition models while two employed a cohort decision-analytic model with probabilistic simulation of refractive outcomes. All four economic evaluations adopted a societal perspective; each applied a 3% annual discount rate to costs in their analyses and reported sensitivity analyses around discounting. Time horizons ranged from 5 years for incident myopia to lifetime horizons capturing myopia complications and vision impairment. Across economic models, LDA was consistently found to be cost-effective or cost-saving compared with standard care. Reported incremental cost-effectiveness ratios (ICERs) included approximately NZ$1,590 per quality-adjusted life year (QALY) gained in a New Zealand Markov cost-utility model, and USD 220-275 per diopter spherical equivalent reduction in a 5-year Hong Kong cost-effectiveness analysis. Evidence from high- and middle-income settings indicates that low-dose atropine is a cost-effective strategy, particularly when long-term progression to high myopia and its associated complications is considered. In European settings, low-dose atropine demonstrated a favorable cost profile compared with standard correction in children at higher risk of myopia progression, with consistent findings of cost-neutrality or cost savings when downstream costs of high myopia were included.
CONCLUSION: Studies demonstrate favourable economic value using diverse metrics, including cost per diopter reduction, cost ratios, and cost-utility estimates, rather than uniformly reported ICERs. Greater economic benefits are observed over longer time horizons, largely driven by the avoidance of high myopia-related complications and associated costs.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251009680, identifier PROSPERO CRD420251009680.},
}
RevDate: 2026-10-31
CmpDate: 2026-10-30
Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration.
International journal of ophthalmology, 19(11):2172-2181.
AIM: To evaluate and compare the efficacy and safety of two treat-and-extend (T&E) regimens (2- and 4-week intervals, Δ2w and Δ4w) of intravitreal conbercept injections in patients with neovascular age-related macular degeneration (nAMD).
METHODS: This 24-month prospective randomized controlled trial at the First Affiliated Hospital of Chongqing Medical University included patients with nAMD. Eyes were randomly assigned (1:1) to receive intravitreal conbercept (0.5 mg) with T&E regimens using 2- or 4-week interval adjustments (Δ2w and Δ4w groups). Key outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), superficial vascular density (SVD), deep vascular density (DVD), and large-medium vascular density (LMVD) within the 3 mm macular foveal region. The primary endpoint was the mean change in BCVA from baseline to the 2-year follow-up (noninferiority cutoff: 4 letters).
RESULTS: Ultimately, 61 participants (68 eyes) completed the 2-year study. Baseline characteristics were similar between the two groups. At week 96, the mean number of injections was 11.17±1.13 in the Δ2w group (36 eyes, with the mean age of 70.42±9.31y) and 9.84±1.02 in the Δ4w group (32 eyes, with the mean age of 71.25±9.99y; P<0.001). The mean changes in BCVA were 5.19±6.58 and 5.91±5.51 letters (P=0.528), and Δ4w being noninferior to Δ2w (difference: 0.71 letters; 95%CI: -3.67 to 2.24). The mean changes in CRT were -118.97±106.97 and -134.98±128.77 µm (P=0.406), and the mean changes in SFCT were -30.03±17.48 and -32.55±22.73 µm (P=0.538), respectively. No significant intergroup differences in vascular densities were observed. Type 1 macular neovascularization had a higher baseline BCVA and required more injections than those with other macular neovascularization subtypes.
CONCLUSION: Intravitreal conbercept injections administered via 2- and 4-week intervals show similar efficacy and safety. The reduced injection frequency in the Δ4w regimen may help lower the overall treatment burden, and individualized therapy based on nAMD subtypes may further optimize clinical outcomes.
Additional Links: PMID-42959616
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42959616,
year = {2026},
author = {Ju, H and Ding, XH and Jin, LY and Qin, XF and Luo, QY and Wang, X and Peng, H},
title = {Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration.},
journal = {International journal of ophthalmology},
volume = {19},
number = {11},
pages = {2172-2181},
pmid = {42959616},
issn = {2222-3959},
abstract = {AIM: To evaluate and compare the efficacy and safety of two treat-and-extend (T&E) regimens (2- and 4-week intervals, Δ2w and Δ4w) of intravitreal conbercept injections in patients with neovascular age-related macular degeneration (nAMD).
METHODS: This 24-month prospective randomized controlled trial at the First Affiliated Hospital of Chongqing Medical University included patients with nAMD. Eyes were randomly assigned (1:1) to receive intravitreal conbercept (0.5 mg) with T&E regimens using 2- or 4-week interval adjustments (Δ2w and Δ4w groups). Key outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), superficial vascular density (SVD), deep vascular density (DVD), and large-medium vascular density (LMVD) within the 3 mm macular foveal region. The primary endpoint was the mean change in BCVA from baseline to the 2-year follow-up (noninferiority cutoff: 4 letters).
RESULTS: Ultimately, 61 participants (68 eyes) completed the 2-year study. Baseline characteristics were similar between the two groups. At week 96, the mean number of injections was 11.17±1.13 in the Δ2w group (36 eyes, with the mean age of 70.42±9.31y) and 9.84±1.02 in the Δ4w group (32 eyes, with the mean age of 71.25±9.99y; P<0.001). The mean changes in BCVA were 5.19±6.58 and 5.91±5.51 letters (P=0.528), and Δ4w being noninferior to Δ2w (difference: 0.71 letters; 95%CI: -3.67 to 2.24). The mean changes in CRT were -118.97±106.97 and -134.98±128.77 µm (P=0.406), and the mean changes in SFCT were -30.03±17.48 and -32.55±22.73 µm (P=0.538), respectively. No significant intergroup differences in vascular densities were observed. Type 1 macular neovascularization had a higher baseline BCVA and required more injections than those with other macular neovascularization subtypes.
CONCLUSION: Intravitreal conbercept injections administered via 2- and 4-week intervals show similar efficacy and safety. The reduced injection frequency in the Δ4w regimen may help lower the overall treatment burden, and individualized therapy based on nAMD subtypes may further optimize clinical outcomes.},
}
RevDate: 2026-10-30
Association of CFH rs1061170 (Y402H), C2 rs9332739 (E318D), and C3 rs2230199 (R102G) gene polymorphism with age-related macular degeneration: an integrative systematic review, meta-analysis, and in-silico approach.
Ophthalmic genetics [Epub ahead of print].
BACKGROUND: Age-related macular degeneration (AMD) is a progressive retinal disorder and a major cause of irreversible blindness in the elderly, with complement pathway dysfunction playing a key role in its pathogenesis.
METHODS: The present aims to examine the impact of CFH rs1061170 (Y402H), C2 rs9332739 (E318D), and C3 rs2230199 (R102G) gene polymorphisms and AMD risk, in addition, Deleterious missense SNPs in CFH, C2, and C3 were analyzed for stability, conservation, and structural impact using multiple computational approaches. Relevant studies were searched in PubMed, Web of Science, and Google Scholar databases between the years Jan 2020 and 30 April 2026 and covered a total of nine case-control articles.
RESULTS: Meta-analysis demonstrated significant associations of CFH rs1061170 and C3 rs2230199 polymorphisms with AMD susceptibility under specific genetic models (p < 0.01), whereas C2 rs9332739 showed only a non-significant trend toward reduced AMD susceptibility. Functional prediction analyses using SIFT, PolyPhen-2, I-Mutant, ConSurf, and Project HOPE suggested that the missense variants in CFH, C2, and C3 may alter protein structure, stability, and intermolecular interactions, providing biological support for their potential role in AMD pathogenesis. ConSurf showed that the SNPs were located in functional residues. Project HOPE revealed alterations in amino acid size, charge, and hydrophobicity, which may impair intermolecular interactions and destabilize protein architecture.
CONCLUSION: The present meta-analysis demonstrated significant associations of CFH rs1061170 (Y402H) and C3 rs2230199 (R102G) polymorphisms with AMD susceptibility, whereas C2 rs9332739 (E318D) showed a nonsignificant trend toward reduced AMD susceptibility. In-silico analyses suggested that these variants may influence complement protein function through localized alterations in electrostatic properties, ligand-binding interactions, and surface physicochemical characteristics rather than major global structural destabilization. These computational findings provide plausible mechanistic insights into complement-mediated retinal dysfunction but require experimental validation before establishing molecular causality.
Additional Links: PMID-42960599
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42960599,
year = {2026},
author = {B, S and Thanigai Arasu, A and Ravichandar, S and Ganapathy, P and Rajagopal, RE and Murali, U and M, K and R, P and Subbaraj, GK},
title = {Association of CFH rs1061170 (Y402H), C2 rs9332739 (E318D), and C3 rs2230199 (R102G) gene polymorphism with age-related macular degeneration: an integrative systematic review, meta-analysis, and in-silico approach.},
journal = {Ophthalmic genetics},
volume = {},
number = {},
pages = {1-22},
doi = {10.1080/13816810.2026.2749870},
pmid = {42960599},
issn = {1744-5094},
abstract = {BACKGROUND: Age-related macular degeneration (AMD) is a progressive retinal disorder and a major cause of irreversible blindness in the elderly, with complement pathway dysfunction playing a key role in its pathogenesis.
METHODS: The present aims to examine the impact of CFH rs1061170 (Y402H), C2 rs9332739 (E318D), and C3 rs2230199 (R102G) gene polymorphisms and AMD risk, in addition, Deleterious missense SNPs in CFH, C2, and C3 were analyzed for stability, conservation, and structural impact using multiple computational approaches. Relevant studies were searched in PubMed, Web of Science, and Google Scholar databases between the years Jan 2020 and 30 April 2026 and covered a total of nine case-control articles.
RESULTS: Meta-analysis demonstrated significant associations of CFH rs1061170 and C3 rs2230199 polymorphisms with AMD susceptibility under specific genetic models (p < 0.01), whereas C2 rs9332739 showed only a non-significant trend toward reduced AMD susceptibility. Functional prediction analyses using SIFT, PolyPhen-2, I-Mutant, ConSurf, and Project HOPE suggested that the missense variants in CFH, C2, and C3 may alter protein structure, stability, and intermolecular interactions, providing biological support for their potential role in AMD pathogenesis. ConSurf showed that the SNPs were located in functional residues. Project HOPE revealed alterations in amino acid size, charge, and hydrophobicity, which may impair intermolecular interactions and destabilize protein architecture.
CONCLUSION: The present meta-analysis demonstrated significant associations of CFH rs1061170 (Y402H) and C3 rs2230199 (R102G) polymorphisms with AMD susceptibility, whereas C2 rs9332739 (E318D) showed a nonsignificant trend toward reduced AMD susceptibility. In-silico analyses suggested that these variants may influence complement protein function through localized alterations in electrostatic properties, ligand-binding interactions, and surface physicochemical characteristics rather than major global structural destabilization. These computational findings provide plausible mechanistic insights into complement-mediated retinal dysfunction but require experimental validation before establishing molecular causality.},
}
RevDate: 2026-10-31
CmpDate: 2026-10-29
Factors associated with loss to follow-up after point-of-care diabetic retinopathy examination in a teleophthalmology program: A retrospective cohort study.
PloS one, 21(10):e0359305.
OBJECTIVE: To identify patient-, clinical-, and system-level factors associated with loss to follow-up after point-of-care diabetic retinopathy examination (DRE).
METHODS: We conducted a retrospective cohort study of adults ≥18 years undergoing DREs at 75 primary care clinics in Pennsylvania, USA (2017-2019), restricted to examinations with recommended follow-up. The unit of analysis was the DRE. Electronic medical records were used to obtain six-month follow‑up outcomes and patient-, clinical-, and system-level variables. Loss to follow-up was defined as failure to attend an eye care visit within 180 days of DRE. Examinations with duplicate results, those from patients who died within six months, or from sites where the program was discontinued were excluded. Multivariable mixed-effects logistic regression models with random intercepts for patient and clinic were used. Analyses were conducted in the full cohort and separately for gradable and indeterminate exams (ungradable/no image).
RESULTS: Among 3,121 DREs from 2,959 patients, 32.3% completed follow-up. In the full cohort, higher odds of loss to follow-up were associated with increasing age (adjusted odds ratio [aOR]=1.02, 95% confidence interval [95%CI]=1.00-1.03, p = 0.019), not being married (aOR=1.36, 95%CI = 1.04-1.77, p = 0.03), findings suggestive of age-related macular degeneration (AMD) on DRE (aOR=1.80, 95%CI = 1.14-2.85, p = 0.012), and higher no-show rates (aOR=1.04, 95%CI = 1.02-1.05, p < 0.0001). History of eye disease (aOR=0.50, 95%CI = 0.37-0.69, p < 0.0001) and patient contact within 30 days (e.g., same/next day: aOR=0.37, 95%CI = 0.20-0.67, p = 0.001) were associated with lower odds of loss to follow-up; contact at 31-60 days was not significantly associated. Findings were consistent across full and gradable models; only no-show rate remained significant in the indeterminate model. Socioeconomic variables, comorbidities, and diabetic retinopathy severity were not independently associated with loss to follow-up after adjustment.
CONCLUSIONS: Adherence was associated with patient (sociodemographic: age, marital status), clinical (AMD on DRE, prior eye disease), and system-level factors (no-show rates, patient contact within 30 days), supporting targeted, multifactorial interventions.
Additional Links: PMID-42955996
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42955996,
year = {2026},
author = {Bonilla-Escobar, FJ and Atta, S and Eibel, MR and Wesalo, JS and Chang, JT and Sánchez-Cano, D and Eller, A and Waxman, EL},
title = {Factors associated with loss to follow-up after point-of-care diabetic retinopathy examination in a teleophthalmology program: A retrospective cohort study.},
journal = {PloS one},
volume = {21},
number = {10},
pages = {e0359305},
pmid = {42955996},
issn = {1932-6203},
mesh = {Humans ; *Diabetic Retinopathy/diagnosis ; Retrospective Studies ; Female ; Male ; Middle Aged ; Aged ; *Lost to Follow-Up ; Telemedicine ; *Point-of-Care Systems ; Pennsylvania ; Ophthalmology ; Follow-Up Studies ; Adult ; },
abstract = {OBJECTIVE: To identify patient-, clinical-, and system-level factors associated with loss to follow-up after point-of-care diabetic retinopathy examination (DRE).
METHODS: We conducted a retrospective cohort study of adults ≥18 years undergoing DREs at 75 primary care clinics in Pennsylvania, USA (2017-2019), restricted to examinations with recommended follow-up. The unit of analysis was the DRE. Electronic medical records were used to obtain six-month follow‑up outcomes and patient-, clinical-, and system-level variables. Loss to follow-up was defined as failure to attend an eye care visit within 180 days of DRE. Examinations with duplicate results, those from patients who died within six months, or from sites where the program was discontinued were excluded. Multivariable mixed-effects logistic regression models with random intercepts for patient and clinic were used. Analyses were conducted in the full cohort and separately for gradable and indeterminate exams (ungradable/no image).
RESULTS: Among 3,121 DREs from 2,959 patients, 32.3% completed follow-up. In the full cohort, higher odds of loss to follow-up were associated with increasing age (adjusted odds ratio [aOR]=1.02, 95% confidence interval [95%CI]=1.00-1.03, p = 0.019), not being married (aOR=1.36, 95%CI = 1.04-1.77, p = 0.03), findings suggestive of age-related macular degeneration (AMD) on DRE (aOR=1.80, 95%CI = 1.14-2.85, p = 0.012), and higher no-show rates (aOR=1.04, 95%CI = 1.02-1.05, p < 0.0001). History of eye disease (aOR=0.50, 95%CI = 0.37-0.69, p < 0.0001) and patient contact within 30 days (e.g., same/next day: aOR=0.37, 95%CI = 0.20-0.67, p = 0.001) were associated with lower odds of loss to follow-up; contact at 31-60 days was not significantly associated. Findings were consistent across full and gradable models; only no-show rate remained significant in the indeterminate model. Socioeconomic variables, comorbidities, and diabetic retinopathy severity were not independently associated with loss to follow-up after adjustment.
CONCLUSIONS: Adherence was associated with patient (sociodemographic: age, marital status), clinical (AMD on DRE, prior eye disease), and system-level factors (no-show rates, patient contact within 30 days), supporting targeted, multifactorial interventions.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Diabetic Retinopathy/diagnosis
Retrospective Studies
Female
Male
Middle Aged
Aged
*Lost to Follow-Up
Telemedicine
*Point-of-Care Systems
Pennsylvania
Ophthalmology
Follow-Up Studies
Adult
RevDate: 2026-10-29
Choroidal Thickness and Axial Length as Independent Correlates of AMD: Korea National Health and Nutrition Examination Survey 2017-2020.
American journal of ophthalmology pii:S0002-9394(26)00574-X [Epub ahead of print].
PURPOSE: To examine how choroidal thickness and axial length relate to age-related macular degeneration (AMD) across disease stages in a nationwide Korean population.
DESIGN: Cross-sectional, population-based study.
METHODS: We analyzed the Korea National Health and Nutrition Examination Survey, 2017-2020, including 15,388 adults aged 40 years or older with gradable fundus photographs; ocular analyses included 13,807 after excluding coexisting macular disease. Axial length (AL), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were measured by partial coherence interferometry and optical coherence tomography. Associations were assessed by survey-weighted logistic regression adjusted for age, sex, and systemic factors.
RESULTS: Weighted AMD prevalence was 14.41% (95% CI, 13.67-15.15; early, 13.46%; late, 0.95%). In multivariable models, greater SFCT was associated with early AMD (OR per 10 µm, 1.03; 95% CI, 1.02-1.03; P < .001), and shorter AL with early AMD (OR per 1 mm, 0.76; 0.71-0.82; P < .001) and late AMD (0.74; 0.57-0.97; P = .030). Greater CMT was associated with late AMD (OR per 10 µm, 1.10; 1.01-1.19; P = .030) and neovascular AMD (1.23; 1.12-1.35; P < .001). SFCT and AL remained associated with early AMD after mutual adjustment (both P < .001). Older age, male sex, non-white-collar occupation, and rural residence were associated with AMD, and anemia with late AMD (1.78; 1.06-2.96; P = .028).
CONCLUSIONS: Greater SFCT and shorter AL were independently associated with early AMD. These findings suggest that choroidal thickness and axial length may reflect distinct structural correlates.
Additional Links: PMID-42957012
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42957012,
year = {2026},
author = {Choi, M and Park, SJ and Kim, BH and Shin, JP and Choi, KS and Jo, YJ and Park, KH},
title = {Choroidal Thickness and Axial Length as Independent Correlates of AMD: Korea National Health and Nutrition Examination Survey 2017-2020.},
journal = {American journal of ophthalmology},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.ajo.2026.10.015},
pmid = {42957012},
issn = {1879-1891},
abstract = {PURPOSE: To examine how choroidal thickness and axial length relate to age-related macular degeneration (AMD) across disease stages in a nationwide Korean population.
DESIGN: Cross-sectional, population-based study.
METHODS: We analyzed the Korea National Health and Nutrition Examination Survey, 2017-2020, including 15,388 adults aged 40 years or older with gradable fundus photographs; ocular analyses included 13,807 after excluding coexisting macular disease. Axial length (AL), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were measured by partial coherence interferometry and optical coherence tomography. Associations were assessed by survey-weighted logistic regression adjusted for age, sex, and systemic factors.
RESULTS: Weighted AMD prevalence was 14.41% (95% CI, 13.67-15.15; early, 13.46%; late, 0.95%). In multivariable models, greater SFCT was associated with early AMD (OR per 10 µm, 1.03; 95% CI, 1.02-1.03; P < .001), and shorter AL with early AMD (OR per 1 mm, 0.76; 0.71-0.82; P < .001) and late AMD (0.74; 0.57-0.97; P = .030). Greater CMT was associated with late AMD (OR per 10 µm, 1.10; 1.01-1.19; P = .030) and neovascular AMD (1.23; 1.12-1.35; P < .001). SFCT and AL remained associated with early AMD after mutual adjustment (both P < .001). Older age, male sex, non-white-collar occupation, and rural residence were associated with AMD, and anemia with late AMD (1.78; 1.06-2.96; P = .028).
CONCLUSIONS: Greater SFCT and shorter AL were independently associated with early AMD. These findings suggest that choroidal thickness and axial length may reflect distinct structural correlates.},
}
RevDate: 2026-10-31
CmpDate: 2026-10-30
Association between anticholinergic burden and geographic atrophy secondary to age-related macular degeneration: a case-control study.
BMC ophthalmology, 26(1):.
BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of visual impairment in older adults. Given the high prevalence of polypharmacy in this population, cumulative medication effects, particularly anticholinergic burden, may represent a clinically relevant factor requiring further investigation. This study aimed to investigate the association between anticholinergic burden, overall drug burden, and geographic atrophy secondary age-related macular degeneration (GA secondary to AMD).
METHODS: In this case-control study, 102 participants aged 55-90 years were included. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden (ACB) scale. Medications regularly used by patients for chronic conditions and continued for a minimum duration of three months were included. Drug burden was defined as polypharmacy (≥ 5 medications). Multivariate logistic regression analyses were performed adjusting for age, gender, and multimorbidity.
RESULTS: Patients with GA secondary to AMD had a higher number of medications and a greater prevalence of both drug burden and anticholinergic burden compared to controls (p = 0.010, p = 0.039, and p = 0.046, respectively). In multivariate analysis, anticholinergic burden (OR: 2.55, 95% CI: 1.11-5.84, p = 0.026) and drug burden (OR: 3.41, 95% CI: 1.21-9.58, p = 0.017) were independently associated with GA secondary to AMD.
CONCLUSIONS: Increased anticholinergic and overall drug burden were independently associated with GA secondary to AMD in older adults. These findings suggest a potential relationship between cumulative medication exposure and AMD. Further prospective studies are needed to determine whether this association has clinical or causal significance.
Additional Links: PMID-42958104
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42958104,
year = {2026},
author = {Katipoğlu, Z and Katipoglu, B and Turan, M},
title = {Association between anticholinergic burden and geographic atrophy secondary to age-related macular degeneration: a case-control study.},
journal = {BMC ophthalmology},
volume = {26},
number = {1},
pages = {},
pmid = {42958104},
issn = {1471-2415},
mesh = {Humans ; Aged ; Female ; Male ; Case-Control Studies ; Aged, 80 and over ; *Geographic Atrophy/etiology/diagnosis/chemically induced ; *Cholinergic Antagonists/adverse effects ; Middle Aged ; *Macular Degeneration/complications ; Polypharmacy ; Prevalence ; Visual Acuity ; },
abstract = {BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of visual impairment in older adults. Given the high prevalence of polypharmacy in this population, cumulative medication effects, particularly anticholinergic burden, may represent a clinically relevant factor requiring further investigation. This study aimed to investigate the association between anticholinergic burden, overall drug burden, and geographic atrophy secondary age-related macular degeneration (GA secondary to AMD).
METHODS: In this case-control study, 102 participants aged 55-90 years were included. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden (ACB) scale. Medications regularly used by patients for chronic conditions and continued for a minimum duration of three months were included. Drug burden was defined as polypharmacy (≥ 5 medications). Multivariate logistic regression analyses were performed adjusting for age, gender, and multimorbidity.
RESULTS: Patients with GA secondary to AMD had a higher number of medications and a greater prevalence of both drug burden and anticholinergic burden compared to controls (p = 0.010, p = 0.039, and p = 0.046, respectively). In multivariate analysis, anticholinergic burden (OR: 2.55, 95% CI: 1.11-5.84, p = 0.026) and drug burden (OR: 3.41, 95% CI: 1.21-9.58, p = 0.017) were independently associated with GA secondary to AMD.
CONCLUSIONS: Increased anticholinergic and overall drug burden were independently associated with GA secondary to AMD in older adults. These findings suggest a potential relationship between cumulative medication exposure and AMD. Further prospective studies are needed to determine whether this association has clinical or causal significance.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Aged
Female
Male
Case-Control Studies
Aged, 80 and over
*Geographic Atrophy/etiology/diagnosis/chemically induced
*Cholinergic Antagonists/adverse effects
Middle Aged
*Macular Degeneration/complications
Polypharmacy
Prevalence
Visual Acuity
RevDate: 2026-10-31
CmpDate: 2026-10-30
Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study.
BMC ophthalmology, 26(1):.
PURPOSE: To evaluate very early anatomical and functional outcomes following a switch from intravitreal bevacizumab to aflibercept-jbvf in patients with exudative macular diseases.
METHODS: This prospective, single-center, single-arm interventional cohort study included 53 eyes of 41 patients with diabetic macular edema (DME), macular neovascularization (MNV) secondary to neovascular age-related macular degeneration, or retinal vein occlusion (RVO). This heterogeneous cohort comprised biologically distinct disease entities; therefore, diagnosis-specific analyses were considered exploratory. All eyes received three monthly intravitreal bevacizumab injections followed by a single aflibercept-jbvf injection. Primary outcomes were changes in BCVA and CST from the post-bevacizumab preswitch baseline, assessed immediately before aflibercept-jbvf administration, to 4 weeks after the injection. The Wilcoxon signed-rank test was used for paired comparisons, and generalized estimating equation models accounted for within-patient intereye correlation in bilateral cases.
RESULTS: Among 53 eyes, 30 (56.6%) had DME, 18 (34.0%) had MNV, and five (9.4%) had RVO. Median CST decreased from 312 μm (IQR, 275-354 μm) at preswitch baseline to 291 μm (IQR, 255-322 μm) at week 4. The mean CST change was - 22.6 ± 68.1 μm (95% CI, - 40.9 to - 4.2; p = 0.001). Median BCVA was 0.699 logMAR at both the post-bevacizumab preswitch baseline (IQR, 0.495-1.000) and week 4 (IQR, 0.398-1.000). The mean BCVA change was - 0.051 ± 0.230 logMAR (95% CI, - 0.114 to + 0.013; p = 0.129). In the GEE analyses, CST reduction remained statistically significant (p = 0.005), whereas BCVA change was not significant after adjustment for within-patient intereye correlation (β = -0.051; p = 0.065). No serious adverse events were observed.
CONCLUSION: Administration of aflibercept-jbvf following three monthly bevacizumab injections was temporally associated with a statistically significant but modest very early reduction in CST at 4 weeks in this heterogeneous cohort of exudative macular diseases. Because DME, neovascular AMD-related MNV, and RVO represent biologically and clinically distinct disease entities, the pooled findings should be interpreted as descriptive cohort-level estimates within this shared treatment pathway rather than as evidence of a uniform treatment effect across these conditions. A small numerical trend toward BCVA improvement was observed, but the change was not statistically significant in either the unadjusted or GEE-adjusted analysis. Because this was a single-arm study without a comparator group, the observed anatomical change cannot be attributed specifically to aflibercept-jbvf and may partly reflect a delayed or cumulative response to prior bevacizumab, regression to the mean, or natural variability in retinal thickness. Diagnosis-specific findings were exploratory, and the 4-week endpoint does not provide information regarding durability of response or longer-term treatment burden.
Additional Links: PMID-42958502
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42958502,
year = {2026},
author = {Horozoglu Ceran, T and Beyatli, S and Dogan, M},
title = {Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study.},
journal = {BMC ophthalmology},
volume = {26},
number = {1},
pages = {},
pmid = {42958502},
issn = {1471-2415},
mesh = {Humans ; *Bevacizumab/administration & dosage/therapeutic use ; *Recombinant Fusion Proteins/administration & dosage/therapeutic use ; *Receptors, Vascular Endothelial Growth Factor/administration & dosage/therapeutic use/antagonists & inhibitors ; Female ; *Angiogenesis Inhibitors/therapeutic use/administration & dosage ; Intravitreal Injections ; Prospective Studies ; Male ; Visual Acuity ; Aged ; *Macular Edema/drug therapy/physiopathology ; *Drug Substitution ; Tomography, Optical Coherence ; Treatment Outcome ; Middle Aged ; *Diabetic Retinopathy/drug therapy ; *Wet Macular Degeneration/drug therapy/physiopathology/diagnosis ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; *Retinal Vein Occlusion/drug therapy ; Follow-Up Studies ; },
abstract = {PURPOSE: To evaluate very early anatomical and functional outcomes following a switch from intravitreal bevacizumab to aflibercept-jbvf in patients with exudative macular diseases.
METHODS: This prospective, single-center, single-arm interventional cohort study included 53 eyes of 41 patients with diabetic macular edema (DME), macular neovascularization (MNV) secondary to neovascular age-related macular degeneration, or retinal vein occlusion (RVO). This heterogeneous cohort comprised biologically distinct disease entities; therefore, diagnosis-specific analyses were considered exploratory. All eyes received three monthly intravitreal bevacizumab injections followed by a single aflibercept-jbvf injection. Primary outcomes were changes in BCVA and CST from the post-bevacizumab preswitch baseline, assessed immediately before aflibercept-jbvf administration, to 4 weeks after the injection. The Wilcoxon signed-rank test was used for paired comparisons, and generalized estimating equation models accounted for within-patient intereye correlation in bilateral cases.
RESULTS: Among 53 eyes, 30 (56.6%) had DME, 18 (34.0%) had MNV, and five (9.4%) had RVO. Median CST decreased from 312 μm (IQR, 275-354 μm) at preswitch baseline to 291 μm (IQR, 255-322 μm) at week 4. The mean CST change was - 22.6 ± 68.1 μm (95% CI, - 40.9 to - 4.2; p = 0.001). Median BCVA was 0.699 logMAR at both the post-bevacizumab preswitch baseline (IQR, 0.495-1.000) and week 4 (IQR, 0.398-1.000). The mean BCVA change was - 0.051 ± 0.230 logMAR (95% CI, - 0.114 to + 0.013; p = 0.129). In the GEE analyses, CST reduction remained statistically significant (p = 0.005), whereas BCVA change was not significant after adjustment for within-patient intereye correlation (β = -0.051; p = 0.065). No serious adverse events were observed.
CONCLUSION: Administration of aflibercept-jbvf following three monthly bevacizumab injections was temporally associated with a statistically significant but modest very early reduction in CST at 4 weeks in this heterogeneous cohort of exudative macular diseases. Because DME, neovascular AMD-related MNV, and RVO represent biologically and clinically distinct disease entities, the pooled findings should be interpreted as descriptive cohort-level estimates within this shared treatment pathway rather than as evidence of a uniform treatment effect across these conditions. A small numerical trend toward BCVA improvement was observed, but the change was not statistically significant in either the unadjusted or GEE-adjusted analysis. Because this was a single-arm study without a comparator group, the observed anatomical change cannot be attributed specifically to aflibercept-jbvf and may partly reflect a delayed or cumulative response to prior bevacizumab, regression to the mean, or natural variability in retinal thickness. Diagnosis-specific findings were exploratory, and the 4-week endpoint does not provide information regarding durability of response or longer-term treatment burden.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Bevacizumab/administration & dosage/therapeutic use
*Recombinant Fusion Proteins/administration & dosage/therapeutic use
*Receptors, Vascular Endothelial Growth Factor/administration & dosage/therapeutic use/antagonists & inhibitors
Female
*Angiogenesis Inhibitors/therapeutic use/administration & dosage
Intravitreal Injections
Prospective Studies
Male
Visual Acuity
Aged
*Macular Edema/drug therapy/physiopathology
*Drug Substitution
Tomography, Optical Coherence
Treatment Outcome
Middle Aged
*Diabetic Retinopathy/drug therapy
*Wet Macular Degeneration/drug therapy/physiopathology/diagnosis
Vascular Endothelial Growth Factor A/antagonists & inhibitors
*Retinal Vein Occlusion/drug therapy
Follow-Up Studies
RevDate: 2026-10-28
CmpDate: 2026-10-27
Artificial Intelligence in Eye Disease: A Systematic Review of Screening, Diagnosis, Prognosis, Treatment-Response Prediction, and Clinical Decision Support.
Journal of clinical medicine, 15(20):.
Background/Objectives: Artificial intelligence (AI) is expanding eye care beyond image-based detection toward prognosis, treatment-response prediction, monitoring, triage, and clinician-facing decision support. We evaluated AI across eye-disease screening, diagnosis, prognosis, treatment response, and decision support, emphasizing validation, explainability, and clinical readiness. Methods: This PROSPERO-registered review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Six databases plus supplementary routes identified English-language literature published from 1 January 2015 through 10 August 2026. Included studies underwent design-mapped Joanna Briggs Institute (JBI)/adapted-JBI item-level appraisal; heterogeneity precluded meta-analysis. Results: The evidence base comprised 270 studies. Diabetic retinopathy/diabetic macular oedema was the largest clinical area (82), followed by retinal/multi-disease AI (52), glaucoma (46), and age-related macular degeneration (AMD)/macular disease (29); convolutional neural network (CNN)/convolutional deep learning was the largest primary method group (136). External validation was confirmed in 130 studies, including 95 with a clinical/geographic/prospective/real-world external-validation component (86 clinical-only and nine mixed clinical + technical); 49 had a strict direct clinical comparator and 90 used explainability. Pediatric/pediatric-relevant evidence accounted for 30 studies, while explicit optometry/optometrist involvement appeared in only three. Conclusions: Ophthalmic AI spans diagnosis through clinical management, but translation remains limited by heterogeneous outcomes, incomplete independent validation, few direct comparators, and sparse evaluation of safety, workflow effects, and patient outcomes.
Additional Links: PMID-42941472
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42941472,
year = {2026},
author = {Alharbi, MM and Alharbi, EM and Alsalamah, AS and Asiri, H and Beati, N and AlAtawi, R and Arafat, A},
title = {Artificial Intelligence in Eye Disease: A Systematic Review of Screening, Diagnosis, Prognosis, Treatment-Response Prediction, and Clinical Decision Support.},
journal = {Journal of clinical medicine},
volume = {15},
number = {20},
pages = {},
pmid = {42941472},
issn = {2077-0383},
support = {//King Saud University/ ; },
abstract = {Background/Objectives: Artificial intelligence (AI) is expanding eye care beyond image-based detection toward prognosis, treatment-response prediction, monitoring, triage, and clinician-facing decision support. We evaluated AI across eye-disease screening, diagnosis, prognosis, treatment response, and decision support, emphasizing validation, explainability, and clinical readiness. Methods: This PROSPERO-registered review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Six databases plus supplementary routes identified English-language literature published from 1 January 2015 through 10 August 2026. Included studies underwent design-mapped Joanna Briggs Institute (JBI)/adapted-JBI item-level appraisal; heterogeneity precluded meta-analysis. Results: The evidence base comprised 270 studies. Diabetic retinopathy/diabetic macular oedema was the largest clinical area (82), followed by retinal/multi-disease AI (52), glaucoma (46), and age-related macular degeneration (AMD)/macular disease (29); convolutional neural network (CNN)/convolutional deep learning was the largest primary method group (136). External validation was confirmed in 130 studies, including 95 with a clinical/geographic/prospective/real-world external-validation component (86 clinical-only and nine mixed clinical + technical); 49 had a strict direct clinical comparator and 90 used explainability. Pediatric/pediatric-relevant evidence accounted for 30 studies, while explicit optometry/optometrist involvement appeared in only three. Conclusions: Ophthalmic AI spans diagnosis through clinical management, but translation remains limited by heterogeneous outcomes, incomplete independent validation, few direct comparators, and sparse evaluation of safety, workflow effects, and patient outcomes.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
Terminalia buceras (Syn. Bucida buceras) and Retinal Oxidative Stress: A Critical Review of Published Evidence and Its Relevance to Dry Age-Related Macular Degeneration.
International journal of molecular sciences, 27(20):.
Dry age-related macular degeneration (dAMD) is a multifactorial retinal disorder involving oxidative stress, mitochondrial dysfunction, chronic para-inflammation, complement dysregulation, and progressive retinal pigment epithelium (RPE) failure. This critical review evaluates the published evidence concerning Terminalia buceras (L.) C.Wright (syn. Bucida buceras L.; Combretaceae), hereafter referred to as T. buceras, and its relevance to dry age-related macular degeneration. The evidence is organized into five categories: species-specific chemical evidence, species-specific retinal evidence, species-specific non-retinal biological evidence, external isolated-compound evidence, and hypothesis-generating comparisons with related plants or experimental systems. The evidence base remains preliminary. Species-specific retinal data are restricted to in vitro observations, and there are currently no epidemiological studies linking T. buceras use to AMD outcomes, no validated animal studies demonstrating efficacy in dAMD, and no clinical studies. Moreover, phytochemical standardization, ocular exposure, metabolism, and retinal bioavailability remain insufficiently characterized. Accordingly, this review does not propose T. buceras as a preventive or therapeutic intervention and does not claim superiority over better-characterized medicinal plants. Instead, this review critically synthesizes published species-specific chemical and biological findings and evaluates their methodological limitations. The direct retinal evidence supports partial cytoprotection in an ARPE-19 oxidative-injury model, whereas the non-retinal inflammatory findings concern different preparations and experimental systems. Chemical characterization, cellular responses, and contextual mechanistic evidence are, therefore, considered separately. The available findings do not establish a disease-modifying effect on dAMD, clinically achievable retinal exposure, or chronic ocular safety.
Additional Links: PMID-42942037
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42942037,
year = {2026},
author = {Lewis-Luján, LM and Iloki-Lewis, AP and Guerrero-Magaña, DE and Galvez-Ruiz, JC and Perez-Martinez, CJ and Vargas-Durazo, JT and Trujillo-López, S and Iloki-Assanga, SB},
title = {Terminalia buceras (Syn. Bucida buceras) and Retinal Oxidative Stress: A Critical Review of Published Evidence and Its Relevance to Dry Age-Related Macular Degeneration.},
journal = {International journal of molecular sciences},
volume = {27},
number = {20},
pages = {},
pmid = {42942037},
issn = {1422-0067},
mesh = {Humans ; *Oxidative Stress/drug effects ; Animals ; *Plant Extracts/pharmacology/chemistry/therapeutic use ; *Terminalia/chemistry ; *Macular Degeneration/drug therapy/metabolism/pathology ; *Retina/drug effects/metabolism/pathology ; Retinal Pigment Epithelium/drug effects/metabolism ; *Geographic Atrophy/drug therapy/metabolism ; },
abstract = {Dry age-related macular degeneration (dAMD) is a multifactorial retinal disorder involving oxidative stress, mitochondrial dysfunction, chronic para-inflammation, complement dysregulation, and progressive retinal pigment epithelium (RPE) failure. This critical review evaluates the published evidence concerning Terminalia buceras (L.) C.Wright (syn. Bucida buceras L.; Combretaceae), hereafter referred to as T. buceras, and its relevance to dry age-related macular degeneration. The evidence is organized into five categories: species-specific chemical evidence, species-specific retinal evidence, species-specific non-retinal biological evidence, external isolated-compound evidence, and hypothesis-generating comparisons with related plants or experimental systems. The evidence base remains preliminary. Species-specific retinal data are restricted to in vitro observations, and there are currently no epidemiological studies linking T. buceras use to AMD outcomes, no validated animal studies demonstrating efficacy in dAMD, and no clinical studies. Moreover, phytochemical standardization, ocular exposure, metabolism, and retinal bioavailability remain insufficiently characterized. Accordingly, this review does not propose T. buceras as a preventive or therapeutic intervention and does not claim superiority over better-characterized medicinal plants. Instead, this review critically synthesizes published species-specific chemical and biological findings and evaluates their methodological limitations. The direct retinal evidence supports partial cytoprotection in an ARPE-19 oxidative-injury model, whereas the non-retinal inflammatory findings concern different preparations and experimental systems. Chemical characterization, cellular responses, and contextual mechanistic evidence are, therefore, considered separately. The available findings do not establish a disease-modifying effect on dAMD, clinically achievable retinal exposure, or chronic ocular safety.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Oxidative Stress/drug effects
Animals
*Plant Extracts/pharmacology/chemistry/therapeutic use
*Terminalia/chemistry
*Macular Degeneration/drug therapy/metabolism/pathology
*Retina/drug effects/metabolism/pathology
Retinal Pigment Epithelium/drug effects/metabolism
*Geographic Atrophy/drug therapy/metabolism
RevDate: 2026-10-28
CmpDate: 2026-10-27
Bridging Mechanism and Therapy in Ocular Disease: Mitochondrial, Vascular, and Immune Pathways in the Eye.
Life (Basel, Switzerland), 16(10):.
There is an increasing global burden of ocular disorders, with an estimated 43.3 million people worldwide currently blind and a further 295 million living with moderate-to-severe vision impairment, driven by a complex pathogenesis that involves multiple cascade failures ranging from mitochondrial dysfunction to chronic neuroinflammation and blood-retinal barrier breakdown. This narrative review synthesizes peer-reviewed literature identified through targeted searches of PubMed/MEDLINE, Embase, and the Cochrane Library, prioritizing publications from the last five years and supplemented by foundational studies where necessary, to examine molecular mechanisms underlying both anterior and posterior segment pathologies, including Fuchs endothelial corneal dystrophy (FECD), diabetic macular edema (DME), age-related macular degeneration (AMD), and antibody-mediated optic neuritis. We link the most recent clinical insights into the structural abnormalities of these disorders with translational research advances, examining how genetic drivers such as the TCF4 trinucleotide repeat expansion, vascular endothelial growth factor (VEGF) signaling, complement system dysregulation, and antibody-specific neuroinflammatory injury converge on shared cellular vulnerabilities across otherwise distinct ocular tissues, while explicitly noting where this convergence is well evidenced and where it remains hypothesis-generating. We also evaluate how novel imaging methods, including optical coherence tomography (OCT) and OCT angiography (OCTA), together with emerging artificial intelligence (AI)-assisted diagnostic tools, are reshaping early disease detection. Within these four index conditions, we examine therapeutic classes across a spectrum of evidentiary maturity, from complement inhibitors and anti-VEGF agents already altering clinical management of AMD and DME, to gene therapy and mitochondrial-stabilizing strategies that remain at the preclinical or early-investigational stage; adjacent pharmacological strategies whose supporting evidence was generated outside these four conditions are addressed separately in an appendix rather than treated as part of the core evidence base. To make the degree of mechanistic convergence explicit rather than assumed, we constructed a four-domain evidentiary matrix grading mitochondrial, microvascular/barrier, complement/innate immune, and neuroinflammatory evidence for each condition; no single condition showed strong evidence across all four domains, and the four conditions differed meaningfully in which domains dominated their pathogenesis. As a narrative rather than systematic review with a non-systematic search strategy and single-reviewer evidence grading, this synthesis should be read with those limitations in mind. Decoding complex networks of cellular and systemic processes in ocular disease remains critical to developing high-efficiency therapeutics that could potentially preserve ocular cellular homeostasis and halt progressive visual decline.
Additional Links: PMID-42942210
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42942210,
year = {2026},
author = {Tejeda, S and Ekaye, SO and Taylor, JM and Sharma, M},
title = {Bridging Mechanism and Therapy in Ocular Disease: Mitochondrial, Vascular, and Immune Pathways in the Eye.},
journal = {Life (Basel, Switzerland)},
volume = {16},
number = {10},
pages = {},
pmid = {42942210},
issn = {2075-1729},
abstract = {There is an increasing global burden of ocular disorders, with an estimated 43.3 million people worldwide currently blind and a further 295 million living with moderate-to-severe vision impairment, driven by a complex pathogenesis that involves multiple cascade failures ranging from mitochondrial dysfunction to chronic neuroinflammation and blood-retinal barrier breakdown. This narrative review synthesizes peer-reviewed literature identified through targeted searches of PubMed/MEDLINE, Embase, and the Cochrane Library, prioritizing publications from the last five years and supplemented by foundational studies where necessary, to examine molecular mechanisms underlying both anterior and posterior segment pathologies, including Fuchs endothelial corneal dystrophy (FECD), diabetic macular edema (DME), age-related macular degeneration (AMD), and antibody-mediated optic neuritis. We link the most recent clinical insights into the structural abnormalities of these disorders with translational research advances, examining how genetic drivers such as the TCF4 trinucleotide repeat expansion, vascular endothelial growth factor (VEGF) signaling, complement system dysregulation, and antibody-specific neuroinflammatory injury converge on shared cellular vulnerabilities across otherwise distinct ocular tissues, while explicitly noting where this convergence is well evidenced and where it remains hypothesis-generating. We also evaluate how novel imaging methods, including optical coherence tomography (OCT) and OCT angiography (OCTA), together with emerging artificial intelligence (AI)-assisted diagnostic tools, are reshaping early disease detection. Within these four index conditions, we examine therapeutic classes across a spectrum of evidentiary maturity, from complement inhibitors and anti-VEGF agents already altering clinical management of AMD and DME, to gene therapy and mitochondrial-stabilizing strategies that remain at the preclinical or early-investigational stage; adjacent pharmacological strategies whose supporting evidence was generated outside these four conditions are addressed separately in an appendix rather than treated as part of the core evidence base. To make the degree of mechanistic convergence explicit rather than assumed, we constructed a four-domain evidentiary matrix grading mitochondrial, microvascular/barrier, complement/innate immune, and neuroinflammatory evidence for each condition; no single condition showed strong evidence across all four domains, and the four conditions differed meaningfully in which domains dominated their pathogenesis. As a narrative rather than systematic review with a non-systematic search strategy and single-reviewer evidence grading, this synthesis should be read with those limitations in mind. Decoding complex networks of cellular and systemic processes in ocular disease remains critical to developing high-efficiency therapeutics that could potentially preserve ocular cellular homeostasis and halt progressive visual decline.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
A Systematic Review of Complement-Targeting Therapies for Geographic Atrophy: Insights into Advanced Drug Delivery Systems and Gene-Based Approaches.
Pharmaceutics, 18(10):.
Background/Objectives: Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), causes irreversible central vision loss and has limited treatment options. Complement dysregulation plays a pivotal role in GA pathogenesis. This systematic review synthesizes the efficacy, safety, tolerability, and pharmacokinetics of approved and investigational complement-targeting therapies, alongside emerging drug delivery systems and gene-based approaches. Methods: Following PRISMA guidelines, PubMed, Embase, and Cochrane were searched and studies screened against predefined eligibility criteria. Risk of bias and pharmacokinetic quality were assessed using the Newcastle-Ottawa Scale and ClinPK Statement checklist, respectively. Results: Thirty-one studies evaluating C3, C5, factor D, and factor B inhibitors; recombinant factor H; soluble CD59 gene therapy; and an indirect anti-amyloid-β strategy were analyzed. Only two agents are FDA-approved: pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor). They both significantly, albeit modestly, slowed GA lesion growth. However, both increased the risk of exudative AMD conversion and required frequent intravitreal injections. Other complement targets showed limited efficacy or failed to meet clinical endpoints. Pharmacokinetic data, largely derived from serum measurements and model-based predictions, suggest that intravitreal half-life and injection volume dose limitations may complicate the translational development of complement inhibitors. Conclusions: Current evidence indicates a modest, agent-, dose-, and regimen-dependent slowing of GA anatomical progression. Clinically meaningful visual function benefit has not been firmly established, although post hoc analyses suggest possible benefits for photoreceptor structure and vision-related risk. Gene therapy and advanced intraocular delivery systems have emerged as potential strategies, but further research must determine whether they can provide sustained, multitarget, patient-centered treatment with acceptable ocular and systemic safety.
Additional Links: PMID-42942801
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42942801,
year = {2026},
author = {Fernández-Muro, P and Del Pozo-Rodríguez, A and Solinís, MÁ and Rodríguez-Gascón, A},
title = {A Systematic Review of Complement-Targeting Therapies for Geographic Atrophy: Insights into Advanced Drug Delivery Systems and Gene-Based Approaches.},
journal = {Pharmaceutics},
volume = {18},
number = {10},
pages = {},
pmid = {42942801},
issn = {1999-4923},
support = {IT2041-26//Basque Government/ ; PID2022-139800OB-I00//MCIU/AEI/FEDER/UE/ ; },
abstract = {Background/Objectives: Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), causes irreversible central vision loss and has limited treatment options. Complement dysregulation plays a pivotal role in GA pathogenesis. This systematic review synthesizes the efficacy, safety, tolerability, and pharmacokinetics of approved and investigational complement-targeting therapies, alongside emerging drug delivery systems and gene-based approaches. Methods: Following PRISMA guidelines, PubMed, Embase, and Cochrane were searched and studies screened against predefined eligibility criteria. Risk of bias and pharmacokinetic quality were assessed using the Newcastle-Ottawa Scale and ClinPK Statement checklist, respectively. Results: Thirty-one studies evaluating C3, C5, factor D, and factor B inhibitors; recombinant factor H; soluble CD59 gene therapy; and an indirect anti-amyloid-β strategy were analyzed. Only two agents are FDA-approved: pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor). They both significantly, albeit modestly, slowed GA lesion growth. However, both increased the risk of exudative AMD conversion and required frequent intravitreal injections. Other complement targets showed limited efficacy or failed to meet clinical endpoints. Pharmacokinetic data, largely derived from serum measurements and model-based predictions, suggest that intravitreal half-life and injection volume dose limitations may complicate the translational development of complement inhibitors. Conclusions: Current evidence indicates a modest, agent-, dose-, and regimen-dependent slowing of GA anatomical progression. Clinically meaningful visual function benefit has not been firmly established, although post hoc analyses suggest possible benefits for photoreceptor structure and vision-related risk. Gene therapy and advanced intraocular delivery systems have emerged as potential strategies, but further research must determine whether they can provide sustained, multitarget, patient-centered treatment with acceptable ocular and systemic safety.},
}
RevDate: 2026-10-29
Retinitis and Choroiditis After the Seventh Intravitreal Pegcetacoplan Injection.
Journal of vitreoretinal diseases [Epub ahead of print].
PURPOSE: To report a case of retinitis and choroiditis after the seventh intravitreal (IVT) injection of pegcetacoplan.
METHODS: A single case was retrospectively reviewed.
RESULTS: An 80-year-old woman with dry age-related macular degeneration with geographic atrophy presented with painless vision loss in the right eye 21 days after her seventh pegcetacoplan injection. Her visual acuity (VA) declined from 20/40 to counting fingers. Examination revealed vitritis, macular edema, and multifocal areas of retinal whitening and retinitis. An anterior chamber tap was performed, and IVT ceftazidime was administered. Gram stain and cultures were negative, and the infectious and inflammatory workup was unremarkable. The patient was started on oral prednisone and received antivascular endothelial growth factor injections. At 5-month follow-up, VA had returned to baseline, and the inflammation had resolved.
CONCLUSIONS: Retinitis and choroiditis were temporally associated with IVT pegcetacoplan, including after multiple prior uneventful injections. Clinicians should be aware of the possibility of intraocular inflammation after repeated pegcetacoplan injections.
Additional Links: PMID-42947883
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42947883,
year = {2026},
author = {Abou-Samra, A and Byrnes, G and Do, B and Marshall, A and Fein, JG},
title = {Retinitis and Choroiditis After the Seventh Intravitreal Pegcetacoplan Injection.},
journal = {Journal of vitreoretinal diseases},
volume = {},
number = {},
pages = {24741264261497612},
pmid = {42947883},
issn = {2474-1272},
abstract = {PURPOSE: To report a case of retinitis and choroiditis after the seventh intravitreal (IVT) injection of pegcetacoplan.
METHODS: A single case was retrospectively reviewed.
RESULTS: An 80-year-old woman with dry age-related macular degeneration with geographic atrophy presented with painless vision loss in the right eye 21 days after her seventh pegcetacoplan injection. Her visual acuity (VA) declined from 20/40 to counting fingers. Examination revealed vitritis, macular edema, and multifocal areas of retinal whitening and retinitis. An anterior chamber tap was performed, and IVT ceftazidime was administered. Gram stain and cultures were negative, and the infectious and inflammatory workup was unremarkable. The patient was started on oral prednisone and received antivascular endothelial growth factor injections. At 5-month follow-up, VA had returned to baseline, and the inflammation had resolved.
CONCLUSIONS: Retinitis and choroiditis were temporally associated with IVT pegcetacoplan, including after multiple prior uneventful injections. Clinicians should be aware of the possibility of intraocular inflammation after repeated pegcetacoplan injections.},
}
RevDate: 2026-10-30
A Mechanistic Dissection of Multifaceted Complement Attack in Age-Related Macular Degeneration Reveals the Superiority of C3 Inhibition.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Epub ahead of print].
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in the elderly, and geographic atrophy (GA) represents its advanced atrophic form. While C5 and C3 inhibitors have shown efficacy in slowing GA progression, the precise pathogenic roles of individual complement effectors and the optimal inhibition strategy remain subjects of ongoing debate. This study employs an in vitro model using A2E-laden retinal pigment epithelium (RPE) cells and normal human serum to systematically investigate complement-mediated RPE degeneration and compare the protective effects of different complement-targeting strategies. We demonstrate that C5 blockade, while preventing lytic cell death caused by the membrane attack complex (MAC), fails to fully restore mitochondrial function or prevent phagolysosomal damage. Crucially, these C5-independent pathologies involve C3 activation products. In contrast, upstream C3 inhibition comprehensively protects RPE cells by ameliorating these diverse pathological processes. Our findings provide a detailed mechanistic understanding of complement-driven RPE degeneration and support a mechanistic rationale for an upstream C3-targeting strategy in GA secondary to AMD.
Additional Links: PMID-42949647
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42949647,
year = {2026},
author = {Chen, Z and Wang, M and Liu, H and Qian, F},
title = {A Mechanistic Dissection of Multifaceted Complement Attack in Age-Related Macular Degeneration Reveals the Superiority of C3 Inhibition.},
journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
volume = {},
number = {},
pages = {},
pmid = {42949647},
issn = {2198-3844},
support = {82473854//National Natural Science Foundation of China/ ; 041500002//Beijing Frontier Research Center for Biological Structure/ ; },
abstract = {Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in the elderly, and geographic atrophy (GA) represents its advanced atrophic form. While C5 and C3 inhibitors have shown efficacy in slowing GA progression, the precise pathogenic roles of individual complement effectors and the optimal inhibition strategy remain subjects of ongoing debate. This study employs an in vitro model using A2E-laden retinal pigment epithelium (RPE) cells and normal human serum to systematically investigate complement-mediated RPE degeneration and compare the protective effects of different complement-targeting strategies. We demonstrate that C5 blockade, while preventing lytic cell death caused by the membrane attack complex (MAC), fails to fully restore mitochondrial function or prevent phagolysosomal damage. Crucially, these C5-independent pathologies involve C3 activation products. In contrast, upstream C3 inhibition comprehensively protects RPE cells by ameliorating these diverse pathological processes. Our findings provide a detailed mechanistic understanding of complement-driven RPE degeneration and support a mechanistic rationale for an upstream C3-targeting strategy in GA secondary to AMD.},
}
RevDate: 2026-10-30
CmpDate: 2026-10-29
Occult Optic Disk Pit Maculopathy Masquerading as Exudative Age-Related Macular Degeneration in an Elderly Patient: A Case Report.
Case reports in ophthalmology, 17(1):1144-1151.
INTRODUCTION: Occult optic disk pit maculopathy (ODPM) is a rare cause of macular retinoschisis in which no pit is visible on funduscopic examination. Optic disk pits are congenital cavitary anomalies thought to arise from incomplete closure of the embryonic fissure during ocular development.
CASE PRESENTATION: This report presents an 83-year-old woman with a history of exudative AMD of the left eye (OS) and low-tension glaucoma having received 11 intravitreal anti-VEGF injections over approximately 18 months without resolution of macular fluid. Fluorescein angiography demonstrated no macular leakage and no macular neovascularization. Spectral-domain optical coherence tomography revealed multilayered peripapillary retinoschisis with fluid extending from the optic disk to the fovea. Dedicated optic disk OCT confirmed a deep crater-like excavation consistent with an occult optic disk pit. Anti-VEGF therapy was discontinued, and the patient was observed. At approximately 10 months after the last injection, best-corrected visual acuity was stable at 20/25 OS with stable nasal macular cysts on OCT.
CONCLUSION: Occult ODPM can closely mimic exudative AMD and may go unrecognized for many months in elderly patients with coexisting retinal disease, resulting in repeated unnecessary anti-VEGF treatment.
Additional Links: PMID-42953591
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42953591,
year = {2026},
author = {Zhao, AT and Caplash, S and Kim, BJ},
title = {Occult Optic Disk Pit Maculopathy Masquerading as Exudative Age-Related Macular Degeneration in an Elderly Patient: A Case Report.},
journal = {Case reports in ophthalmology},
volume = {17},
number = {1},
pages = {1144-1151},
pmid = {42953591},
issn = {1663-2699},
abstract = {INTRODUCTION: Occult optic disk pit maculopathy (ODPM) is a rare cause of macular retinoschisis in which no pit is visible on funduscopic examination. Optic disk pits are congenital cavitary anomalies thought to arise from incomplete closure of the embryonic fissure during ocular development.
CASE PRESENTATION: This report presents an 83-year-old woman with a history of exudative AMD of the left eye (OS) and low-tension glaucoma having received 11 intravitreal anti-VEGF injections over approximately 18 months without resolution of macular fluid. Fluorescein angiography demonstrated no macular leakage and no macular neovascularization. Spectral-domain optical coherence tomography revealed multilayered peripapillary retinoschisis with fluid extending from the optic disk to the fovea. Dedicated optic disk OCT confirmed a deep crater-like excavation consistent with an occult optic disk pit. Anti-VEGF therapy was discontinued, and the patient was observed. At approximately 10 months after the last injection, best-corrected visual acuity was stable at 20/25 OS with stable nasal macular cysts on OCT.
CONCLUSION: Occult ODPM can closely mimic exudative AMD and may go unrecognized for many months in elderly patients with coexisting retinal disease, resulting in repeated unnecessary anti-VEGF treatment.},
}
RevDate: 2026-10-29
CmpDate: 2026-10-29
The Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial.
Translational vision science & technology, 15(10):50.
PURPOSE: To evaluate the effect of resveratrol, quercetin, and curcumin (RQC) compared with curcumin alone on drusen volume and clinical outcomes in patients with age-related macular degeneration (AMD).
METHODS: In this open-label, randomized phase 2a clinical trial, patients with early and intermediate AMD were randomized 2:1 to oral RQC or curcumin for 24 months. The primary outcome was the mean change in central drusen volume from baseline measured using spectral-domain optical coherence tomography (SD-OCT). Secondary outcomes included analyses of drusen volume and number by baseline size, categorical analyses of individual drusen response, change in best-corrected visual acuity (BCVA), frequency of vision loss, progression to advanced AMD, and safety.
RESULTS: Thirty-eight patients were included in the final analysis. After 24 months, central drusen volume decreased significantly with RQC compared with curcumin (-13.4% vs. +6.9%; P = 0.02). Mean BCVA increased by 0.8 letters in the RQC group and decreased by 2.1 letters in the curcumin group (P = 0.08). The frequencies of both mild and moderate vision loss were lower in the RQC group. Progression to advanced AMD occurred in 3.7% of participants and 2.3% of eligible eyes in the RQC group.
CONCLUSIONS: RQC treatment was associated with reductions in drusen volume, low rates of progression to advanced AMD, and maintenance of BCVA over 24 months.
TRANSLATIONAL RELEVANCE: This study provides preliminary clinical evidence that this oral therapy may reduce drusen burden and warrants further evaluation as a potential treatment for early to intermediate AMD.
Additional Links: PMID-42954735
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42954735,
year = {2026},
author = {Pfahler, NM and Knepper, PA},
title = {The Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial.},
journal = {Translational vision science & technology},
volume = {15},
number = {10},
pages = {50},
doi = {10.1167/tvst.15.10.50},
pmid = {42954735},
issn = {2164-2591},
mesh = {Humans ; *Curcumin/therapeutic use/administration & dosage ; *Resveratrol/therapeutic use/administration & dosage ; *Macular Degeneration/drug therapy/complications ; *Retinal Drusen/drug therapy/pathology ; Visual Acuity/physiology ; Tomography, Optical Coherence ; Aged ; Female ; Male ; *Quercetin/therapeutic use/administration & dosage ; Aged, 80 and over ; Treatment Outcome ; Antioxidants/therapeutic use ; },
abstract = {PURPOSE: To evaluate the effect of resveratrol, quercetin, and curcumin (RQC) compared with curcumin alone on drusen volume and clinical outcomes in patients with age-related macular degeneration (AMD).
METHODS: In this open-label, randomized phase 2a clinical trial, patients with early and intermediate AMD were randomized 2:1 to oral RQC or curcumin for 24 months. The primary outcome was the mean change in central drusen volume from baseline measured using spectral-domain optical coherence tomography (SD-OCT). Secondary outcomes included analyses of drusen volume and number by baseline size, categorical analyses of individual drusen response, change in best-corrected visual acuity (BCVA), frequency of vision loss, progression to advanced AMD, and safety.
RESULTS: Thirty-eight patients were included in the final analysis. After 24 months, central drusen volume decreased significantly with RQC compared with curcumin (-13.4% vs. +6.9%; P = 0.02). Mean BCVA increased by 0.8 letters in the RQC group and decreased by 2.1 letters in the curcumin group (P = 0.08). The frequencies of both mild and moderate vision loss were lower in the RQC group. Progression to advanced AMD occurred in 3.7% of participants and 2.3% of eligible eyes in the RQC group.
CONCLUSIONS: RQC treatment was associated with reductions in drusen volume, low rates of progression to advanced AMD, and maintenance of BCVA over 24 months.
TRANSLATIONAL RELEVANCE: This study provides preliminary clinical evidence that this oral therapy may reduce drusen burden and warrants further evaluation as a potential treatment for early to intermediate AMD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Curcumin/therapeutic use/administration & dosage
*Resveratrol/therapeutic use/administration & dosage
*Macular Degeneration/drug therapy/complications
*Retinal Drusen/drug therapy/pathology
Visual Acuity/physiology
Tomography, Optical Coherence
Aged
Female
Male
*Quercetin/therapeutic use/administration & dosage
Aged, 80 and over
Treatment Outcome
Antioxidants/therapeutic use
RevDate: 2026-10-29
CmpDate: 2026-10-29
Red Light Therapy and Mitochondrial Rejuvenation in Age-Related Disorders.
Molecular neurobiology, 63(1):.
Aging is associated with mitochondrial dysfunction, impaired ATP production, and a decline in tissue regenerative capacity, leading to the development of age-related diseases. This review summarizes current evidence regarding the effects of photobiomodulation (PBM) on mitochondrial function and age-related disorders. PBM using red and near-infrared light may enhance proper mitochondrial function by acting on cytochrome c oxidase (CCO) and other signaling pathways, including the transient receptor potential vanilloid 1 (TRPV1) channel, leading to increased ATP production, modulation of ROS signaling, and improved cellular homeostasis. We review in vitro, animal, and clinical studies investigating PBM in metabolic, neurodegenerative, hepatic, cardiovascular, age-related macular degeneration (AMD), and skeletal muscle disorders associated with aging, as well as its application in the management of cancer therapy-related oral mucositis. Current studies demonstrate beneficial effects on glucose metabolism, cardiovascular function, neuronal function, lipid metabolism, liver function, muscle regeneration, and visual function in AMD, as well as the safety and efficacy of PBM in the management of cancer therapy-induced oral mucositis. The therapeutic effects of PBM appear to be dose-dependent and influenced by treatment parameters including wavelength, fluence, irradiance, and exposure protocol. Although photobiomodulation still lacks standardized treatment protocols and differences exist in the wavelengths used, dosage, and frequency among studies, it represents a promising therapeutic approach for the treatment of age-related diseases.
Additional Links: PMID-42955214
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42955214,
year = {2026},
author = {Iglewska, M and Flis, KA and Kołakowska, M and Hryniewicz, WW and Pluto-Prądzyńska, A},
title = {Red Light Therapy and Mitochondrial Rejuvenation in Age-Related Disorders.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {42955214},
issn = {1559-1182},
mesh = {Humans ; Animals ; *Aging/pathology ; *Red Light ; *Mitochondria/metabolism/radiation effects ; *Rejuvenation/physiology ; *Low-Level Light Therapy ; },
abstract = {Aging is associated with mitochondrial dysfunction, impaired ATP production, and a decline in tissue regenerative capacity, leading to the development of age-related diseases. This review summarizes current evidence regarding the effects of photobiomodulation (PBM) on mitochondrial function and age-related disorders. PBM using red and near-infrared light may enhance proper mitochondrial function by acting on cytochrome c oxidase (CCO) and other signaling pathways, including the transient receptor potential vanilloid 1 (TRPV1) channel, leading to increased ATP production, modulation of ROS signaling, and improved cellular homeostasis. We review in vitro, animal, and clinical studies investigating PBM in metabolic, neurodegenerative, hepatic, cardiovascular, age-related macular degeneration (AMD), and skeletal muscle disorders associated with aging, as well as its application in the management of cancer therapy-related oral mucositis. Current studies demonstrate beneficial effects on glucose metabolism, cardiovascular function, neuronal function, lipid metabolism, liver function, muscle regeneration, and visual function in AMD, as well as the safety and efficacy of PBM in the management of cancer therapy-induced oral mucositis. The therapeutic effects of PBM appear to be dose-dependent and influenced by treatment parameters including wavelength, fluence, irradiance, and exposure protocol. Although photobiomodulation still lacks standardized treatment protocols and differences exist in the wavelengths used, dosage, and frequency among studies, it represents a promising therapeutic approach for the treatment of age-related diseases.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Animals
*Aging/pathology
*Red Light
*Mitochondria/metabolism/radiation effects
*Rejuvenation/physiology
*Low-Level Light Therapy
RevDate: 2026-10-28
CmpDate: 2026-10-27
Astaxanthin and Related Carotenoids as a Dual Modulator of Nrf2 and NF-κB in Bisretinoid-Induced Retinal Damage: Mechanistic Rationale and Evidence Gaps.
Antioxidants (Basel, Switzerland), 15(10):.
The retinal pigment epithelium (RPE) plays a key role in age-related macular degeneration (AMD). With aging, bisretinoids such as A2E accumulate in RPE lysosomes, and this accumulation is markedly accelerated by ABCA4 loss of function, which impairs the clearance of retinaldehyde from photoreceptor disc membranes. A2E acts as a blue-light photosensitizer, generating reactive oxygen species that cause oxidative stress, lysosomal impairment, and mitochondrial dysfunction. This oxidative burden disrupts the balance between Nrf2-mediated antioxidant defense and NF-κB-driven inflammation. Astaxanthin, a marine-derived xanthophyll carotenoid, may regulate this balance by activating Nrf2/ARE-mediated cytoprotective responses and suppressing NF-κB-dependent inflammation. This review summarizes mechanistic, preclinical, and clinical evidence for astaxanthin's protective effects on RPE cells, with emphasis on bisretinoid-induced retinal injury. Astaxanthin reduces oxidative stress, inhibits NF-κB activity, and enhances Nrf2-dependent antioxidant defenses in hydrogen peroxide-, light-, and ischemia-induced retinal damage; however, because these models do not directly reproduce A2E-mediated phototoxicity, A2E-specific protection remains an untested hypothesis. Standardized A2E-specific models are needed to determine whether these protective effects extend to A2E and its photoproducts. Clinical evidence is also limited and largely based on multi-carotenoid formulations, which prevents the isolation of the effects of astaxanthin.
Additional Links: PMID-42939848
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939848,
year = {2026},
author = {Baniya, BK and Kim, HJ},
title = {Astaxanthin and Related Carotenoids as a Dual Modulator of Nrf2 and NF-κB in Bisretinoid-Induced Retinal Damage: Mechanistic Rationale and Evidence Gaps.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {10},
pages = {},
pmid = {42939848},
issn = {2076-3921},
support = {No. RS-2024-00344799//National Research Foundation of Korea/ ; No. RS-2024-00402577//bythe Korea Basic Science Institute (National Research Facilities and EquipmentCenter) grant funded by the Korean government (MSIT)/ ; },
abstract = {The retinal pigment epithelium (RPE) plays a key role in age-related macular degeneration (AMD). With aging, bisretinoids such as A2E accumulate in RPE lysosomes, and this accumulation is markedly accelerated by ABCA4 loss of function, which impairs the clearance of retinaldehyde from photoreceptor disc membranes. A2E acts as a blue-light photosensitizer, generating reactive oxygen species that cause oxidative stress, lysosomal impairment, and mitochondrial dysfunction. This oxidative burden disrupts the balance between Nrf2-mediated antioxidant defense and NF-κB-driven inflammation. Astaxanthin, a marine-derived xanthophyll carotenoid, may regulate this balance by activating Nrf2/ARE-mediated cytoprotective responses and suppressing NF-κB-dependent inflammation. This review summarizes mechanistic, preclinical, and clinical evidence for astaxanthin's protective effects on RPE cells, with emphasis on bisretinoid-induced retinal injury. Astaxanthin reduces oxidative stress, inhibits NF-κB activity, and enhances Nrf2-dependent antioxidant defenses in hydrogen peroxide-, light-, and ischemia-induced retinal damage; however, because these models do not directly reproduce A2E-mediated phototoxicity, A2E-specific protection remains an untested hypothesis. Standardized A2E-specific models are needed to determine whether these protective effects extend to A2E and its photoproducts. Clinical evidence is also limited and largely based on multi-carotenoid formulations, which prevents the isolation of the effects of astaxanthin.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
ATF4 Activation Promotes All-trans-Retinal-Driven Retinopathies in Mice.
Antioxidants (Basel, Switzerland), 15(10):.
Impaired clearance of all-trans-retinal (atRAL) during the visual cycle leads to retinal degeneration, which is closely associated with autosomal recessive Stargardt disease (STGD1) and dry age-related macular degeneration (dry AMD). Transient activation of activating transcription factor 4 (ATF4) generally supports cellular adaptation to stress, whereas excessive ATF4 expression or prolonged activation can become maladaptive and promote oxidative and metabolic disturbances. Here, we reported that activation of ATF4 promoted atRAL-induced photoreceptor damage through mitochondria-caspase/DNA damage-dependent apoptosis and gasdermin E (GSDME)-dependent pyroptosis and apoptosis, and identified ATF4 as an upstream transcriptional regulator of GSDME. Genetic ablation of Atf4 or pharmacological attenuation of ATF4 signaling with the integrated stress response inhibitor ISRIB visibly preserved the viability and morphology of atRAL-treated 661W cone photoreceptor cells. Both interventions lowered GSDME N-terminal fragment (GSDME-N) abundance, decreased intracellular and mitochondrial reactive oxygen species (ROS) production, and blunted damage to mitochondria and DNA. Notably, pharmacologically suppressing ATF4 expression in the neural retina effectively prevented retinal function loss and structural injury as well as photoreceptor apoptosis and pyroptosis in light-exposed Abca4[-/-]Rdh8[-/-] mice, which exhibit severe defects in atRAL clearance and recapitulate key features of STGD1 and dry AMD. Our findings demonstrate that ATF4 is a critical mediator of atRAL-induced retinal atrophy, suggesting that ATF4 inhibition represents a promising therapeutic strategy for STGD1 and dry AMD.
Additional Links: PMID-42939902
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939902,
year = {2026},
author = {Yang, K and Yu, C and He, D and Tao, L and Yang, B and Chen, Y and Chen, J and Wu, Y},
title = {ATF4 Activation Promotes All-trans-Retinal-Driven Retinopathies in Mice.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {10},
pages = {},
pmid = {42939902},
issn = {2076-3921},
support = {82471093//National Natural Science Foundation of China/ ; },
abstract = {Impaired clearance of all-trans-retinal (atRAL) during the visual cycle leads to retinal degeneration, which is closely associated with autosomal recessive Stargardt disease (STGD1) and dry age-related macular degeneration (dry AMD). Transient activation of activating transcription factor 4 (ATF4) generally supports cellular adaptation to stress, whereas excessive ATF4 expression or prolonged activation can become maladaptive and promote oxidative and metabolic disturbances. Here, we reported that activation of ATF4 promoted atRAL-induced photoreceptor damage through mitochondria-caspase/DNA damage-dependent apoptosis and gasdermin E (GSDME)-dependent pyroptosis and apoptosis, and identified ATF4 as an upstream transcriptional regulator of GSDME. Genetic ablation of Atf4 or pharmacological attenuation of ATF4 signaling with the integrated stress response inhibitor ISRIB visibly preserved the viability and morphology of atRAL-treated 661W cone photoreceptor cells. Both interventions lowered GSDME N-terminal fragment (GSDME-N) abundance, decreased intracellular and mitochondrial reactive oxygen species (ROS) production, and blunted damage to mitochondria and DNA. Notably, pharmacologically suppressing ATF4 expression in the neural retina effectively prevented retinal function loss and structural injury as well as photoreceptor apoptosis and pyroptosis in light-exposed Abca4[-/-]Rdh8[-/-] mice, which exhibit severe defects in atRAL clearance and recapitulate key features of STGD1 and dry AMD. Our findings demonstrate that ATF4 is a critical mediator of atRAL-induced retinal atrophy, suggesting that ATF4 inhibition represents a promising therapeutic strategy for STGD1 and dry AMD.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
The Environmental Exposome and Age-Related Macular Degeneration: Oxidative Stress as a Molecular Link.
Antioxidants (Basel, Switzerland), 15(10):.
Age-related macular degeneration (AMD) is a multifactorial retinal disease in which genetic susceptibility, aging, metabolic dysfunction, and environmental factors interact to determine disease onset and progression. Although environmental exposures are increasingly recognized as modifiable risk factors for AMD, the molecular mechanisms linking cumulative environmental stress to retinal degeneration remain incompletely understood. In this review, we examine the environmental exposome relevant to AMD and propose oxidative stress as a central molecular link connecting diverse environmental exposures with retinal aging and AMD susceptibility. Epidemiological evidence linking air pollution, particulate matter, cigarette smoke, and other environmental stressors to AMD is reviewed, followed by an analysis of their effects on redox homeostasis and the retinal pigment epithelium (RPE)-Bruch's membrane-choriocapillaris complex. We further discuss how chronic oxidative stress promotes mitochondrial dysfunction, lipid peroxidation, ferroptosis, autophagy and mitophagy impairment, cellular senescence, and senescence-associated inflammation. These processes interact with complement activation, microglial activation, and chronic retinal inflammation, ultimately contributing to RPE dysfunction, choriocapillaris and Bruch's membrane abnormalities, photoreceptor degeneration, and AMD progression. Integrating these mechanisms, we propose an environmental exposome-oxidative stress-retinal aging axis in which cumulative environmental exposures progressively reduce retinal resilience and increase susceptibility to AMD. We also evaluate antioxidant and redox-modulating strategies, including the established evidence for AREDS/AREDS2 supplementation and emerging approaches targeting Nrf2 signaling, glutathione homeostasis, mitochondria, and ferroptosis. Importantly, antioxidant supplementation should not be equated with primary prevention of environmentally induced AMD. Future studies integrating individual exposure monitoring, oxidative stress biomarkers, genetic susceptibility, and retinal phenotyping may enable precision prevention and personalized redox-based interventions. This framework positions environmental exposure as a potentially modifiable driver of retinal biological aging and provides a mechanistic basis for understanding and preventing environmentally driven AMD.
Additional Links: PMID-42939925
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939925,
year = {2026},
author = {Mimura, T and Noma, H},
title = {The Environmental Exposome and Age-Related Macular Degeneration: Oxidative Stress as a Molecular Link.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {10},
pages = {},
pmid = {42939925},
issn = {2076-3921},
abstract = {Age-related macular degeneration (AMD) is a multifactorial retinal disease in which genetic susceptibility, aging, metabolic dysfunction, and environmental factors interact to determine disease onset and progression. Although environmental exposures are increasingly recognized as modifiable risk factors for AMD, the molecular mechanisms linking cumulative environmental stress to retinal degeneration remain incompletely understood. In this review, we examine the environmental exposome relevant to AMD and propose oxidative stress as a central molecular link connecting diverse environmental exposures with retinal aging and AMD susceptibility. Epidemiological evidence linking air pollution, particulate matter, cigarette smoke, and other environmental stressors to AMD is reviewed, followed by an analysis of their effects on redox homeostasis and the retinal pigment epithelium (RPE)-Bruch's membrane-choriocapillaris complex. We further discuss how chronic oxidative stress promotes mitochondrial dysfunction, lipid peroxidation, ferroptosis, autophagy and mitophagy impairment, cellular senescence, and senescence-associated inflammation. These processes interact with complement activation, microglial activation, and chronic retinal inflammation, ultimately contributing to RPE dysfunction, choriocapillaris and Bruch's membrane abnormalities, photoreceptor degeneration, and AMD progression. Integrating these mechanisms, we propose an environmental exposome-oxidative stress-retinal aging axis in which cumulative environmental exposures progressively reduce retinal resilience and increase susceptibility to AMD. We also evaluate antioxidant and redox-modulating strategies, including the established evidence for AREDS/AREDS2 supplementation and emerging approaches targeting Nrf2 signaling, glutathione homeostasis, mitochondria, and ferroptosis. Importantly, antioxidant supplementation should not be equated with primary prevention of environmentally induced AMD. Future studies integrating individual exposure monitoring, oxidative stress biomarkers, genetic susceptibility, and retinal phenotyping may enable precision prevention and personalized redox-based interventions. This framework positions environmental exposure as a potentially modifiable driver of retinal biological aging and provides a mechanistic basis for understanding and preventing environmentally driven AMD.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
MAFF Expression Reshapes Key Stress-Response Proteins During Light-Induced Injury.
Antioxidants (Basel, Switzerland), 15(10):.
MAFF is a small MAF family transcription factor involved in antioxidant signaling and cytoprotective gene regulation. MAFF is differentially expressed across retinal regions, with particularly low expression in macular Müller cells, which play a central role in retinal redox balance. Reduced MAFF expression may weaken macular resilience to oxidative stress (OS), increasing susceptibility to age-related macular degeneration (AMD) and macular telangiectasia type 2. However, the function of MAFF in Müller cells remains unclear. Human primary Müller cells (huPMCs) from non-diseased human donor eyes were used to investigate MAFF modulation under stress. Cells were transfected with MAFF plasmid DNA to evaluate intracellular reactive oxygen species (ROS) following H2O2-induced stress. For functional and proteomic analyses, MAFF was overexpressed using mRNA or knocked down using siRNA and validated by Western blot. huPMCs were exposed to light stress and cell viability was assessed using the AlamarBlue assay. Molecular changes were characterized by liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based quantitative proteomics. MAFF upregulation significantly reduced intracellular ROS following H2O2-induced stress. MAFF protein expression decreased following siRNA-mediated knockdown (KD) and increased following mRNA-mediated overexpression (OE). MAFF OE improved Müller cell viability under light stress, whereas MAFF KD reduced viability. Exploratory proteomic profiling quantified 5907 proteins and identified candidate molecular changes associated with MAFF expression. Pathway analyses suggested that reduced MAFF expression was associated with oxidative-stress response signatures, whereas elevated MAFF expression was associated with changes in mitochondrial and immune/inflammatory pathways. KEAP1, BMP2K, VPS28, and PDCD4 were negatively associated with MAFF expression, suggesting potential regulation of antioxidant defense, vesicle trafficking, and apoptosis-related processes. Elevated MAFF expression was associated with reduced ROS accumulation and improved cell viability, while exploratory proteomic analysis identified changes in mitochondrial, oxidative-stress, and immune/inflammatory pathways. These findings support further investigation of MAFF as a contributor to macular stress susceptibility and as a candidate for future therapeutic studies.
Additional Links: PMID-42939928
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939928,
year = {2026},
author = {Zhang, J and Zhang, T and Arafah, ADB and Lee, S and Yam, M and Zeng, J and Chang, CC and Wang, X and Gillies, MC and Zhu, L},
title = {MAFF Expression Reshapes Key Stress-Response Proteins During Light-Induced Injury.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {10},
pages = {},
pmid = {42939928},
issn = {2076-3921},
support = {//The Lowy Medical Research Institute/ ; //Australian Vision Research (AVR)/ ; },
abstract = {MAFF is a small MAF family transcription factor involved in antioxidant signaling and cytoprotective gene regulation. MAFF is differentially expressed across retinal regions, with particularly low expression in macular Müller cells, which play a central role in retinal redox balance. Reduced MAFF expression may weaken macular resilience to oxidative stress (OS), increasing susceptibility to age-related macular degeneration (AMD) and macular telangiectasia type 2. However, the function of MAFF in Müller cells remains unclear. Human primary Müller cells (huPMCs) from non-diseased human donor eyes were used to investigate MAFF modulation under stress. Cells were transfected with MAFF plasmid DNA to evaluate intracellular reactive oxygen species (ROS) following H2O2-induced stress. For functional and proteomic analyses, MAFF was overexpressed using mRNA or knocked down using siRNA and validated by Western blot. huPMCs were exposed to light stress and cell viability was assessed using the AlamarBlue assay. Molecular changes were characterized by liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based quantitative proteomics. MAFF upregulation significantly reduced intracellular ROS following H2O2-induced stress. MAFF protein expression decreased following siRNA-mediated knockdown (KD) and increased following mRNA-mediated overexpression (OE). MAFF OE improved Müller cell viability under light stress, whereas MAFF KD reduced viability. Exploratory proteomic profiling quantified 5907 proteins and identified candidate molecular changes associated with MAFF expression. Pathway analyses suggested that reduced MAFF expression was associated with oxidative-stress response signatures, whereas elevated MAFF expression was associated with changes in mitochondrial and immune/inflammatory pathways. KEAP1, BMP2K, VPS28, and PDCD4 were negatively associated with MAFF expression, suggesting potential regulation of antioxidant defense, vesicle trafficking, and apoptosis-related processes. Elevated MAFF expression was associated with reduced ROS accumulation and improved cell viability, while exploratory proteomic analysis identified changes in mitochondrial, oxidative-stress, and immune/inflammatory pathways. These findings support further investigation of MAFF as a contributor to macular stress susceptibility and as a candidate for future therapeutic studies.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
Choriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applications.
Biomedicines, 14(10):.
The choriocapillaris is the terminal capillary bed that sustains the retinal pigment epithelium (RPE) and the outer retina, and its integrity is inseparable from that of the RPE-Bruch's membrane complex it supplies. Histopathological work established decades ago that choriocapillaris density declines with age and falls further in disease, but for most of that period, the layer could not be assessed reliably in living eyes. Optical coherence tomography angiography (OCTA), particularly with swept-source instrumentation, signal compensation and validated thresholding, has changed this: choriocapillaris flow deficits can now be quantified reproducibly and followed over time. A flow deficit is, however, a signal-level measurement that does not by itself establish anatomical capillary loss, and this distinction is maintained throughout. This review examines what that capability has revealed. We first summarize choriocapillaris anatomy, its functional coupling to the RPE through polarized vascular endothelial growth factor secretion, and the mechanisms implicated in its failure, including complement-mediated endothelial injury, Bruch's membrane thickening, oxidative stress and venous overload. We then address the methodology in detail-slab definition, shadow compensation, binarization, averaging and the artefacts that inflate or mask flow deficits-because the comparability of published values depends almost entirely on these choices. The clinical sections review choriocapillaris involvement in age-related macular degeneration, where baseline flow impairment has been associated with subsequent drusen formation and with the rate of geographic atrophy enlargement, an association that is temporal rather than proven causal and that rests on a small number of cohorts; in the pachychoroid spectrum, where the layer is thought to be compressed rather than primarily diseased; and in diabetic retinopathy, myopia, inherited retinal dystrophies, inflammatory chorioretinopathies and systemic vascular disease. We conclude by considering structure-function relationships with outer retinal integrity and visual sensitivity, the relevance of choriocapillaris metrics as trial endpoints and stratification variables in the complement inhibitor era, and the standardization, validation and automation required before these biomarkers can be used in individual patients.
Additional Links: PMID-42939979
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939979,
year = {2026},
author = {Menna, F and Meduri, A and De Luca, L and Baldascino, A and Lupo, S and Vingolo, EM},
title = {Choriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applications.},
journal = {Biomedicines},
volume = {14},
number = {10},
pages = {},
pmid = {42939979},
issn = {2227-9059},
abstract = {The choriocapillaris is the terminal capillary bed that sustains the retinal pigment epithelium (RPE) and the outer retina, and its integrity is inseparable from that of the RPE-Bruch's membrane complex it supplies. Histopathological work established decades ago that choriocapillaris density declines with age and falls further in disease, but for most of that period, the layer could not be assessed reliably in living eyes. Optical coherence tomography angiography (OCTA), particularly with swept-source instrumentation, signal compensation and validated thresholding, has changed this: choriocapillaris flow deficits can now be quantified reproducibly and followed over time. A flow deficit is, however, a signal-level measurement that does not by itself establish anatomical capillary loss, and this distinction is maintained throughout. This review examines what that capability has revealed. We first summarize choriocapillaris anatomy, its functional coupling to the RPE through polarized vascular endothelial growth factor secretion, and the mechanisms implicated in its failure, including complement-mediated endothelial injury, Bruch's membrane thickening, oxidative stress and venous overload. We then address the methodology in detail-slab definition, shadow compensation, binarization, averaging and the artefacts that inflate or mask flow deficits-because the comparability of published values depends almost entirely on these choices. The clinical sections review choriocapillaris involvement in age-related macular degeneration, where baseline flow impairment has been associated with subsequent drusen formation and with the rate of geographic atrophy enlargement, an association that is temporal rather than proven causal and that rests on a small number of cohorts; in the pachychoroid spectrum, where the layer is thought to be compressed rather than primarily diseased; and in diabetic retinopathy, myopia, inherited retinal dystrophies, inflammatory chorioretinopathies and systemic vascular disease. We conclude by considering structure-function relationships with outer retinal integrity and visual sensitivity, the relevance of choriocapillaris metrics as trial endpoints and stratification variables in the complement inhibitor era, and the standardization, validation and automation required before these biomarkers can be used in individual patients.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
Brain Blindness Versus Eye Blindness: Genetic and Molecular Connections Between Alzheimer's Disease and Visual Impairment.
Current issues in molecular biology, 48(10):.
Visual dysfunctions were observed among Alzheimer's disease (AD) patients, including posterior cortical degeneration, retinal abnormalities, or coexisting ocular disease. Posterior cortical atrophy (PCA) is a clinical syndrome characterized by progressive higher-order visual impairment and is most frequently associated with AD pathology, although other neurodegenerative causes may be possible. Pathogenic variants in PSEN1 and PSEN2 were reported in individual cases of PCA and may support a possible monogenic contribution to selected early-onset posterior phenotypes. By contrast, variants and common AD risk genes, including GRN, MAPT, TREM2, BIN1, PICALM, ABCA7, and APOE E4 allele, represented broader genetic associations whose specific contribution to posterior cortical vulnerability remains incompletely defined. These forms of evidence should be interpreted separately. Genome-wide association studies identified overlapping loci associated with AD and glaucoma, including loci on chromosome 11 involving MTCH2, NDUFS3, and SPI1. This overlap reflected shared genetic susceptibility, pleiotropy, or putative convergent biological pathways involving mitochondrial function, immune regulation, and cellular stress. However, shared loci and pathway associations did not establish direct signaling, anatomical communication, or a causal relationship between brain and ocular tissues. The opposing tissue-specific effects reported for APOE further indicated that data in the brain may not be extrapolated to the retina. Future studies should clarify the cell-specific effects, causal direction, and clinical significance of shared genetic factors using well-characterized cohorts and tissue-specific experimental models. Overall, current evidence supported the partially overlapping genetic and cellular mechanisms in AD and selected ocular disorders, while further studies should be needed on the biological relationship between the brain and eye.
Additional Links: PMID-42939619
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939619,
year = {2026},
author = {Bagyinszky, E and An, SSA},
title = {Brain Blindness Versus Eye Blindness: Genetic and Molecular Connections Between Alzheimer's Disease and Visual Impairment.},
journal = {Current issues in molecular biology},
volume = {48},
number = {10},
pages = {},
pmid = {42939619},
issn = {1467-3045},
abstract = {Visual dysfunctions were observed among Alzheimer's disease (AD) patients, including posterior cortical degeneration, retinal abnormalities, or coexisting ocular disease. Posterior cortical atrophy (PCA) is a clinical syndrome characterized by progressive higher-order visual impairment and is most frequently associated with AD pathology, although other neurodegenerative causes may be possible. Pathogenic variants in PSEN1 and PSEN2 were reported in individual cases of PCA and may support a possible monogenic contribution to selected early-onset posterior phenotypes. By contrast, variants and common AD risk genes, including GRN, MAPT, TREM2, BIN1, PICALM, ABCA7, and APOE E4 allele, represented broader genetic associations whose specific contribution to posterior cortical vulnerability remains incompletely defined. These forms of evidence should be interpreted separately. Genome-wide association studies identified overlapping loci associated with AD and glaucoma, including loci on chromosome 11 involving MTCH2, NDUFS3, and SPI1. This overlap reflected shared genetic susceptibility, pleiotropy, or putative convergent biological pathways involving mitochondrial function, immune regulation, and cellular stress. However, shared loci and pathway associations did not establish direct signaling, anatomical communication, or a causal relationship between brain and ocular tissues. The opposing tissue-specific effects reported for APOE further indicated that data in the brain may not be extrapolated to the retina. Future studies should clarify the cell-specific effects, causal direction, and clinical significance of shared genetic factors using well-characterized cohorts and tissue-specific experimental models. Overall, current evidence supported the partially overlapping genetic and cellular mechanisms in AD and selected ocular disorders, while further studies should be needed on the biological relationship between the brain and eye.},
}
RevDate: 2026-10-28
CmpDate: 2026-10-27
Environmental Pollution and Related Redox Pathways Contributing to Retinal Diseases.
Antioxidants (Basel, Switzerland), 15(10):.
Environmental pollution, a detrimental consequence of industrialization and globalization, is increasingly recognized as a potential risk factor for a wide range of human diseases, including retinal disorders. The retina is particularly vulnerable to environmental stressors, including particulate matter, nitrogen oxides, carbon monoxide, traffic-related noise, and extreme environmental conditions such as elevated temperatures. Epidemiological and experimental evidence suggests that these exposures may contribute to the development and progression of retinal diseases through mechanisms involving oxidative stress, chronic inflammation, immune dysregulation, and vascular dysfunction. These processes may ultimately contribute to retinal vasculopathies and degenerative disorders. Consequently, the pathophysiological mechanisms linking environmental exposures to retinal injury have received increasing attention in recent years. This review provides a disease-centered perspective on the relationship between environmental pollution and retinal diseases, integrating epidemiological evidence with experimental findings across specific retinal disorders. Among the environmental pollutants investigated to date, fine particulate matter (PM2.5) and nitrogen dioxide (NO2) have the most consistent epidemiological evidence for adverse effects on retinal health, particularly in relation to age-related macular degeneration (AMD). The review also discusses the methodological limitations and heterogeneity of the available evidence, as well as current knowledge gaps and future research perspectives.
Additional Links: PMID-42939831
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42939831,
year = {2026},
author = {Zhang, L and Tang, Q and Böhm, EW and Wagner, FM and Gericke, A},
title = {Environmental Pollution and Related Redox Pathways Contributing to Retinal Diseases.},
journal = {Antioxidants (Basel, Switzerland)},
volume = {15},
number = {10},
pages = {},
pmid = {42939831},
issn = {2076-3921},
abstract = {Environmental pollution, a detrimental consequence of industrialization and globalization, is increasingly recognized as a potential risk factor for a wide range of human diseases, including retinal disorders. The retina is particularly vulnerable to environmental stressors, including particulate matter, nitrogen oxides, carbon monoxide, traffic-related noise, and extreme environmental conditions such as elevated temperatures. Epidemiological and experimental evidence suggests that these exposures may contribute to the development and progression of retinal diseases through mechanisms involving oxidative stress, chronic inflammation, immune dysregulation, and vascular dysfunction. These processes may ultimately contribute to retinal vasculopathies and degenerative disorders. Consequently, the pathophysiological mechanisms linking environmental exposures to retinal injury have received increasing attention in recent years. This review provides a disease-centered perspective on the relationship between environmental pollution and retinal diseases, integrating epidemiological evidence with experimental findings across specific retinal disorders. Among the environmental pollutants investigated to date, fine particulate matter (PM2.5) and nitrogen dioxide (NO2) have the most consistent epidemiological evidence for adverse effects on retinal health, particularly in relation to age-related macular degeneration (AMD). The review also discusses the methodological limitations and heterogeneity of the available evidence, as well as current knowledge gaps and future research perspectives.},
}
RevDate: 2026-10-25
CmpDate: 2026-10-25
An Inducible Model of RPE-Associated Hydroxyapatite Mineralization with Relevance to Drusen Formation in Age-Related Macular Degeneration.
bioRxiv : the preprint server for biology pii:2026.10.08.757467.
A cardinal feature of nonexudative age-related macular degeneration (AMD) is the accumulation of drusen between the retinal pigment epithelium (RPE) and Bruch's membrane, yet the mechanisms that initiate and promote drusen formation remain to be fully understood. Hydroxyapatite (HAP), a calcium-phosphate mineral identified within human drusen, has been proposed to contribute to drusen nucleation and is associated with increased likelihood of RPE atrophy. However, mechanistic studies providing insight into RPE-associated mineralization have been limited by a lack of easy-to-use and manipulatable culture models. Here, we established a rapid, inducible ARPE-19-based model of HAP mineralization. We found that ARPE-19 cells cultured in minimum essential media (MEM) supplemented with nicotinamide (NIC), sodium phosphate, and ascorbic acid (NaPAA) reproducibly formed HAP positive deposits, whereas mineralization was not observed while using standard DMEM/F12 medium, DMEM/F12 with NaPAA, MEM-NIC medium, or MEM-NIC medium with alternative osteogenic supplements (such as β-glycerophosphate, ascorbic acid, and dexamethasone). Scanning electron microscopy with energy dispersive X ray spectroscopy demonstrated that the formed deposits were enriched in calcium (Ca) and phosphorus (P) with Ca/P ratios comparable to drusen-associated HAP deposits from AMD donor tissue. ARPE-19-based HAP deposits were also closely associated with neutral lipid-rich material, staining positive for BODIPY around their core structure. Bulk RNA sequencing of mineralized ARPE-19 cells revealed extracellular matrix, angiogenic, inflammatory, and metabolic transcriptional changes in the absence of strong enrichment of canonical osteogenic pathways. Co-treatment of mineralizing cells with either pyrophosphate, EDTA, or sodium citrate significantly reduced mineral deposition, but these approaches were not able to reverse it. Together, these findings establish a tractable RPE mineralization model that recapitulates key features of AMD-associated HAP and provides a platform for investigating mechanisms of drusen-associated mineral formation.
Additional Links: PMID-42926770
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42926770,
year = {2026},
author = {Yang, J and Daniel, S and Hulleman, JD},
title = {An Inducible Model of RPE-Associated Hydroxyapatite Mineralization with Relevance to Drusen Formation in Age-Related Macular Degeneration.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.08.757467},
pmid = {42926770},
issn = {2692-8205},
abstract = {A cardinal feature of nonexudative age-related macular degeneration (AMD) is the accumulation of drusen between the retinal pigment epithelium (RPE) and Bruch's membrane, yet the mechanisms that initiate and promote drusen formation remain to be fully understood. Hydroxyapatite (HAP), a calcium-phosphate mineral identified within human drusen, has been proposed to contribute to drusen nucleation and is associated with increased likelihood of RPE atrophy. However, mechanistic studies providing insight into RPE-associated mineralization have been limited by a lack of easy-to-use and manipulatable culture models. Here, we established a rapid, inducible ARPE-19-based model of HAP mineralization. We found that ARPE-19 cells cultured in minimum essential media (MEM) supplemented with nicotinamide (NIC), sodium phosphate, and ascorbic acid (NaPAA) reproducibly formed HAP positive deposits, whereas mineralization was not observed while using standard DMEM/F12 medium, DMEM/F12 with NaPAA, MEM-NIC medium, or MEM-NIC medium with alternative osteogenic supplements (such as β-glycerophosphate, ascorbic acid, and dexamethasone). Scanning electron microscopy with energy dispersive X ray spectroscopy demonstrated that the formed deposits were enriched in calcium (Ca) and phosphorus (P) with Ca/P ratios comparable to drusen-associated HAP deposits from AMD donor tissue. ARPE-19-based HAP deposits were also closely associated with neutral lipid-rich material, staining positive for BODIPY around their core structure. Bulk RNA sequencing of mineralized ARPE-19 cells revealed extracellular matrix, angiogenic, inflammatory, and metabolic transcriptional changes in the absence of strong enrichment of canonical osteogenic pathways. Co-treatment of mineralizing cells with either pyrophosphate, EDTA, or sodium citrate significantly reduced mineral deposition, but these approaches were not able to reverse it. Together, these findings establish a tractable RPE mineralization model that recapitulates key features of AMD-associated HAP and provides a platform for investigating mechanisms of drusen-associated mineral formation.},
}
RevDate: 2026-10-26
CmpDate: 2026-10-25
Factor H polymorphism elevates granzyme B and impairs complement inhibition in human and mouse models.
iScience, 29(11):117957.
The complement factor H (CFH) Y402H polymorphism is a leading genetic risk factor for age-related macular degeneration (AMD). Here, we identify extracellular granzyme B (GzmB) as a crucial mediator connecting complement dysregulation to structural pathology. In non-AMD human donor eyes, the high-risk CFH genotype was associated with increased GzmB-positive choroidal mast cells, membrane attack complex deposition, and distinct vitronectin redistribution. Using in vitro human retinal pigment epithelium (RPE) cells, we demonstrate that complement fragment C5a triggers GzmB secretion and zonula occludens-1 disruption. RNA sequencing of GzmB-stimulated RPE cells confirmed transcriptomic signatures of barrier dysfunction and cellular stress. Furthermore, GzmB-deficient mice displayed preserved choroidal vitronectin compared with wild-type controls, supporting a role for GzmB in cleaving this terminal complement inhibitor. These findings delineate a pathogenic C5a-GzmB pathway compromising extracellular matrix integrity, implicating extracellular GzmB as a critical downstream mediator linking genetic risk to early AMD onset.
Additional Links: PMID-42927272
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42927272,
year = {2026},
author = {Chakravarthy, H and Xi, J and Yoo, HS and Buss, A and Li, B and Bell, R and Haegert, A and Le Bihan, S and Granville, DJ and Matsubara, JA},
title = {Factor H polymorphism elevates granzyme B and impairs complement inhibition in human and mouse models.},
journal = {iScience},
volume = {29},
number = {11},
pages = {117957},
pmid = {42927272},
issn = {2589-0042},
abstract = {The complement factor H (CFH) Y402H polymorphism is a leading genetic risk factor for age-related macular degeneration (AMD). Here, we identify extracellular granzyme B (GzmB) as a crucial mediator connecting complement dysregulation to structural pathology. In non-AMD human donor eyes, the high-risk CFH genotype was associated with increased GzmB-positive choroidal mast cells, membrane attack complex deposition, and distinct vitronectin redistribution. Using in vitro human retinal pigment epithelium (RPE) cells, we demonstrate that complement fragment C5a triggers GzmB secretion and zonula occludens-1 disruption. RNA sequencing of GzmB-stimulated RPE cells confirmed transcriptomic signatures of barrier dysfunction and cellular stress. Furthermore, GzmB-deficient mice displayed preserved choroidal vitronectin compared with wild-type controls, supporting a role for GzmB in cleaving this terminal complement inhibitor. These findings delineate a pathogenic C5a-GzmB pathway compromising extracellular matrix integrity, implicating extracellular GzmB as a critical downstream mediator linking genetic risk to early AMD onset.},
}
RevDate: 2026-10-27
CmpDate: 2026-10-26
The potential of ruxolitinib as a senomorphic therapy in alleviating neovascular age-related macular degeneration : Ruxolitinib inhibits CNV.
Journal of translational medicine, 24(1):.
BACKGROUND: Cellular senescence plays a key role in the pathogenesis of neovascular age-related macular degeneration (nAMD). Senomorphic therapy, which targets the senescence-associated secretory phenotype (SASP), holds promise for treating age-related diseases; however, effective senomorphic treatments for nAMD remain lacking.
METHODS: We screened a panel of senomorphic agents in bleomycin- and ionizing radiation (IR)-induced senescent ARPE-19 cells to identify a lead compound for nAMD. Bulk and single-cell RNA sequencing data were analyzed to explore JAK-STAT signaling activation. Ruxolitinib and siRNA were used to validate the role of the JAK1/2-STAT3 pathway in senescent retinal pigment epithelium (RPE). A laser-induced choroidal neovascularization (CNV) model was established in Brown-Norway rats for in vivo studies.
RESULTS: Ruxolitinib, a JAK1/2 inhibitor, most effectively suppressed SASP factors and complement C3 expression while restoring pigment epithelium-derived factor (PEDF) levels in senescent ARPE-19 cells. Knockdown of JAK1 or JAK2 significantly reversed the expression of vascular endothelial growth factor (VEGF), C3, and PEDF. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) revealed activation of the JAK-STAT pathway in nAMD patient samples, CNV models, and senescent RPE cells, which was corroborated in the CNV rat model. Inhibition of JAK1/2-STAT3 with ruxolitinib markedly reduced vascular leakage and CNV area, and accelerated recovery of retinal function. The combination of ruxolitinib with anti-VEGF therapy presented a better effect on inhibiting CNV area. Furthermore, intravitreal injection of ruxolitinib showed no significant structural or functional toxicity in normal rat retinas over one month.
CONCLUSIONS: Our study identifies the JAK1/2-STAT3 pathway as a key regulator of the SASP in senescent RPE and confirms its activation in nAMD and experimental CNV. Pharmacologic inhibition of this pathway with ruxolitinib effectively attenuates CNV progression with a favorable short-term safety profile, supporting its potential as a senomorphic therapy for nAMD.
Additional Links: PMID-42928338
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42928338,
year = {2026},
author = {Wang, Y and Huang, Z and Tseng, Y and Ma, H and Chen, K and Pan, X and Ye, H and Cheng, T and Ge, J and Deng, J and Wang, X and Xia, J and Shen, J and Du, C and Lei, W and Mao, Z and Cui, H and Sheng, Y},
title = {The potential of ruxolitinib as a senomorphic therapy in alleviating neovascular age-related macular degeneration : Ruxolitinib inhibits CNV.},
journal = {Journal of translational medicine},
volume = {24},
number = {1},
pages = {},
pmid = {42928338},
issn = {1479-5876},
support = {82401265//National Natural Science Foundation of China/ ; 82271619//National Natural Science Foundation of China/ ; SDCX-ZG-202503121//Postdoctoral Innovation Program of Shandong Province/ ; LZ24H120002//Natural Science Foundation of Zhejiang Province/ ; },
mesh = {Animals ; Pyrimidines ; Nitriles ; *Pyrazoles/therapeutic use/pharmacology ; *Choroidal Neovascularization/drug therapy/pathology/complications ; Humans ; *Macular Degeneration/drug therapy/pathology/complications ; *Cellular Senescence/drug effects ; Signal Transduction/drug effects ; Janus Kinase 2/metabolism ; Rats, Inbred BN ; Retinal Pigment Epithelium/pathology/drug effects ; STAT3 Transcription Factor/metabolism ; Janus Kinase 1/metabolism ; Rats ; Cell Line ; Janus Kinases/metabolism ; Male ; },
abstract = {BACKGROUND: Cellular senescence plays a key role in the pathogenesis of neovascular age-related macular degeneration (nAMD). Senomorphic therapy, which targets the senescence-associated secretory phenotype (SASP), holds promise for treating age-related diseases; however, effective senomorphic treatments for nAMD remain lacking.
METHODS: We screened a panel of senomorphic agents in bleomycin- and ionizing radiation (IR)-induced senescent ARPE-19 cells to identify a lead compound for nAMD. Bulk and single-cell RNA sequencing data were analyzed to explore JAK-STAT signaling activation. Ruxolitinib and siRNA were used to validate the role of the JAK1/2-STAT3 pathway in senescent retinal pigment epithelium (RPE). A laser-induced choroidal neovascularization (CNV) model was established in Brown-Norway rats for in vivo studies.
RESULTS: Ruxolitinib, a JAK1/2 inhibitor, most effectively suppressed SASP factors and complement C3 expression while restoring pigment epithelium-derived factor (PEDF) levels in senescent ARPE-19 cells. Knockdown of JAK1 or JAK2 significantly reversed the expression of vascular endothelial growth factor (VEGF), C3, and PEDF. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) revealed activation of the JAK-STAT pathway in nAMD patient samples, CNV models, and senescent RPE cells, which was corroborated in the CNV rat model. Inhibition of JAK1/2-STAT3 with ruxolitinib markedly reduced vascular leakage and CNV area, and accelerated recovery of retinal function. The combination of ruxolitinib with anti-VEGF therapy presented a better effect on inhibiting CNV area. Furthermore, intravitreal injection of ruxolitinib showed no significant structural or functional toxicity in normal rat retinas over one month.
CONCLUSIONS: Our study identifies the JAK1/2-STAT3 pathway as a key regulator of the SASP in senescent RPE and confirms its activation in nAMD and experimental CNV. Pharmacologic inhibition of this pathway with ruxolitinib effectively attenuates CNV progression with a favorable short-term safety profile, supporting its potential as a senomorphic therapy for nAMD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
Pyrimidines
Nitriles
*Pyrazoles/therapeutic use/pharmacology
*Choroidal Neovascularization/drug therapy/pathology/complications
Humans
*Macular Degeneration/drug therapy/pathology/complications
*Cellular Senescence/drug effects
Signal Transduction/drug effects
Janus Kinase 2/metabolism
Rats, Inbred BN
Retinal Pigment Epithelium/pathology/drug effects
STAT3 Transcription Factor/metabolism
Janus Kinase 1/metabolism
Rats
Cell Line
Janus Kinases/metabolism
Male
RevDate: 2026-10-26
AKT1-phosphorylated TERT assembles a FOXO3-MYC transcriptional complex that drives ERphagy and proteostasis in post-mitotic RPE.
Autophagy [Epub ahead of print].
The retinal pigment epithelium (RPE) sustains lifelong proteostasis under chronic stress, yet how post-mitotic cells activate macroautophagy/autophagy when canonical kinase pathways suppress it remains unresolved. Here we demonstrate that AKT1 (protein kinase B alpha), drives autophagy through a non-canonical transcriptional mechanism triggered by isoform imbalance. In RPE and age-related macular degeneration (AMD) models, AKT2 (protein kinase B beta) hyperactivation destabilizes MTORC2 (mechanistic target of rapamycin complex 2) and engages RPS6KB/S6K (ribosomal protein S6 kinase beta) -mediated IRS-1 (insulin Receptor Substrate 1) inhibition, creating a feedforward autophagic arrest. Compensatory AKT1 activation via MTORC2 phosphorylates TERT (telomerase reverse transcriptase) at serine 824, driving nuclear translocation that is independent of telomere maintenance. In the nucleus, TERT assembles with FOXO3 (forkhead Box O3) and MYC (MYC proto-oncogene, bHLH transcription factor) into a tripartite transcriptional complex that occupies the EIF2AK3/PERK promoter (eukaryotic translation initiation factor 2-alpha kinase 3/ protein kinase R-like endoplasmic reticulum kinase), enabling EIF2AK3 transcriptional activation. This activity converts the unfolded protein response from pro-apoptotic to cytoprotective: EIF2AK3-ATF4 (activating transcription factor 4) signaling promotes core autophagy machinery biogenesis and selective ERphagy through the receptors TEX264 (testis expressed 264) and CCPG1(cell cycle progression 1), which prevents pathological EIF2AK3 clustering and preserves tubular ER architecture in diseased RPE. Using C. elegans phosphorylation-deficient mutants, mouse models and AMD patient iPSC-RPE, we establish that AKT1-mediated TERT phosphorylation is an evolutionarily conserved prerequisite for FOXO/DAF-16 nuclear function and lysosomal homeostasis in post-mitotic cells, offering therapeutic potential through targeted pharmacologic inhibition of AKT2.Abbreviations: ACTB: actin, beta; AKT1: AKT serine/threonine kinase 1; AKT2: AKT serine/threonine kinase 2; ALP: autophagy-lysosomal pathway; AMD: age-related macular degeneration, ATF4: activating transcription factor 4; ATG3: autophagy related 3; ATG4B: autophagy related 4B cysteine peptidase; ATG7: autophagy related 7; CCPG1: cell cycle progression 1; CFH: complement factor H; C57BL/6J: C57 black 6J; DMSO: dimethyl sulfoxide; MYC: MYC proto-oncogene, bHLH transcription factor; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; ER: endoplasmic reticulum; ERN1/IRE-1α: endoplasmic reticulum to nucleus signaling 1; ERphagy: endoplasmic reticulum-selective autophagy; FOXO1: forkhead box O1; FOXO3: forkhead box O3; iPSC-RPE: induced pluripotent stem cell-derived retinal pigment epithelium; ITGB1/integrin β1: integrin subunit beta 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPKAP1/SIN1: MAPK associated protein 1; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; MTORC2: MTOR complex 2; PBS: phosphate-buffered saline; PI3K: phosphoinositide 3-kinase; RICTOR: RPTOR independent companion of MTOR complex 2; RPE: retinal pigment epithelium; RPTOR: regulatory associated protein of MTOR complex 1; SQSTM1/p62: sequestosome 1; TERT: telomerase reverse transcriptase; TEX264: testis expressed 264, ER-phagy receptor; UPR: unfolded protein response; VCL: vinculin; WT: wild type.
Additional Links: PMID-42929416
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42929416,
year = {2026},
author = {Babu, VS and Ghosh, S and Bammidi, S and Jiwon, R and Sharma, R and Meyer, D and Hose, S and Pattabiraman, PP and Sahel, JA and Kidley, NJ and Braz, NF and Slater, MJ and Lang, S and Ghosh, A and Handa, JT and Yi, J and Sripathi, S and Kannan, RM and Bharti, K and Sinha, D},
title = {AKT1-phosphorylated TERT assembles a FOXO3-MYC transcriptional complex that drives ERphagy and proteostasis in post-mitotic RPE.},
journal = {Autophagy},
volume = {},
number = {},
pages = {1-28},
doi = {10.1080/15548627.2026.2750048},
pmid = {42929416},
issn = {1554-8635},
abstract = {The retinal pigment epithelium (RPE) sustains lifelong proteostasis under chronic stress, yet how post-mitotic cells activate macroautophagy/autophagy when canonical kinase pathways suppress it remains unresolved. Here we demonstrate that AKT1 (protein kinase B alpha), drives autophagy through a non-canonical transcriptional mechanism triggered by isoform imbalance. In RPE and age-related macular degeneration (AMD) models, AKT2 (protein kinase B beta) hyperactivation destabilizes MTORC2 (mechanistic target of rapamycin complex 2) and engages RPS6KB/S6K (ribosomal protein S6 kinase beta) -mediated IRS-1 (insulin Receptor Substrate 1) inhibition, creating a feedforward autophagic arrest. Compensatory AKT1 activation via MTORC2 phosphorylates TERT (telomerase reverse transcriptase) at serine 824, driving nuclear translocation that is independent of telomere maintenance. In the nucleus, TERT assembles with FOXO3 (forkhead Box O3) and MYC (MYC proto-oncogene, bHLH transcription factor) into a tripartite transcriptional complex that occupies the EIF2AK3/PERK promoter (eukaryotic translation initiation factor 2-alpha kinase 3/ protein kinase R-like endoplasmic reticulum kinase), enabling EIF2AK3 transcriptional activation. This activity converts the unfolded protein response from pro-apoptotic to cytoprotective: EIF2AK3-ATF4 (activating transcription factor 4) signaling promotes core autophagy machinery biogenesis and selective ERphagy through the receptors TEX264 (testis expressed 264) and CCPG1(cell cycle progression 1), which prevents pathological EIF2AK3 clustering and preserves tubular ER architecture in diseased RPE. Using C. elegans phosphorylation-deficient mutants, mouse models and AMD patient iPSC-RPE, we establish that AKT1-mediated TERT phosphorylation is an evolutionarily conserved prerequisite for FOXO/DAF-16 nuclear function and lysosomal homeostasis in post-mitotic cells, offering therapeutic potential through targeted pharmacologic inhibition of AKT2.Abbreviations: ACTB: actin, beta; AKT1: AKT serine/threonine kinase 1; AKT2: AKT serine/threonine kinase 2; ALP: autophagy-lysosomal pathway; AMD: age-related macular degeneration, ATF4: activating transcription factor 4; ATG3: autophagy related 3; ATG4B: autophagy related 4B cysteine peptidase; ATG7: autophagy related 7; CCPG1: cell cycle progression 1; CFH: complement factor H; C57BL/6J: C57 black 6J; DMSO: dimethyl sulfoxide; MYC: MYC proto-oncogene, bHLH transcription factor; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; ER: endoplasmic reticulum; ERN1/IRE-1α: endoplasmic reticulum to nucleus signaling 1; ERphagy: endoplasmic reticulum-selective autophagy; FOXO1: forkhead box O1; FOXO3: forkhead box O3; iPSC-RPE: induced pluripotent stem cell-derived retinal pigment epithelium; ITGB1/integrin β1: integrin subunit beta 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPKAP1/SIN1: MAPK associated protein 1; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; MTORC2: MTOR complex 2; PBS: phosphate-buffered saline; PI3K: phosphoinositide 3-kinase; RICTOR: RPTOR independent companion of MTOR complex 2; RPE: retinal pigment epithelium; RPTOR: regulatory associated protein of MTOR complex 1; SQSTM1/p62: sequestosome 1; TERT: telomerase reverse transcriptase; TEX264: testis expressed 264, ER-phagy receptor; UPR: unfolded protein response; VCL: vinculin; WT: wild type.},
}
RevDate: 2026-10-26
CmpDate: 2026-10-26
AI-Based OCT Assessment of Anatomic Response During the Loading Phase of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.
Investigative ophthalmology & visual science, 67(12):62.
PURPOSE: To compare functional and anatomic outcomes after the loading phase of intravitreal bevacizumab, aflibercept 2 mg, or faricimab in treatment-naive neovascular age-related macular degeneration (nAMD), using artificial intelligence (AI)-based optical coherence tomography (OCT) analysis.
METHODS: This multicenter retrospective cohort study included 224 eyes. Patients received three monthly injections of bevacizumab (n = 80), aflibercept 2 mg (n = 78), or faricimab (n = 66). Best-corrected visual acuity (BCVA) and spectral-domain OCT were assessed at baseline and week 12. AI-based segmentation quantified volumetric measurements of intraretinal fluid (IRFv), subretinal fluid (SRFv), and pigment epithelial detachment. The primary outcome was qualitative dry macula (absence of intraretinal fluid and subretinal fluid). An exploratory composite OCT biomarker (ΔCOMBO), defined as the lesser percentage reduction between IRFv and SRFv, was evaluated as a hypothesis-generating metric using receiver operating characteristic analysis. Baseline-adjusted analyses and multivariable logistic regression were performed.
RESULTS: Descriptive within-group analyses showed improvement in BCVA and reduction in OCT parameters at week 12 in treatment groups. BCVA improvement was statistically significant in the bevacizumab and faricimab groups. In baseline-adjusted analyses, between-group differences emerged for OCT outcomes, whereas no significant between-group differences were observed for BCVA. Higher rates of dry macula were observed with faricimab (80.3%) and aflibercept 2 mg (67.9%) compared with bevacizumab (41.3%) (P < 0.001). The exploratory composite metric ΔCOMBO showed high discriminative performance (area under the curve = 0.959; 95% confidence interval, 0.907-0.999).
CONCLUSIONS: All agents improved functional and anatomic outcomes after the loading phase in treatment-naive nAMD. Baseline-adjusted analyses showed differences in anatomic response patterns across treatments. Exploratory AI-based OCT biomarkers may help characterize short-term anatomic response; however, these findings require external validation.
Additional Links: PMID-42929689
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42929689,
year = {2026},
author = {Nassisi, M and Eandi, CM and Donà, C and Pozzo Giuffrida, F and Cattaneo, J and Lavia, CA and Malerba, A and Galli, D and Mainetti, C and Gambaro, L and Faraldi, F and Dell'Arti, L and Mapelli, C and Casalino, G and Viola, F},
title = {AI-Based OCT Assessment of Anatomic Response During the Loading Phase of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.},
journal = {Investigative ophthalmology & visual science},
volume = {67},
number = {12},
pages = {62},
doi = {10.1167/iovs.67.12.62},
pmid = {42929689},
issn = {1552-5783},
mesh = {Humans ; *Tomography, Optical Coherence/methods ; Retrospective Studies ; *Angiogenesis Inhibitors/administration & dosage/therapeutic use ; Intravitreal Injections ; Receptors, Vascular Endothelial Growth Factor/administration & dosage/therapeutic use ; Recombinant Fusion Proteins/administration & dosage/therapeutic use ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; *Bevacizumab/administration & dosage/therapeutic use ; Female ; Visual Acuity ; Male ; *Wet Macular Degeneration/drug therapy/diagnosis/physiopathology ; Aged ; Aged, 80 and over ; Treatment Outcome ; },
abstract = {PURPOSE: To compare functional and anatomic outcomes after the loading phase of intravitreal bevacizumab, aflibercept 2 mg, or faricimab in treatment-naive neovascular age-related macular degeneration (nAMD), using artificial intelligence (AI)-based optical coherence tomography (OCT) analysis.
METHODS: This multicenter retrospective cohort study included 224 eyes. Patients received three monthly injections of bevacizumab (n = 80), aflibercept 2 mg (n = 78), or faricimab (n = 66). Best-corrected visual acuity (BCVA) and spectral-domain OCT were assessed at baseline and week 12. AI-based segmentation quantified volumetric measurements of intraretinal fluid (IRFv), subretinal fluid (SRFv), and pigment epithelial detachment. The primary outcome was qualitative dry macula (absence of intraretinal fluid and subretinal fluid). An exploratory composite OCT biomarker (ΔCOMBO), defined as the lesser percentage reduction between IRFv and SRFv, was evaluated as a hypothesis-generating metric using receiver operating characteristic analysis. Baseline-adjusted analyses and multivariable logistic regression were performed.
RESULTS: Descriptive within-group analyses showed improvement in BCVA and reduction in OCT parameters at week 12 in treatment groups. BCVA improvement was statistically significant in the bevacizumab and faricimab groups. In baseline-adjusted analyses, between-group differences emerged for OCT outcomes, whereas no significant between-group differences were observed for BCVA. Higher rates of dry macula were observed with faricimab (80.3%) and aflibercept 2 mg (67.9%) compared with bevacizumab (41.3%) (P < 0.001). The exploratory composite metric ΔCOMBO showed high discriminative performance (area under the curve = 0.959; 95% confidence interval, 0.907-0.999).
CONCLUSIONS: All agents improved functional and anatomic outcomes after the loading phase in treatment-naive nAMD. Baseline-adjusted analyses showed differences in anatomic response patterns across treatments. Exploratory AI-based OCT biomarkers may help characterize short-term anatomic response; however, these findings require external validation.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Tomography, Optical Coherence/methods
Retrospective Studies
*Angiogenesis Inhibitors/administration & dosage/therapeutic use
Intravitreal Injections
Receptors, Vascular Endothelial Growth Factor/administration & dosage/therapeutic use
Recombinant Fusion Proteins/administration & dosage/therapeutic use
Vascular Endothelial Growth Factor A/antagonists & inhibitors
*Bevacizumab/administration & dosage/therapeutic use
Female
Visual Acuity
Male
*Wet Macular Degeneration/drug therapy/diagnosis/physiopathology
Aged
Aged, 80 and over
Treatment Outcome
▼ ▼ LOAD NEXT 100 CITATIONS
RJR Experience and Expertise
Researcher
Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.
Educator
Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.
Administrator
Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.
Technologist
Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.
Publisher
While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.
Speaker
Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.
Facilitator
Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.
Designer
Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.
RJR Picks from Around the Web (updated 11 MAY 2018 )
Old Science
Weird Science
Treating Disease with Fecal Transplantation
Fossils of miniature humans (hobbits) discovered in Indonesia
Paleontology
Dinosaur tail, complete with feathers, found preserved in amber.
Astronomy
Mysterious fast radio burst (FRB) detected in the distant universe.
Big Data & Informatics
Big Data: Buzzword or Big Deal?
Hacking the genome: Identifying anonymized human subjects using publicly available data.